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1. Transglutaminase type 2 (TG2) 
The term transglutaminase was introduced by Clarke et al. in 1957 to describe 
the calcium-dependent incorporation of low molecular weight primary amines 
into proteins observed in guinea-pig liver.1,2 This so-called transamidation activity 
led to the discovery of the first member of the transglutaminase family, which is 
now known as tissue transglutaminase or transglutaminase type 2 (TG2; EC 
2.3.2.13). Besides the conjugation of small amines to specific glutamines in 
polypeptide chains, transglutaminases also catalyzes the formation of -(-
glutamyl)lysine bonds between a selected glutamine residue of one protein and a 
lysine residue of another protein, leading to protein crosslinking.3-5 In 1994, it was 
shown that TG2 also acts as a G protein (guanine nucleotide-binding protein),6 
which underlines the multifunctional character of this protein. Intensive research 
in the last decades has implicated TG2 in a wide variety of cellular processes and 
has demonstrated the association of deregulated TG2 expression and/or activity 
with various pathological processes. 
 
1.1 The transglutaminase family 
Transglutaminase family members are widely distributed and can be found in 
organisms ranging from mammals and plants to unicellular organisms. Nine 
different transglutaminase genes have been identified in the human genome 
(Table 1).5,7 The best characterized transglutaminases are TG1, TG2, TG3, TG5 and 
Factor XIIIa, while still little is known about TG4, TG6, TG7 and Band 4.2. 
Remarkably, TG2 is the only ubiquitously expressed family member and while 
other isotypes are mostly associated with tissue specific functions, TG2 plays a 
crucial role in general cellular events like cell differentiation, death and adhesion. 
All transglutaminases, except for Band 4.2, are characterized by their (potential) 
calcium-dependent crosslinking activity. TG1, TG3 and TG5 participate in the 
formation of the cornified cell envelope by catalyzing the crosslinking of proteins 
resulting in stable high-molecular weight components. This occurs during 
keratinocyte differentiation and is crucial for stabilization of the protective barrier 
of the outermost layer of the skin epidermis.8 Factor XIIIa is, besides TG2, the only 
transglutaminase that is secreted and is best known for its function in blood 
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clotting, in which it stabilizes the fibrin clot by forming crosslinks between the 
fibrin chains. Additionally, Factor XIIIa plays a role in bone growth and wound 
healing. 
 
Table 1. Important features of the human transglutaminase protein family. Adapted by 
permission from Macmillan Publishers Ltd: Nature Reviews Molecular Cell Biology 4 (2), 
140-156, Lorand, L. and Graham, R.M., Transglutaminases: crosslinking enzymes with 
pleiotropic functions, copyright 2003. 
Protein Synonyms Tissue expression Localization Main 
functions 
Disease 
TG1 Keratinocyte 
TG 
Keratynocytes, brain Membrane, 
cytosolic 
Cell envelope 
formation 
Lamellar ichthyosis 
TG2 Tissue TG 
(tTG), Ghα 
Ubiquitous Cytosolic, 
nuclear, 
membrane, 
extracellular 
Cell death, cell 
differentiation, 
cell adhesion 
and migration 
Inflammatory 
diseases, 
neurodegenerative 
diseases, cancer 
TG3 Epidermal 
TG (TGE) 
Squamous epithelium, 
brain 
Cytosolic Cell envelope 
formation 
Cancer 
TG4 Prostate TG 
(TGP) 
Prostate Unknown Semen 
coagulation 
Unknown 
TG5 TGX Ubiquitous (except for 
the CNS and lymphatic 
system) 
Unknown Cornified cell 
envelope 
formation 
Ichthyosis, 
psoriasis 
TG6 TGY Testis, lung Unknown Unknown Unknown 
TG7 TGZ Predominantly in testis 
and lung 
Unknown Unknown Unknown 
Factor 
XIIIa 
FXIIIa, 
Plasma TG, 
Fibrin-
stabilizing 
factor 
Platelets, astrocytes, 
dermal dendrytic cells, 
chondrocytes, placenta, 
plasma, synovial fluid, 
osteoblasts 
Cytosolic, 
extracellular 
Blood clotting, 
bone growth, 
wound healing 
FXIIIa deficiency 
Band 
4.2 
Erythrocyte 
membrane 
protein 
band 4.2 
Red blood cells, bone 
marrow, fetal liver, 
spleen 
Membrane Membrane 
skeletal 
component 
Hereditary 
spherocytosis 
 
  
General introduction 
___________________________________________________________________ 
15 
 
1.2 Structure of TG2  
TG2 is closely related to other members of the human transglutaminase 
family, which all show a high degree of sequence similarity.9 Also the secondary 
and tertiary structures are highly preserved between the different family 
members, which is supported by the crystal structures reported for human TG2,10 
TG311 and Factor XIIIa.12 The tertiary structure of TG2, but also of TG3 and Factor 
XIIIa, consists of an N-terminal β-sandwich, a catalytic core containing a 
combination of α and β structures and two C-terminal β-barrels (Figure 1A). The 
catalytic core contains a well-conserved catalytic triad consisting of cysteine 277, 
which is the essential nucleophile in the transamidation reaction,12 histidine 335 
and aspartate 358.13 TG2 can undergo a large conformational change between a 
closed inactive form and an open active form (Figure 1).14 In the inactive 
conformation the catalytic triad is blocked by two loops, while the active site 
cysteine is hydrogen-bonded to a tyrosine residue.10 The conformation of the 
open active TG2 has been determined with the help of the crystal structure of TG2 
in complex with an irreversible active site inhibitor. The open and closed 
conformation of TG2 have distinct biochemical functions (discussed in paragraph 
1.3) and are allosterically regulated by calcium and GDP/GTP.15 Binding of a 
guanidine nucleotide occurs in a cleft between the catalytic core and the first β-
barrel10 and stabilizes the closed inactive conformation (Figure 1A). Recently, ATP 
was shown to interact with TG2 in a similar manner, although binding was weaker 
than observed for GTP.16 Inhibition by GTP has also been reported for TG3,17 TG418 
and TG5,19 but GTP does not appear to affect the activity of TG1.20 Besides the 
nucleotide binding site, TG2 also contains six calcium binding sites.21 Calcium ions 
bind on the surface of the catalytic core with an affinity constant of approximately 
90 µM, thereby inducing the open active conformation. Calcium serves as the 
main switch between the two conformations, but can be inhibited to some extent 
by nucleotide binding.22,23 The affinity of calcium ion-binding to TG2 is fine-tuned 
by additional molecular interactions, for which lipids and carbohydrates are the 
most likely candidates.24 Binding to sphingosylphosphocholine, which occurs in 
membrane-bound TG2, reduces the calcium concentration required for TG2 
activation from 160 to 10 µM.25 For TG2 associated with lipid vesicles, activation 
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has even been observed at a calcium concentration of 2.3 µM.26 
Recently, Stamnaes et al. reported a third allosteric regulatory mechanism, 
which is responsible for the oxidative inactivation of TG2.27 Under oxidative 
conditions, a disulfide bond is formed between cysteine 230 and 370, which 
subsequently facilitates the formation of a vicinal disulfide bond between cysteine 
370 and 371 resulting in an open but inactive conformation. Cysteine 230, which 
serves as the redox sensor, is not conserved in other transglutaminases, indicating 
that this redox sensitive regulatory mechanism is unique for TG2. It is important 
to note that the oxidative inactivation of TG2 is a reversible process.  
 
 
Figure 1. Overall structures of the (A) GDP-bound closed conformation and (B) inhibitor-
bound open conformation of TG2. The N-terminal β-sandwich is shown in blue (N), the 
catalytic domain (Core) in green, and the C-terminal β-barrels (β1 and β2) in yellow and 
red, respectively. Adapted from PLoS Biology 5 (12), 2788-2796, Pinkas, D.M. et al., 
Transglutaminase 2 undergoes a large conformational change upon activation, copyright 
2007. 
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1.3 Biochemical functions of TG2  
TG2 is predominantly a cytoplasmic protein, but can also be found in the 
nucleus, the mitochondria and on the plasma membrane and is, despite the 
absence of a leader sequence, even transported to the extracellular space where 
it is bound to the cell surface and ECM. The mechanism by which TG2 is exported 
is still unclear, although several possibilities have been proposed.28 The subcellular 
localization strongly affects the conformation as well as the biochemical functions 
of TG2 due to cellular factors such as calcium, GTP/GDP and the redox state.29 In 
the intracellular environment, the low calcium and high GTP concentrations keep 
TG2 in the inactive closed conformation. Under various stress conditions, which 
are associated with elevated intracellular calcium levels, TG2 is activated and 
displays transamidation activity. It is still unclear whether intracellular TG2 also 
displays crosslinking activity under normal conditions.30 When secreted into the 
extracellular environment, TG2 may adapt the open active conformation due to 
high calcium and low GTP levels. However, activation of TG2 upon secretion is 
only transient due to the oxidative conditions in the extracellular space, which 
result in an open but inactive conformation.31  
 
1.3.1 Calcium-independent functions 
In the closed conformation, intracellular TG2 can bind and hydrolyze GTP 
thereby acting as a G protein involved in transmembrane signaling (Figure 2, 
lower part).6 As a G protein, intracellular TG2 mediates agonist-induced signaling 
from the α1B- and α1D-adrenoreceptors to downstream effectors such as 
phospholipase C (PLC).32 Inhibition of PLC by GDP-bound TG2 is suspended when 
TG2 binds GTP, affecting downstream events such as the production of inositol 
phosphate. TG2 has also been implicated in other signaling pathways, for example 
via the oxytocin33 and the TPα thromboxane A2 receptors.34 
In the extracellular space, inactive TG2 plays an important role as a structural 
protein by directly interacting with various extracellular proteins (Figure 2, middle 
part). The N-terminal β-sandwich domain of TG2 contains binding sites for 
fibronectin and integrin.35,36 Other extracellular interaction partners of TG2 are 
syndecan-4,37 matrix metalloproteinase 238 and endostatin,39 which is the C-
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terminal fragment of the α1 chain of collagen XVIII. In this way, TG2 may act as an 
adapter protein facilitating cell-extracellular matrix (ECM) interactions (discussed 
in paragraph 1.5.3).  
 
 
Figure 2. Biochemical activities of TG2. TG2 catalyzes Ca
2+
-dependent acyl-transfer 
reaction between -carboxamide group of a specific protein-bound glutamine and either 
the ε-amino group of a distinct protein-bound lysine residue (crosslinking of proteins) or 
primary amines such as polyamines and histamine (incorporation of amines into proteins). 
Water can replace amine-donor substrates, leading to deamidation of the recognized 
glutamines. TG2 has Ca
2+
-dependent isopeptidase activity and can hydrolyze : 
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isopeptides. TG2 can be exposed on the external leaflet of the plasma membrane. The 
presence of TG2 outside the cell has been proposed to depend on its interaction with 
fibronectin and integrins. Intracellular TG2 binds and thereby activates phospholipase C 
following stimulation of several kinds of cell surface receptors; its endogenous GTPase 
activity ensures proper regulation of transmembrane signaling through these receptors. 
Functions of TG2 are performed in the cytosol (C), the nucleus (N), at the cell membrane 
(M) and in the extracellular space (E). Except for its isopeptidase activity, all other 
functions have been shown to occur in intact cells and/or tissues. Adapted from TRENDS in 
Biochemical Sciences 27 (10), 534-539, Fesus, L. and Piacentini, M., Transglutaminase 2: an 
enigmatic enzyme with diverse functions, copyright 2002, with permission from Elsevier. 
 
1.3.2 Calcium-dependent functions 
TG2 may adapt the open active conformation upon secretion in the 
extracellular space or after elevation of intracellular calcium levels, for example 
during stress conditions or cell death (see also paragraph 1.5). The transamidating 
or crosslinking activity present in the open calcium-bound conformation is a two-
step reaction which starts with a nucleophilic attack by the thiol of the TG2 active-
site cysteine on the -carboxamide functionality of a peptidylglutamine, leading to 
the formation of a thioester intermediate and the release of ammonia.40 The 
glutamine-containing peptide or protein is referred to as the ‘(amine) acceptor’ or 
‘Q’ substrate. In the subsequent step a second substrate, known as the ‘(amine) 
donor’ or ‘K’ substrate, attacks the thioester intermediate and thereby releases 
TG2 with its active-site cysteine re-established in the original form. Depending on 
the nature of the donor substrate, various products can be generated (Figure 2, 
upper part). In most cases, the donor substrate contains a primary amine, which 
can either be the -amino group of a peptidyllysine, leading to intra- or 
intermolecular protein crosslinking, or a small primary amine substrate, leading to 
the conjugation of amines to proteins. Alternatively, water or alcohols can replace 
the amine-donor substrate resulting in either deamidation or esterification of the 
glutamine residue. TG2 may also hydrolyze previously formed -(-glutamyl)lysine 
crosslinks, resulting in indirect deamidation of the glutamine residue.41,42  
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1.4 Substrate specificity of TG2 
A large number of proteins have been identified as TG2 substrates.43,44 Based 
on the recognized target sites, it is clear that TG2 is quite selective towards lysine, 
but even more towards glutamine residues. As already mentioned in paragraph 
1.3.1, the amine-donor substrate can be replaced by other small primary amines 
including putrescine, spermidine and histamine, or by water. The type of donor 
substrate that is incorporated by TG2 depends on the reaction conditions as well 
as the acceptor substrate itself.42,45 For instance, protein deamidation is favored at 
low pH or in the absence of suitable amines, but can also be specific for certain 
glutamine residues. In small heat shock protein B6 (HspB6/Hsp20), highly efficient 
deamidation of glutamine 66 has been reported to occur simultaneously with 
crosslinking of glutamine 31.45 This site-specific deamidation might be explained 
by steric hindrance, where access of the amine-donor to the active site of TG2 is 
blocked upon binding of certain peptidylglutamines, thereby forcing deamidation 
of these glutamines.  
Crucial factors for the recognition of a peptidylglutamine by TG2 are the 
surrounding residues as well as the overall folding of the peptide or protein, which 
determines the accessibility.43,44 In contrast, recognition of a peptidyllysine 
primarily depends on its accessibility.46 The ability of some proteins to act as TG2 
substrates can therefore be affected by conformational changes, for example due 
to proteolytic processing, posttranslational modifications or interactions with 
other molecules. For glutamine-substrates, a consensus sequence has been 
determined by studying peptides acting as TG2 substrates and by phage display 
approaches. The latter revealed the consensus sequences pQx(P,T,S)l and QxPhDP 
(where h, l, p and x indicate hydrophobic, aliphatic, polar and any amino acids, 
respectively).47,48 Especially the proline on the +2 position (relative to the 
glutamine) strongly enhances substrate recognition, but discourages the TG2 
reaction when present at the +1 or +3 position. Furthermore, a clear preference 
was observed for glycines and asparagines adjacent to the target glutamine, 
which may enhance substrate accessibility. Also positively charged residues have 
been reported to enhance substrate recognition when present at the +3 or +5 
position (QxxZ+ or QxxxxZ+, where Z+ indicates the positively charged residue), 
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whereas these residues have the opposite effect when they directly flank the 
target glutamine.  
 
1.5 Physiological functions of TG2 
In this paragraph the main physiological functions of TG2 will be discussed in 
relation to the subcellular localization and (enzymatic) activities of TG2.  
  
1.5.1 The role of TG2 in cell death 
TG2 plays an important role in various signaling pathways leading to apoptotic 
cell death, but also during the process of cell death itself. TG2 may exert both pro- 
and anti-apoptotic effects depending on several parameters such as the 
subcellular localization of TG2, the cell type and the kind of apoptotic stimuli.49 In 
several cancer cell lines, TG2 has been reported to activate the NF-B pathway, 
thereby protecting against apoptosis.50 Furthermore, extracellular TG2 protects 
against detachment-induced apoptosis, also known as anoikis, when bound to 
fibronectin and cell surface heparan sulfate chains.51 In contrast, pro-apoptotic 
effects might be induced by the crosslinking of dual leucine zipper-bearing kinase 
resulting in an oligomeric active complex of this pro-apoptotic kinase.52 TG2 has 
also been associated with the release of apoptosis-inducing factor from 
mitochondria.53 The catalytic core of TG2 contains a BH3-like domain which has 
been suggested to bind Bax, thereby inducing a conformational change and 
translocation of Bax to the mitochondria resulting in cytochrome c release.54 
During either apoptotic or necrotic cell death, elevated intracellular calcium 
levels lead to extensive intracellular protein crosslinking catalyzed by TG2. The 
resulting protective shells are believed to prevent leakage of cell components, 
which otherwise might trigger an inflammatory response that could lead to the 
development of autoimmunity.55 Furthermore, there are also indications that TG2 
is involved in the clearance of apoptotic cells by macrophages, for instance by 
promoting the formation of chemoattractants and the exposure of 
phosphatidylserine.56  
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1.5.2 The role of TG2 in cell differentiation 
TG2 is involved in the differentiation of various cell types including 
granulocytes57 and neurons.58 In addition, TG2 has been proposed to be 
implicated in the epithelial-to-mesenchymal transition, which is believed to play 
an important role in inflammation, fibrosis and tumor invasiveness and 
metastasis.59 Especially the nuclear pool of TG2 affects cell differentiation, where 
it may regulate gene expression by modifying or interacting with transcriptional 
factors and histones.60 TG2 has been reported to contribute in a partially 
transamidation-dependent manner to the all-trans-retinoic acid induced 
differentiation of NB4 promyelocytic leukemia cells towards neutrophil 
granulocytes.57,61 During this differentiation process, TG2 is induced, partially 
translocated to the nucleus and activated. The latter is presumably triggered by 
the release of calcium ions from internal stores. During neuronal differentiation, 
TG2 has been suggested to contribute to the adhesion and morphology by 
catalyzing the crosslinking of cell surface proteins.62 
 
1.5.3 The role of TG2 in cell adhesion and migration 
A large number of studies suggests that different biochemical activities of TG2 
may affect cell-ECM interactions, thereby mediating cell adhesion and 
migration.35,36 As mentioned before, TG2 interacts with various extracellular 
proteins in a calcium-independent manner. In fact, the entire pool of cell surface 
TG2 exists in a 1:1 complex with integrin receptors.63 In addition, TG2 has a strong 
association with the abundant ECM protein fibronectin and thus may serve as a 
bridge between integrins and fibronectin, which by themselves only interact 
weakly.35,36 The formation of this stable ternary complex promotes cell adhesion, 
cell migration and the assembly of fibronectin fibrillar matrices.64,65  
On the other hand, extracellular TG2 may also affect cell-ECM interactions in a 
calcium dependent manner by crosslinking various extracellular proteins including 
fibronectin, fibrinogen, vitronectin and collagen.66 This extracellular 
transamidation activity of TG2 does not only contribute to cell adhesion and 
migration, but is also involved in the assembly, remodeling and stabilization of the 
ECM in various tissues.66,67 As mentioned before, the majority of extracellular TG2 
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is catalytically inactive under normal physiological conditions, but can be activated 
upon tissue injury or inflammatory stimuli.31 The oxidative environment is most 
likely responsible for the inactivation of extracellular TG2.27 During wound healing, 
secretion and subsequent activation of TG2 plays an important role in the 
stabilization of the ECM and modulating cell-ECM interactions, which facilitates 
the migration of cells to the wound site.68,69  
TG2 located in the intracellular environment may also contribute to cell 
adhesion and migration, because it has been reported to contribute to 
cytoskeletal rearrangements through crosslinking of various cytoskeletal proteins 
amongst which actin and β-tubulin.70 TG2 may also affect cytoskeletal 
rearrangements in an indirect manner. Transamidation of RhoA by TG2 leads to its 
constitutive activation resulting in the formation of stress fibers and focal 
adhesion complexes.71 Finally, the G protein function of cell membrane associated 
TG2 has been reported to affect cell adhesion and migration via regulation of 
phospholipase C activity.72  
 
1.6 TG2 and disease 
Since TG2 is implicated in various important biological processes, it is not 
surprising that deregulated expression and/or activity of TG2 is associated with 
the pathogenesis of several well-known diseases (see Table 1). As a consequence, 
TG2 is believed to be a valuable therapeutic target. In this paragraph the most 
important diseases, divided into inflammatory diseases, neurodegenerative 
diseases and cancers, will be discussed.  
 
1.6.1 Inflammatory diseases 
TG2 has been associated with various inflammatory diseases including celiac 
disease, multiple sclerosis and several diseases associated with fibrosis. Celiac 
disease is a gluten-hypersensitivity disorder which is characterized by a 
pathological immune response against gluten peptides. The initial immune 
response against these peptides is thought to be triggered by TG2-catalyzed 
deamidation of specific glutamine residues.73 Essentially all celiac disease patients 
develop antibodies to TG2, which have become a widely used diagnostic marker 
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for this disease.74  
Several reports have also implicated TG2 in the pathology of multiple 
sclerosis, which is a chronic neuro-inflammatory disease characterized by the 
presence of demyelinated white matter lesions in the central nervous system.75 
TG2 mediates the enhanced interaction of astrocytes with fibronectin in the 
extracellular matrix of multiple sclerosis lesions, thereby contributing to migration 
to the lesions, resulting in tissue remodeling and possibly glial scarring.76 It has 
been demonstrated that inhibition of TG2 activity may lead to remyelination, 
suggesting that TG2 might serve as a new therapeutic target in multiple sclerosis 
and other demyelinating diseases.77  
A large amount of evidence implicates TG2 in abnormal wound healing, which 
may lead to fibrosis or scarring.69 These conditions may occur when the 
inflammatory response during wound healing becomes chronic, for example as a 
result of autoimmunity, and are characterized by an excess of ECM that is highly 
crosslinked by TG2. Increased TG2 activity has been linked to progressive scarring 
in several tissues including the lung, liver, heart and kidney.67,69 Furthermore, 
treatment with TG2 inhibitors reduces the extent of scarring in for example renal 
fibrosis, thereby highlighting the potential of TG2 as therapeutic target in diseases 
characterized by tissue fibrosis.78  
 
1.6.2 Protein folding diseases 
Many diseases are characterized by the accumulation and deposition of toxic 
protein aggregates in affected tissues. It has been suggested that the crosslinking 
activity of TG2 plays an important role in the formation of these insoluble 
aggregates. In support of this hypothesis, elevated TG2 expression and activity 
have been reported for various diseases including neurodegenerative diseases 
such as Alzheimer’s disease, Parkinson’s disease and various polyglutamine 
diseases such as Huntington’s disease.79,80 Many of the proteins that are prone to 
aggregation, including α-synuclein, huntingtin, amyloid and tau, are well known 
TG2 substrates. Furthermore, both TG2 itself and the -(-glutamyl)lysine 
crosslinks have been found to colocalize with the protein aggregates in the 
diseased brain. TG2 inhibitors have already been demonstrated to reduce the 
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amount of α-synuclein aggregation in Parkinson’s disease models and are 
considered as potentially valuable tools in the treatment of neurodegenerative 
diseases.80,81  
 
1.6.3 Cancer 
A role for TG2 has been proposed in many stages of the tumor progression 
cascade. Most types of cancer have elevated levels of TG2, which has been 
demonstrated to correlate with a reduced overall patient survival in for example 
ovarian and colorectal cancer.59 However, reduced TG2 expression levels and 
activity during tumor progression have also been reported for some types of 
cancer including prostate adenocarcinoma, indicating that also a low TG2 
expression may contribute to cancer development.82 These contradictory 
observations may be explained by the pro- and anti-apoptotic functions of TG2 
(see paragraph 1.5.2). In cancer cells TG2 is able to constitutively activate cell 
survival pathways, thereby contributing to metastasis and drug resistance. On the 
other hand, TG2 is also involved in cell sensitization and commitment to 
apoptosis. Extracellular TG2 is involved in the stabilization of the ECM by 
crosslinking ECM proteins (paragraph 1.5.4), which impedes cell migration 
resulting in inhibition of tumor growth, metastasis and angiogenesis. Overall, TG2 
may act in favor or against tumor progression depending on various parameters 
such as the stage of the tumor and the localization of (active) TG2.83 Therefore, 
precise understanding of the functions of TG2 is needed before TG2 can be used 
as a therapeutic target for the treatment of cancer.  
 
1.7 Tools for detecting TG2 activity 
Various methods have been developed to detect the transamidating activity 
of TG2 and/or to identify the crosslinked protein substrates.43,84,85 The latter is a 
challenging task, since TG2 tends to convert substrate proteins into insoluble high 
molecular weight complexes consisting of multiple highly modified proteins. In 
this paragraph, the most commonly applied methods will be discussed including 
the use of tagged TG2 substrates or inhibitors, but also approaches that enable 
detection of endogenous crosslinked products.  
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1.7.1 Labeling of TG2 substrate proteins 
Several tagged TG2 substrates have been developed that enable, after being 
conjugated to substrate proteins by TG2, visualization and/or identification of 
these proteins. Since TG2 is less restrictive towards the amine-donor, the most 
commonly used substrates are small primary alkylamines such as 
monodansylcadaverine, FITC-cadaverine and 5-(biotinamido)pentylamine (BPA). 
These mono-N-functionalized pentane-1,5-diamines mimic the -amino group of a 
peptidyllysine, which is essential for effective recognition by TG2.86,87 When 
present in excess, these compounds mostly replace the natural donor substrates 
thereby reducing the formation of high molecular weight protein complexes. 
Depending on the type of tag used, labeled Q substrate proteins can either be 
visualized via western blot analysis or fluorescence microscopy, or purified via 
affinity pull-down techniques, which allows subsequent identification of these 
somewhat less complex products via mass spectrometry (MS).  
For the labeling of K substrate proteins, various biotinylated or fluorescently 
labeled glutamine-containing peptides have been designed. These peptides 
usually have sequences derived from natural TG2-acceptor substrates or are 
based on consensus sequences obtained by phage display studies (paragraph 1.4). 
An important advantage is that these peptides, depending on their sequence, may 
show high selectivity towards TG2 compared to other types of 
transglutaminases,48 whereas small primary amine substrates are thought to be 
equally well recognized by different transglutaminase family members. 
Furthermore, these peptides are often designed such that they allow purification 
and subsequent identification of K substrate proteins for TG2.  
For the detection of TG2 activity in cell or tissue extracts, various often ELISA-
based assays have been developed. These assays contain one covalently 
immobilized substrate and one biotinylated or fluorescently labeled substrate and 
have also been developed for measuring isoform-specific activities of TG1, TG2 or 
Factor XIIIa by using glutamine-containing peptides that are selectively recognized 
only by one transglutaminase isoform.86,88  
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1.7.2 Labeling of catalytically active TG2 
Many classes of irreversible TG2 inhibitors have been reported so far.89,90 
These compounds are primarily developed for studying the effect of TG2 
inhibition and as potential drug candidates. However, fluorescently labeled 
analogs have also been reported, which allow visualization of catalytically active 
TG2 in cells or tissues.91 Recently, ‘clickable’ inhibitors have been developed which 
contain a small chemical tag that allows derivatization with for example a 
fluorophore (this strategy will be discussed in more detail in paragraph 2.5).92 
These functionalized inhibitors may have important additional value when 
studying the transamidation activity of TG2 since they allow the localization of 
active TG2 itself rather than its modified substrate proteins.  
 
1.7.3 Detection of endogenous transamidation products 
Although the previously described methods are valuable tools for the 
detection of TG2 activity and/or substrates in vitro or in situ, they cannot be used 
to detect or identify crosslinks formed within or between endogenous proteins in 
vivo. The latter is crucial for studying biological specimens such as postmortem 
brain tissues of patients that suffered from neurodegenerative diseases. 
Therefore, additional approaches are needed that allow direct detection and 
identification of these endogenous N--(-glutamyl)lysine protein crosslinks. 
For the detection of protein-protein crosslinks generated by TG2, various 
antibodies have been developed against the N--(-glutamyl)lysine entity. 
Unfortunately, these antibodies are not completely specific for transglutaminase 
induced crosslinks due to the presence of highly similar chemical structures such 
as -acetyl-lysines, a common posttranslational modification introduced by lysine 
acetyltransferases. Furthermore, the specificity of anti- N--(-glutamyl)lysine 
antibodies is often affected by the flanking amino acids, most likely because the 
epitopes are generally larger than just the isopeptide bond.93 As a result, such 
antibodies should only be used in combination with other techniques to detect 
protein-protein crosslinks. Nevertheless, these antibodies have been successfully 
applied for immunostaining of various tissue sections, immunoprecipitation and 
western blot analysis.  
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An alternative way to measure the amount of protein-protein crosslinks is via 
the degradation product N--(-glutamyl)lysine isodipeptide. The N--(-
glutamyl)lysine isopeptide bond is not recognized by proteases and the 
corresponding isodipeptide accumulates after the degradation of crosslinked 
protein complexes and can be detected via high-performance liquid 
chromatography (HPLC). These isodipeptides are present in blood serum and/or 
cerebrospinal fluid and their concentration may increase under various 
pathological conditions.94,95 For the detection of crosslinks between proteins by 
this approach an exhaustive protease digestion is required, often in combination 
with chemical proteolysis, prior to HPLC analysis.96,97  
Nowadays, MS is by far the most valuable tool for the identification of 
transamidated protein substrates and their modification sites. Alternative 
methods such as N-terminal protein sequencing by Edman degradation are less 
commonly used due to fast developments in the field of MS.84 However, the 
analysis of covalently crosslinked proteins remains challenging due to the 
structural complexity of these branched proteins. Therefore, multiple steps are 
included in the preparation of biological samples that enable identification of the 
protein-protein crosslinks. These usually include dissociation of the crosslinked 
protein networks into small peptide fragments by protease digestion and/or 
chemical proteolysis, enrichment of N--(-glutamyl)lysine containing peptides by 
immunoprecipitation or affinity pull-down techniques and separation of the 
obtained peptide mixture by SDS-PAGE and/or HPLC.84 The enrichment step 
requires either antibodies directed against the N--(-glutamyl)lysine protein 
crosslink or tagged TG2 substrates (paragraph 1.7.1). Besides protein crosslinking, 
MS analysis also enables the identification of other TG2-catalyzed modifications, 
such as the incorporation of small primary amines and deamidation.  
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2. Click chemistry 
 
2.1 Concept of click chemistry 
Inspired by nature’s way to synthesize its biomolecules using only a small set 
of building blocks and just a handful of different reactions, Sharpless, Kolb and 
Finn introduced the click chemistry philosophy in 2001.98 Their ultimate goal was 
to select a limited number of reaction types that can be used for the efficient 
synthesis of all kinds of materials. These so-called click reactions must therefore 
be versatile, proceed rapidly under ambient conditions, and give a single product 
in high yields. To obtain these characteristics, click reactions need a high 
thermodynamic driving force, while being orthogonal to other functional groups. 
Furthermore, these reactions should generate no or only inoffensive byproducts, 
which can be easily removed by nonchromatographic methods. The product 
should be stable under physiological conditions. Also the solvent, if required, 
should be benign and easy to remove. In the following paragraphs, the most 
common click reactions as well as their application in bioconjugation will be 
discussed. 
 
2.2 Types of click reactions 
Based on the above mentioned criteria, Sharpless, Kolb and Finn envisioned 
that most click reactions can be classified into the following categories: 1) 
cycloadditions of unsatured species (e.g. 1,3-dipolar cycloadditions and Diels-
Alder cycloadditions), 2) nucleophilic ring opening reactions (e.g. the opening of 
epoxides and aziridines), 3) carbonyl reactions of the non-aldol type (e.g. the 
formation of amides, (thio)ureas and heterocycles) and 4) addition reactions to 
carbon – carbon multiple bonds (e.g. epoxidations, aziridinations, and certain 
Michael additions).98 Of course, these reactions fulfill the click chemistry criteria 
to varying extents and therefore it is arguable which of these reaction types may 
or may not be considered as true click reactions. The reaction that truly stands out 
and is considered as the prototypical click reaction is the copper(I)-catalyzed 1,3-
dipolar cycloaddition between azides and terminal alkynes.99,100 In addition, 
several other reactions with azides have been reported that (closely) meet the 
Chapter 1 
___________________________________________________________________ 
30 
 
click chemistry criteria, including the reactions between azides and strained 
alkynes, triarylphosphines (Staudinger ligation) and oxanorbornadienes.101 
Furthermore, azides may also be replaced by other 1,3 dipoles such as nitrones 
and nitrile oxides.102,103 Since the cycloaddition between azides and (strained) 
alkynes plays an important role in chapters 2 – 4 of this thesis, these reaction 
types will be discussed in more detail in the next paragraph.  
 
2.3 The azide-alkyne cycloaddition 
The 1,3-dipolar cycloaddition between azides and alkynes to yield 1,2,3-
triazoles was first reported in 1893 by Arthur Michael (Figure 3A).104 The reaction 
is also known as the Huisgen azide-alkyne cycloaddition, named after Rolf Huisgen 
who further developed the reaction in the 1960s.105,106 Initially, the reaction 
required organic solvents and high temperatures or pressures, which severely 
limited its applications. However in 2002, both Sharpless et al. and Meldal et al. 
independently reported a copper(I)-catalyzed variant, also known as the 
copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC, Figure 3B).99,100 Copper(I) 
is able to activate terminal alkynes through formation of copper(I)-acetylide, 
which reacts rapidly with azides at room temperature, even in polar solvents such 
as water. Furthermore, CuAAC can be accelerated by using specific copper(I)-
ligands107 and is, in contrast to the uncatalyzed variant, highly regioselective with 
a clear preference for the 1,4-disubstituted triazole product. Thanks to these 
dramatically improvements, CuAAC truly meets all of the click chemistry criteria 
and is therefore often simply referred to as the click reaction. In the last decade, 
numerous studies have demonstrated the advantages of this cycloaddition in 
different applications,108 which are briefly discussed in paragraph 2.4 of this 
chapter.  
Although CuAAC is a versatile reaction, the toxic copper(I)-catalyst limits its 
applicability for in vivo labeling. Fortunately, an alternative way to enhance the 
reactivity, namely by using strained cyclooctynes, was reported by Bertozzi et al. 
in 2004.109 This variant is also known as the strain-promoted azide-alkyne 
cycloaddition (SPAAC, Figure 3C). Nowadays, numerous cyclooctyne variants have 
been developed with improved characteristics for in vivo labeling. Since the 
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initially developed plain cyclooctynes reacted relatively slow, more activated 
cyclooctynes have been developed by increasing ring strain and/or adding 
electron-withdrawing groups. The former was achieved through additional 
aromatic rings. In the case of dibenzocyclooctyne (DIBO), this resulted in an 
increased rate constant of approximately three orders of magnitude.110 
Electronwithdrawing groups are mostly added on the α position of the triple 
bond. Well-known examples are the mono- or difluorinated cyclooctynes 
developed by the group of Bertozzi.111,112 These improved cyclooctynes exhibit 
reaction kinetics comparable to those of CuAAC. However, a drawback is that 
these more activated cyclooctynes also show increased reactivity towards 
endogenous cellular molecules such as thiols.113 Furthermore, the hydrophobic 
nature of most cyclooctynes also facilitates nonspecific hydrophobic binding. The 
latter was circumvented by developing more hydrophilic cyclooctyne variants, for 
example by introducing a nitrogen atom within the strained ring system.114,115 The 
conjugated probe may also influence the behavior of cyclooctynes such as 
membrane  permeability.113  For  these  reasons,  it  is  obvious  that  different 
 
Figure 3. Overview of azide-alkyne cycloadditions. (A) Standard thermal cycloaddition, (B) 
copper(I)-catalyzed cycloaddition and (C) strain-promoted cycloaddition. 
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applications may require different types of cyclooctyne structures. Thanks to the 
diversity in developed cyclooctynes, various biomolecules can now be successfully 
labeled via SPAAC in vitro as well as in vivo, as briefly pointed out in paragraph 2.5 
of this chapter. 
 
2.4 Application of click chemistry in bioconjugation 
Since the introduction of the click chemistry concept, it has been widely 
applied in diverse research areas ranging from materials science to drug discovery 
and bioconjugation.116 In the field of bioconjugation, click reactions have been 
applied for the labeling of various biomolecules, including nucleic acids, peptides, 
proteins and glycans. Numerous studies demonstrated the highly efficient and 
specific click chemistry-based conjugation of different biomolecules to 
fluorophores, affinity tags, solid surfaces and many other desired functionalities. 
Although many of these studies were performed ex vivo, often using synthetic 
analogs of biomolecules, click chemistry had the most profound impact on the 
selective labeling of biomolecules within a complex biological environment, e.g. a 
cell lysate, tissue extract and even living cells or animals. The latter requires a 
slightly more specific set of criteria. Reactions must have fast rates under 
physiological conditions, while its components do not interfere with biological 
processes. Reactions that meet these criteria are known as bioorthogonal 
reactions and include the SPAAC and Staudinger ligation.117 CuAAC is also 
considered as a bioorthogonal reaction, but because of its need for the toxic 
copper(I)-catalyst it is rarely used in living biological systems.118 Bioorthogonal 
reactions are particularly useful for the chemical reporter strategy.117,119 This 
strategy is used in chapters 2 – 4 of this thesis and is therefore discussed in more 
detail in the following paragraph. 
 
2.5 Bioorthogonal chemical reporter strategy 
In the bioorthogonal chemical reporter strategy, one bioorthogonal functional 
group, referred to as the reporter, is incorporated into target biomolecules within 
living cells or animals. This is achieved by linking the chemical reporter to a 
General introduction 
___________________________________________________________________ 
33 
 
substrate that allows metabolic incorporation. In a second labeling step, the 
reporter serves as a handle that allows specific and efficient labeling of the target 
biomolecule via a bioorthogonal reaction, thereby enabling detection and/or 
purification of the target biomolecule (Figure 4). Depending of the purpose of the 
experiment, the bioorthogonal labeling step may either be performed in living 
cells and animals or in cell lysates and tissue extracts. An important advantage of 
the chemical reporter strategy is that it has eliminated the need for a large probe 
during metabolic incorporation, thereby reducing potential limitations resulting 
from steric effects. In addition, large probes often result in poor pharmacokinetic 
properties, thereby limiting in vivo applications.120 Another advantage is that the 
bioorthogonal ligation step increases the flexibility of the method, since the 
reporter allows conjugation to a probe containing any desired label, enabling 
either biotinylation, fluorescent labeling or covalent linkage to a solid support. 
The bioorthogonal chemical reporter strategy has been widely applied for 
global and site-selective labeling of various biomolecules.117 Global protein 
labeling has been achieved using unnatural amino acids such as 
azidohomoalanine, which allows visualization and identification of newly 
synthesized proteins via the CuAAC121 or SPAAC.113 On the other hand, site-specific 
protein  labeling  has  also  been  achieved  via  CuAAC  using  genetically  encoded 
 
Figure 4. Schematic representation of the bioorthogonal chemical reporter strategy based 
on SPAAC. The target biomolecule, which is depicted in red, is first metabolically labeled by 
using a specific substrate containing an azide-handle. In a second step, the target 
biomolecule is functionalized with the desired tag via the azide-alkyne cycloaddition, 
enabling detection and/or purification of the target biomolecule.  
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incorporation of alkyne-functionalized amino acids.122 For the CuAAC-based 
detection of global DNA and RNA synthesis, azide- and alkyne-functionalized 
analogues of thymidine123 and uridine124 have been developed. In addition, 
various modified biosynthetic precursors of glycans and lipids have been designed 
that allow click chemistry-based detection of global glycan and lipid synthesis as 
well as detection and identification of glycosylated and lipidated proteins.125,126 
The chemical reporter strategy proved to be particularly useful for studying 
glycans, which could not be visualized before since the enzymes involved in the 
metabolic labeling pathways do not tolerate metabolic precursor molecules that 
are conjugated to large tags. Other posttranslational modifications that have been 
monitored using the chemical reporter strategy include protein acetylation,127 
prenylation128 and methylation.129 Also the visualization of enzyme activities has 
been significantly improved by the introduction of a click chemistry variant of 
activity-based protein profiling (ABPP). Conventional ABPP relies on a labeled 
warhead group designed to react with residues in the target enzyme’s active site. 
In click chemistry-based ABPP, this warhead is modified with a small chemical tag 
instead of a bulky reporter tag, e.g. fluorophore or biotin.130 Recently, this 
strategy has also been applied for the labeling and visualization of catalytically 
active TG2 by using azide- and alkyne-functionalized TG2 inhibitors.92  
The above presented applications of the bioorthogonal chemical reporter 
strategy clearly indicate the significance of this method for the elucidation of 
biological processes as they occur in living cells or animals. Although in most 
studies the bioorthogonal labeling step is still performed ex vivo, recent 
improvements in bioorthogonal labeling reactions such as the SPAAC and the 
Staudinger ligation have demonstrated their applicability for in vivo imaging. For 
instance, SPAAC-based imaging of membrane-associated glycans has successfully 
been applied in living cells109 and even animals including zebrafish131 and mice.132 
Recently, also cell permeable cyclooctynes have been designed which may allow 
SPAAC-based labeling of azide-functionalized cellular proteins inside living cells.113  
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3. Outline of this thesis 
TG2-catalyzed crosslinking of proteins plays an important role in various 
cellular as well as pathological processes, as discussed in paragraphs 1.5 and 1.6 
of this chapter. Despite extensive research, the molecular mechanism by which 
TG2 affects many of these processes is still largely unknown. Much effort has 
been spent in the development of different methods for studying TG2-catalyzed 
crosslinking in vitro as well as in vivo. Although much improved, these methods 
are still limited in their applications.  
Chapters 2 – 4 describe the development of a click chemistry-based method 
to improve the detection of TG2 activity and/or its amine-acceptor substrates. As 
described above, click chemistry has been widely applied for the labeling of 
various biomolecules and has proven to be a valuable tool for studying different 
enzymatic activities, including posttranslational modifications. The advantage of 
this approach is that it eliminates the need for a large probe during the enzymatic 
labeling step, while simultaneously more flexibility is introduced during the 
ligation step.  
In Chapter 2 I describe the synthesis and characterization of a panel of four 
‘clickable’ amine-donor substrates for TG2, which contain an alkyne- or azide-
handle. These substrates allow, after being crosslinked to amine-acceptor 
substrates by TG2, specific labeling of these peptide or protein substrates via a 
bioorthogonal click reaction, namely the azide-alkyne cycloaddition.  
To ensure sensitive detection of the crosslinked azide- or alkyne-containing 
substrates, it is crucial that the azide-alkyne cycloaddition occurs in a highly 
specific and efficient manner. Chapter 3 presents a detailed characterization of 
the potential nonspecific protein labeling by alkynes, particularly cyclooctynes, 
when performing the azide-alkyne cycloaddition in a cell lysate. An optimized 
labeling procedure is described which allows a complete conversion of azide-
functionalized proteins, while limiting the amount of nonspecific protein labeling.  
The substrate properties of the azide- and alkyne-containing compounds are 
evaluated in Chapter 4 using HeLa and Movas cell lines as model systems. The 
incorporation of the azide- or alkyne-handle into TG2 substrate proteins is 
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detected by conjugating a fluorescent- or biotin-moiety via the optimized azide-
alkyne cycloaddition.  
Chapters 5 and 6 deal with functional aspects of TG2. It is believed that redox-
regulated activation/inactivation plays an important role in the functioning of TG2 
localized in the extracellular environment. Therefore, we investigated whether 
the redox state may affect the activity as well as physiological functions of 
extracellular TG2. In Chapter 5, we address the role of TG2 in inward remodeling 
of small arteries, which is a hallmark of essential hypertension and a strong 
predictor of cardiovascular events, including ischemic heart disease, heart failure, 
cerebral ischemic attacks and renal failure. In Chapter 6 we focus on the role of 
extracellular TG2 activity in cell migration using HeLa and Movas cell lines as 
model systems. Both chapters describe the effect of the redox state on the 
activity of extracellular TG2 and its potential implications in either arterial 
remodeling or cell migration.  
The most important findings of the research described in this thesis are 
discussed in Chapter 7. 
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Abstract 
Transglutaminase 2 catalyzes an acyl transfer reaction between a glutamine 
residue of a protein and either the -amino group of lysine, which, when this 
lysine is part of a polypeptide, leads to protein-protein crosslinking, or a primary 
amine substrate, leading to the conjugation of amines to proteins. Here, we 
describe the synthesis and characterization of a panel of four azide- or alkyne-
containing primary amine substrates for transglutaminase 2 that can be used for 
the specific labeling of the glutamine-donor proteins via the azide-alkyne 
cycloaddition. These substrates are characterized by their relatively small size and 
allow conjugation to any desired label or tag. The relatively straightforward 
synthetic routes, each consisting of 3 or 4 steps, yielded these substrates in more 
than 90% purity.  
 
 
Introduction 
Transglutaminase 2 (TG2; EC 2.3.2.13), also called tissue transglutaminase, 
catalyzes an acyl-transfer reaction in which the -carboxamide functionality of a 
peptidylglutamine acts as an acyl-donor. The most common acyl-acceptor in 
reactions catalyzed by TG2 is the -amino functionality of a peptidyllysine leading 
to the formation of an intermolecular or intramolecular -(-glutamyl)lysine bond. 
Alternatively, various small primary alkylamines can be used as amine-donor 
substrate, leading to the formation of different monosubstituted -amides (see 
Figure 2 of Chapter 1).3,4,133 The reaction mechanism of TG2 is based on a catalytic 
triad formed by Cys, His, and Asp residues and proceeds via an acyl-enzyme 
intermediate in which the active site cysteine is covalently bound to the 
peptidylglutamine via a thioester. In a second reaction step, a nucleophilic attack 
of the primary amine substrate on the thioester carbonyl results in the covalent 
bond between the peptidylglutamine and the peptidyllysine or small primary 
alkylamine. Since TG2 is less restrictive towards the amine-donor substrate, its 
crosslinking activity is generally detected using small primary alkylamines labeled 
with biotin, or with a radio-active or fluorescent group.85,134 
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In an attempt to improve the detection of TG2 activity, we designed four 
different amine-donor substrates functionalized with either an azide- or alkyne-
handle. These substrates can be crosslinked by TG2 to glutamine-donor proteins, 
after which specific labeling via the azide-alkyne cycloaddition can be 
performed.105,106 Two variants of this reaction, i.e. the copper(I)-catalyzed azide-
alkyne cycloaddition (CuAAC, see Figure 3B of Chapter 1)99,100 and the strain-
promoted azide-alkyne cycloaddition (SPAAC, see Figure 3C of Chapter 1),119,135 
are widely applied for the efficient and specific labeling of biomolecules in 
complex biological systems.109,126,128,131,132,136 The additional chemical ligation step 
has the advantage that, due to the relatively small size of the azide- or alkyne-
handle, the TG2 reaction will be less easily affected by steric interference and the 
substrates are predicted to pass biological membranes more efficiently. 
Furthermore, it allows more flexible labeling since any desired label can be 
introduced after the conjugation of the amine-donor substrate to the target 
molecule.  
Here we describe the synthesis and characterization of three azide- and one 
alkyne-functionalized amine-donor substrates for TG2 (Figure 1). All substrates 
contain a pentylamine moiety, which is required for efficient TG2-catalyzed 
crosslinking86,87 and is also present in other commonly used TG2 substrates, such 
as dansylcadaverine,137 5-(biotinamido)pentylamine (BPA)87 and FITC-
cadaverine.138 In substrate 1, which is the smallest of the four TG2 substrates, the 
azide is directly conjugated to the pentylamine. It has been demonstrated that the 
affinity of TG2 for both amine- and glutamine-donor substrates can be enhanced 
by introducing a small hydrophobic region, which was hypothesized to bind to a 
hydrophobic pocket near the active site of TG2.137,139 Therefore, substrate 2, 3 and 
4 also contain a linker region consisting of an amide bond and a small hydrophobic 
alkyl chain of variable length. A similar entity is also present in other commonly 
used TG2 substrates, such as BPA. Substrate 4, which is functionalized with an 
alkyne instead of an azide, was synthesized to analyze labeling via the azide-
alkyne cycloaddition in the reverse orientation. It also allowed us to determine 
whether the azide- or alkyne-moiety affects the substrate behaviour of the 
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molecule. The results of the TG2-catalyzed crosslinking and subsequent labeling 
step will be discussed in Chapter 4. 
 
Figure 1. Overview of the synthesized azide- and alkyne-functionalized TG2 amine-donor 
substrates 1-4.  
 
 
Materials and methods 
Reagents and solvents were used as commercially provided, unless stated 
otherwise. NMR spectra were recorded on a Varian Inova 400 (400 MHz for 1H) 
and a Bruker Avance III 500 (125 MHz for 13C). Chemical shifts () are reported in 
ppm and coupling constants (J) are reported in Hertz (Hz). ESI-MS analyses were 
performed using a Thermo Scientific Advantage LCQ linear-ion trap (LRMS). HPLC 
was conducted on a Shimadzu system (DGU-20A5, LC-20AT, SIL-20A, CMB-20A 
and CTO-20A) equipped with a Reprosil 100 C18, 3 µm, 150 mm × 3 mm analytical 
column (Screening Devices), UV-Vis (SPD-20A) and evaporative light scattering 
detector (Alltech ELSD 200ES). The following mobile phase gradient profile was 
applied: 0-5 minutes 5% acetonitrile/95% water, 5-30 minutes gradient to 95% 
acetonitrile/5% water, 30-40 minutes 95% acetonitrile/5% water. The mobile 
phase was supplemented with 0.1% trifluoroacetic acid. Infrared spectroscopy 
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was performed on a Thermo Mattson Nicolet 300 FTIR. Thin layer 
chromatography was carried out on Merck precoated silica gel 60 F-254 plates 
and the retardation factor (RF) is reported where applicable. Column 
chromatography was performed using Merck silica gel 60 (0.015-0.040 mm).  
 
N-tert-butoxycarbonyl-pentane-1,5-diamine (5) 
1,5-Diaminopentane was converted into the mono-protected N-tert-
butoxycarbonyl-pentane-1,5-diamine 5 as previously described.140 Shortly, a 
solution of di-tert-butyl dicarbonate (2.52 g, 12 mmol) in dioxane (30 mL) was 
added over a period of 2 hours to a solution of 1,5-diaminopentane (5.25 g, 51 
mmol) in dioxane (30 mL) and stirred overnight at room temperature. The solvent 
was removed using a rotary evaporator and the residue was taken up in water (50 
mL) and filtered. The filtrate was extracted with methylene chloride (3 × 50 mL). 
The organic layers were combined, washed with water (50 mL), dried over MgSO4 
and the solvent was removed using a rotary evaporator. N-Boc-pentane-1,5-
diamine 5 was obtained as a brown yellowish oil (2.05 g, 83%); RF = 0.17 
(chloroform/MeOH/H2O 65:25:4); LRMS (ESI+, m/z) [M+H]
+ calculated for 
C10H23N2O2: 203.2; found: 203.3. 
 
2-Azidoacetic acid (6) 
2-Chloroacetic acid (1.36 g, 14.4 mmol) was dissolved in water (15 mL) and 
cooled using an ice-bath. After adding NaN3 (4.00 g, 61.5 mmol) the mixture was 
allowed to warm to RT during a period of 16 hours. The mixture was acidified with 
concentrated HCl to pH 1, while contact with the formed toxic hydrazoic acid was 
avoided, and extracted with EtOAc (3 × 50 mL). The organic layers were combined, 
dried over MgSO4 and concentrated using a rotary evaporator. After co-
evaporation with methylene chloride (4 × 50 mL) the product was obtained as a 
slightly yellow liquid (1.16 g, 80%); RF = 0.59 (AcOH/MeOH/CH2Cl2 1:9:90); LRMS 
(ESI-, m/z) [M-H]- calculated for C2H3N3O2: 100.0; found: 100.3. 
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6-Azidohexanoic acid (7) 
Imidazole-1-sulfonyl azide hydrochloride (2.50 g, 11.9 mmol) was added to 6-
aminohexanoic acid (1.33 g, 10.1 mmol), K2CO3 (3.19 g, 23.1 mmol) and 
CuSO4·5H2O (25 mg, 0.1 mmol) in MeOH (50 mL) and stirred overnight at room 
temperature. The solution was filtered and the solvent was removed using a 
rotary evaporator. The residue was taken up in 1 M KHSO4 (75 mL) and extracted 
with EtOAc (3 × 50 mL). The organic layers were combined, dried over MgSO4 and 
the solvent was removed using a rotary evaporator. The product was obtained as 
a slightly yellow liquid (1.52 g, 96%); RF = 0.35 (chloroform/MeOH/H2O 65:25:4); 
LRMS (ESI-, m/z) [M-H]- calculated for C6H10N3O2: 156.1; found: 156.1. 
 
Substrate 1 (5-azidopentylamine hydrochloride) 
The unprotected primary amine of N-Boc-pentane-1,5-diamine 5 was 
converted into an azide using imidazole-1-sulfonyl azide hydrochloride as 
diazotransfer reagent.141 Imidazole-1-sulfonyl azide hydrochloride (1.00 g, 5 
mmol) was added to N-Boc-pentane-1,5-diamine (0.67 g, 3.3 mmol), K2CO3, (0.76 
g, 5.5 mmol) and CuSO4.5H2O (25 mg, 0.1 mmol) in MeOH (50 mL) and stirred 
overnight at room temperature. The solution was filtered and the solvent was 
removed using a rotary evaporator. The residue was taken up in 1 M KHSO4 (75 
mL) and extracted with EtOAc (3 × 50 mL). The organic layers were combined and 
the solvent was evaporated using a rotary evaporator. The residue was purified by 
column chromatography on silica gel (EtOAC/n-heptane 1:3) to afford tert-butyl 5-
azidopentylcarbamate as brown yellowish oil. A solution of the crude product in 
EtOAc (5 mL) was added dropwise to 2.3 M HCl in EtOAc (10 mL) and stirred 
overnight at room temperature. The solvent was evaporated using a rotary 
evaporator and the residue was dissolved in t-BuOH (20 mL) followed by 
evaporation of the solvent, the latter was repeated once. The residue was 
lyophilized from water (5 mL) to give 5-azidopentylamine hydrochloride 1 as an 
off-white solid (257 mg, 47%); 1H NMR (400 MHz, DMSO-d6)  7.94 (s, 3H), 3.29 (t, 
2H, J = 6.8 Hz), 2.71 (se, 2H, J = 6.2 Hz), 1.51 (m, 4H), 1.31 (m, 2H); 13C NMR (125 
MHz, CD3OD)  52.1, 40.6, 29.4, 28.1, 24.7; FT-IR max film: 3412, 2933, 2090, 
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1606, 1502, 1467, 1282, 1256; LRMS (ESI+, m/z) [M+H]+ calculated for C5H13N4: 
129.1; found: 129.1. 
 
Substrate 2 (N-(5-aminopentyl)-2-azidoacetamide hydrochloride) 
Dicyclohexylcarbodiimide (DCC) (0.76 g, 3.7 mmol) was dissolved in EtOAc (3.7 
mL) and added dropwise to a solution of N-Boc-pentane-1,5-diamine 5 (0.75 g, 3.7 
mmol) and 2-azidoacetic acid 6 (0.37 g, 3.7 mmol) in EtOAc (50 mL). The mixture 
was stirred overnight at room temperature and filtered. The filtrate was washed 
subsequently with 1 M KHSO4 (50 mL), water (50 mL), 5% NaHCO3 (50 mL), water 
(50 mL) and brine (50 mL). The EtOAc layer was concentrated using a rotary 
evaporator yielding tert-butyl 5-(2-azidoacetamido)pentylcarbamate as a brown 
yellowish oil, which was further purified by column chromatography on silica gel 
(EtOAC/n-heptane 1:1). Tert-butyl 5-(2-azidoacetamido)pentylcarbamate 
dissolved in EtOAc (5 mL) was added dropwise to 2.3 M HCl in EtOAc (10 mL) and 
the mixture was stirred overnight at room temperature. The solvent was 
evaporated using a rotary evaporator and the residue was dissolved in t-BuOH (20 
mL) followed by evaporation of the solvent, the latter was repeated once. The 
residue was dissolved in water (5 mL) and lyophilized to give N-(5-aminopentyl)-2-
azidoacetamide hydrochloride 2 as a slightly yellow oil which solidified in time to 
yield an off-white solid (345 mg, 42%); 1H NMR (400 MHz, DMSO-d6)  8.14 (t, 1H, 
J = 5.4 Hz), 7.86 (s, 3H), 3.76 (s, 2H), 3.04 (q, 2H, J = 6.5 Hz), 2.70 (se, 2H, J = 6.6 
Hz), 1.51 (m, 2H), 1.38 (m, 2H), 1.27 (m, 2H); 13C NMR (125 MHz, CD3OD)  170.2, 
53.0, 40.6, 40.0, 29.8, 28.1, 24.6; FT-IR max film: 3257, 2933, 2107, 1653, 1550, 
1260; LRMS (ESI+, m/z) [M+H]+ calculated for C7H16N5O: 186.1; found: 186.9. 
 
Substrate 3 (N-(5-aminopentyl)-6-azidohexanamide hydrochloride) 
N-(5-aminopentyl)-6-azidohexanamide hydrochloride 3 was synthesized 
according to the procedure described for N-(5-aminopentyl)-2-azidoacetamide 
hydrochloride 2 with the use of 6-azidohexanoic acid 7 instead of 2-azidoacetic 
acid 6 and EtOAC/n-heptane 3:1 as eluent for column chromatography. The 
product was obtained as an off-white solid (298 mg, 29%); 1H NMR (400 MHz, 
DMSO-d6)  7.84 (s, 3H), 7.76 (t, 1H, J = 5.4), 3.26 (t, 2H, J = 6.9), 2.97 (q, 2H, J = 
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6.5), 2.69 (se, 2H, J = 6.5 Hz), 2.01 (t, 2H, J = 7.3 Hz), 1.48 (m, 6H), 1.34 (qu, 2H, J = 
7.0 Hz), 1.24 (m, 4H); 13C NMR (125 MHz, CD3OD)  176.5, 52.3, 40.6, 40.3, 36.5, 
29.6, 29.5, 28.1, 27.3, 26.6, 24.7; FT-IR max film: 3265, 2928, 2094, 1632, 1554, 
1256; LRMS (ESI+, m/z) [M+H]+ calculated for C11H24N5O: 242.2; found: 242.3. 
 
Substrate 4 (N-(5-aminopentyl)pent-4-ynamide hydrochloride) 
N-(5-aminopentyl)pent-4-ynamide hydrochloride 4 was synthesized according 
to the procedure described for N-(5-aminopentyl)-2-azidoacetamide 
hydrochloride 2 with N-Boc-pentane-1,5-diamine 5 (0.97 g, 4.8 mmol) and the use 
of 4-pentynoic acid (471 mg, 4.8 mmol) instead of 2-azidoacetic acid 6. 
MeOH/CH2Cl2 1:9 was used as eluent for column chromatography. The product 
was obtained as an off-white solid (114 mg, 11%); 1H NMR (400 MHz, DMSO-d6)  
7.88 (m, 4H), 2.98 (q, 2H, J = 6.4), 2.71 (s, 1H), 2.67 (se, 2H, J = 6.5 Hz), 2.30 (m, 
2H), 2.20 (dt, 2H, J = 7.2 and 1.6 Hz), 1.49 (qu, 2H, J = 7.6 Hz), 1.34 (qu, 2H, J = 7.9 
Hz), 1.25 (qu, 2H, J = 7.5 Hz); 13C NMR (125 MHz, CD3OD)  174.1, 83.5, 70.4, 40.6, 
40.0, 36.0, 29.8, 28.1, 24.6, 15.8; FT-IR max film: 3300, 2941, 1632, 1558; LRMS 
(ESI+, m/z) [M+H]+ calculated for C10H19N2O: 183.2; found: 183.3. 
 
 
Results and discussion  
 
Introducing a single protective group into 1,5-diaminopentane 
All four TG2 substrates were synthesized using 1,5-diaminopentane, a well-
known TG2 substrate itself, as starting material. To ensure preservation of one 
amine-donor for TG2 in the final product, 1,5-diaminopentane was first converted 
into its mono-protected derivative using N-tert-butoxycarbonyl (Boc) as a 
protective group (Figure 2A). This was done by reacting di-tert-butyl dicarbonate 
((Boc)2O) with approximately 4.5 equivalents of 1,5-diaminopentane, which has 
previously been reported to provide a high yield of the mono-protected 1,5-
diaminopentane.140 After removal of the organic solvent and suspending the 
residue in water, the water-insoluble bis adduct could easily be removed from the 
reaction  mixture  by  filtration.  After  extraction  with  methylene  chloride,  the 
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Figure 2. Synthetic routes for azide- and alkyne-functionalized TG2 amine-donor 
substrates. (A) Conversion of 1,5-diaminopentane into mono-protected N-tert-
butoxycarbonyl-pentane-1,5-diamine 5. (B) Conversion of primary amines into azides using 
the diazo transfer reaction. (C) Introduction of azides through nucleophilic substitution. (D) 
Formation of the amide bonds.  
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mono-protected adduct 5, as confirmed by MS (Table 1), was obtained in 83% 
yield without any detectable impurities according to thin layer chromatography 
(TLC) analysis (data not shown). 
 
Introducing azide-moieties through the diazo transfer reaction 
Imidazole-1-sulfonyl azide hydrochloride is a diazo-transfer reagent allowing 
to convert primary amines into azides. This reaction proceeds via nucleophilic 
attack of the amine nucleophile onto the azide of imidazole-1-sulfonyl azide, 
resulting in the transfer of the diazo group and formation of imidazole-1-
sulfonamide. In the presence of a Cu(II)-catalyst, this reagent has been shown to 
efficiently convert a diverse range of primary amines into their corresponding 
azides under mild conditions.141 The Boc-protected derivative of substrate 1 was 
obtained by treating N-Boc-pentane-1,5-diamine 5 with the diazo-transfer reagent 
(Figure 2B). After purification and subsequent deprotection of the amine with HCl, 
substrate 1 was obtained in an overall yield of 43%.  
For the synthesis of substrates 2 and 3, the intermediate compounds 2-
azidoacetic acid 6 and 6-azidohexanoic acid 7 needed to be prepared (Figure 2B 
and 2C). Treatment of 2-aminoacetic acid (glycine) with the diazo-donor gave only 
small amounts of intermediate 6, which after purification by extraction was still 
contaminated with traces of unreacted starting material. To obtain intermediate 6 
in higher yields, an alternative approach using sodium azide was applied (see next 
 
Table 1. Overview of calculated and experimentally determined masses for compounds 1 – 7. 
Compound Structural 
formula 
(M+H)
+
 
calculated 
(M+H)
+
 
observed 
Substrate 1 C5H13N4 129.1 129.1 
Substrate 2 C7H16N5O 186.1 186.9 
Substrate 3 C11H24N5O 242.2 242.3 
Substrate 4 C10H19N2O 183.2 183.3 
N-tert-butoxycarbonyl-pentane-1,5-
diamine 5 
C10H23N2O2 203.2 203.3 
2-Azidoacetic acid 6 C2H3N3O2 100.0 100.3 
6-Azidohexanoic acid 7 C6H10N3O2 156.1 156.1 
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paragraph). Treatment of 6-aminohexanoic acid with the diazo-donor followed by 
purification by extraction gave a single reaction product according to TLC analysis 
(data not shown). MS analysis confirmed that the desired 6-azidohexanoic acid 7 
was obtained (Table 1). The yield of the product was 96%.  
 
Introducing azide-moieties through nucleophilic substitution 
In the alternative synthetic route towards 2-azidoacetic acid 6, the azide-
moiety was introduced via a nucleophilic substitution reaction (Figure 2C). This 
conventional method for the synthesis of organic azides is generally carried out 
using sodium azide as source for the azide anion.142 2-chloroacetic acid was 
reacted with approximately 4 equivalents of sodium azide, which gave the azide-
functionalized compound 6, as confirmed by MS (Table 1). After extraction the 
product was obtained in 80% yield without any detectable impurities according to 
TLC analysis (data not shown). 
 
Formation of the amide bonds using dicyclohexylcarbodiimide 
To obtain the Boc-protected derivatives of substrates 2, 3 and 4, the 
intermediate compound 5 was coupled via an amide bond to 2-azidoacetic acid 6, 
6-azidohexanoic acid 7 and 4-pentynoic acid, respectively (Figure 2D). These 
reactions were carried out in the presence of the coupling agent 
dicyclohexylcarbodiimide (DCC), which is commonly used for the formation of 
amides, anhydrides and esters.143,144 The advantage of DCC is that the N,N’-
dicyclohexylurea by-product can, due to its low solubility, be removed to a large 
extent by filtration. After purification and deprotection of the amine moiety, 
substrates 2, 3 and 4 were obtained in overall yields of 42, 29 and 11%, 
respectively.  
 
Characterization of TG2 substrates 1 – 4 
To confirm the presence of the introduced functional groups, we employed 
infrared spectroscopy. A strong absorption peak around 2100 cm-1, which is 
typical for N≡N asymmetric stretching, indicates the presence of the azide-
functionalities in substrates 1 - 3 (Figure 3, indicated with closed arrowheads). In 
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addition, substrates 2 - 4 showed strong absorption peaks around 1550 and 1630 - 
1650 cm-1 (Figure 3, indicated with asterisks). These peaks are typical for the 
carbonyl stretching vibrations of N-monosubstituted amides in solid state and 
therefore suggest the presence of the amide bonds in these substrates. All 
substrates show an absorption peak around 2930 cm-1, which may be explained 
by the presence of methylene groups (Figure 3, indicated with open arrowheads). 
Protonated primary amines typically show absorption peaks around 1500 and 
 
Figure 3.  Infrared  spectra  for  substrates  1 - 4.  Bands  corresponding  to  -CH2-,  -N3  and  
-CONH- functionalities are indicated with open arrowheads, closed arrowheads and 
asterisks, respectively. 
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1600 cm-1 caused by N-H bending vibrations. While substrate 1 indeed showed 
relatively weak peaks at 1502 and 1606 cm-1, this was not observed for the other 
substrates due to overlapping absorption peaks corresponding to the amides. 
Little evidence was obtained for the presence of a terminal alkyne in substrate 4. 
The stretching vibrations of the triple bond typically results in a weak absorption 
peak around 2100 - 2150 cm-1, which was not present. On the other hand, the 
weak absorption peak at 3300 cm-1 may be due to the stretching vibrations of the 
hydrogen of the alkyne.  
For a more detailed characterization of the structures of substrates 1 - 4, we 
used NMR spectroscopy. A detailed analysis of the 1H and 13C NMR spectra is 
shown in Figures 4 and 5, respectively (More detailed information regarding 
chemical shifts, splitting patterns and coupling constants can be found in the 
Materials and Methods section). Both 1H and 13C NMR confirmed the structures of 
all four TG2 substrates. Also the presence of a terminal alkyne in substrate 4, 
which was difficult to detect by infrared spectroscopy, could be confirmed (Figure 
4, proton j shows a singlet at 2.71 ppm; Figure 5, carbon 9 and 10 show a peak at 
70.4 and 83.5 ppm). Furthermore, only small amounts of impurities were 
detected by 1H NMR and 13C NMR (Figure 4 and 5, unassigned peaks). Also HPLC 
traces of substrates 1 - 4 indicate a high purity (Figure 6). Based upon the NMR 
and HPLC data, the purity was estimated at 90% for substrate 2 and 95% for 
substrates 1, 3 and 4 (The H2O solvent peak observed in the 
1H NMR spectrum of 
substrate 2 was also found in a DMSO control sample and therefore not included 
as impurity). Finally, the masses found for substrates 1, 3 and 4 correspond to the 
calculated masses (Table 1), although the mass of substrate 2 was slightly higher 
than expected. Altogether, these data show that all four substrates have been 
obtained in high purity. In Chapter 4, the TG2-catalyzed crosslinking of these 
substrates to glutamine-donor proteins and peptides will be evaluated both in 
vitro and in vivo. Furthermore, the capacity of the azide or alkyne handles to 
introduce labels via the azide-alkyne cycloaddition will be investigated.  
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Figure 4. 
1
H NMR spectra for substrates 1 - 4 in DMSO-d6. Product peaks are marked with 
the characters a-l corresponding to the protons as indicated in the insets. DMSO-d6 and 
H2O solvent peaks are indicated with arrowheads and asterisk, respectively. More detailed 
information regarding chemical shifts, splitting patterns and coupling constants is given in 
the Materials and Methods section. 
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Figure 5. 
13
C NMR spectra for substrates 1 - 4 in CD3OD. Product peaks are marked with 
the numbers 1-11 corresponding to the carbons as indicated in the insets. CD3OD solvent 
peaks are indicated with arrowheads. The exact values of the chemical shifts can be found 
in the Materials and Methods section. 
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Figure 6. Analytical HPLC traces of substrates 1 - 4. (A) Signals observed with the 
evaporative light scattering detector (ELSD). Substrate 1 could not by detected by ELSD due 
to its low boiling point. (B) Absorbance at 214 nm. The retention time of substrate 4 
overlapped with the DMSO solvent peak. 
 
 
Conclusions 
Here we report the successful synthesis of a panel of four amine-donor 
substrates for TG2. The substrates are functionalized with either an azide or 
alkyne, allowing derivatization via the azide-alkyne cycloaddition. The relatively 
straightforward synthetic route consists of only 3 or 4 steps leading to the 
production of substrates with purities above 90%.   
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Abstract 
The 1,3-dipolar cycloaddition of azides with ring-strained alkynes is one of the 
few bioorthogonal reactions suitable for specific biomolecule labeling in complex 
biological systems. Nevertheless, azide-independent labeling of proteins by 
strained alkynes can occur to a varying extent, thereby limiting the sensitivity of 
assays based on strain-promoted azide-alkyne cycloaddition (SPAAC). In this study 
a subset of three cyclooctynes, dibenzocyclooctyne (DIBO), azadibenzo-
cyclooctyne (DIBAC) and bicyclo[6.1.0]nonyne (BCN), was used to evaluate the 
azide-independent labeling of proteins in vitro. For all three cyclooctynes we show 
that thiol-yne addition with reduced peptidylcysteines is responsible for most of 
the azide-independent polypeptide labeling. The identity of the reaction product 
was confirmed by LC-MS and NMR analysis. Moreover, we show that undesired 
thiol-yne reactions can be prevented by alkylating peptidylcysteine thiols with 
iodoacetamide (IAM). Since IAM is compatible with SPAAC, a more specific azide-
dependent labeling is achieved by preincubating proteins containing reduced 
cysteines with IAM. 
 
 
Introduction 
Click chemistry refers to a set of chemical reactions that proceed rapidly in a 
highly specific and efficient manner, even within a complex chemical 
environment.98 Thanks to these unique properties click chemistry has become 
increasingly popular in diverse research areas, including polymer science, 
combinatorial drug development and the labeling and imaging of biomolecules in 
biological systems.116 The latter includes labeling of newly synthesized or modified 
biomolecules such as proteins, DNA or RNA.117,145 These applications require 
bioorthogonality, meaning that the reaction occurs efficiently under physiological 
conditions while its components are inert to biological functionalities.  
One of the most well-known click chemistry reactions is the 1,3-dipolar 
cycloaddition of azides with alkynes to form triazoles, which is also known as the 
azide-alkyne Huisgen cycloaddition (Figure 1A).105,106 The reaction with a terminal 
alkyne proceeds with tremendous rate enhancement upon addition of 
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substoichiometric amounts of copper(I), known as the copper(I)-catalyzed azide-
alkyne cycloaddition (CuAAC) or click reaction. CuAAC is characterized by efficient 
and specific conversion in aqueous solutions under mild conditions99,100 and has 
found numerous applications including the labeling of various biomolecules.108 
The use of a highly reactive strained cyclooctyne allows efficient and specific 
labeling under physiological conditions without the toxic copper(I) catalyst, 
enabling labeling of biomolecules in vivo.119,135 The strain-promoted azide-alkyne 
cycloaddition (SPAAC) has been applied for studying protein-protein 
interactions,146 determining DNA modifications147 and biological processes such as 
protein synthesis113 and lipidation of cell surface proteins.126 Furthermore, it has 
been used to detect biomolecules, such as glycoconjugates, in living cells109 and 
even in living animals such as zebrafish131 and mice.132  
The SPAAC is considered one of the very few bioorthogonal reactions suitable 
for labeling of biomolecules in vivo. However, it has been noted that strained 
alkynes can bind to a varying extent to biological functionalities in an azide-
independent manner, thereby limiting the sensitivity of assays based on this 
reaction.113,119 To improve the understanding of this reaction we investigated the 
azide-independent labeling for a panel of three strained cyclooctynes, 
dibenzocyclooctyne (DIBO), azadibenzocyclooctyne (DIBAC) and 
bicyclo[6.1.0]nonyne (BCN), all applicable for SPAAC (Figure 1B). DIBO is 
characterized by aromatic rings that provide excellent reaction kinetics in SPAAC, 
presumably due to additional ring strain and conjugation with the alkyne. DIBO 
was initially applied successfully for labeling of cell-surface glycoconjugates in 
living cells,110 but also appeared more generally applicable.114,147 DIBAC was 
designed to reduce the hydrophobicity of DIBO, which might compromise its 
bioavailability, while retaining the excellent reaction kinetics. This was done by 
introducing a nitrogen atom in the strained ring system and thereby interrupting 
the hydrophobic surface area. Conveniently, DIBAC proved to be slightly more 
reactive than DIBO when applied for the PEGylation of azido-containing protein 
CalB.114 Bicyclo[6.1.0]nonyne (BCN) is even less lipophilic due to the absence of 
the aromatic rings. The fused cyclopropane moiety strongly enhances the 
reactivity of plain cyclooctyne, resulting in comparable reaction kinetics as 
Improving the specificity of SPAAC 
___________________________________________________________________ 
61 
 
observed for DIBAC. Its relatively straightforward and scalable synthetic route 
makes this strained alkyne readily accessible. BCN was applied successfully for 
labeling of azido-containing virus capsid proteins and for labeling of cell-surface 
glycoconjugates in living cells.148 
Here we report that azide-independent protein labeling by strained 
cyclooctynes mainly occurs via thiol-yne addition at reduced peptidylcysteine 
residues. We show that blocking of the free thiol groups with the alkylating agent 
iodoacetamide (IAM) increases the specificity of SPAAC significantly without 
affecting the efficiency of the azide-alkyne cycloaddition itself. The latter is 
demonstrated using a SPAAC-based chemical reporter strategy117,119 to detect 
proteins post-translationally modified by transglutaminase 2 (TG2). 
 
 
Figure 1.  Azide-alkyne  cycloadditions  and  structures  of  alkynes  used  in  this  study.  
(A) Copper(I)-catalyzed (CuAAC) or strain-promoted azide-alkyne cycloaddition (SPAAC). 
(B) Biotinylated terminal and ring-strained alkynes. 
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Materials and methods 
Reagents and solvents were used as commercially provided, unless stated 
otherwise. Bovine serum albumin was purchased from Sigma. 1H NMR spectra 
were recorded on a Varian Inova 400. 1H NMR Chemical shifts () are reported in 
ppm and coupling constants (J) are reported in Hertz (Hz). ESI-MS analyses were 
performed using a Thermo Scientific Advantage LCQ linear-ion trap (LRMS). For 
LC-MS analysis the system was equipped with a Reprosil 100 C18, 3 µm, 150 mm x 
3 mm analytical column (Screening Devices) and a MeCN/water gradient 
containing 0.1% formic acid was applied (5-95%, 5-30 minutes). Thin layer 
chromatography (TLC) was carried out on Merck precoated silica gel 60 F-254 
plates and the retardation factor (RF) is reported where applicable. Column 
chromatography was performed using Merck silica gel 60 (0.015-0.040 mm). 5-
Azidopentylamine hydrochloride (Chapter 2) and the strained cyclooctynes 
DIBO,110 DIBAC114 and BCN,148 were synthesized as previously described. 
Expression and purification of recombinant rat HspB6 was performed as 
previously described.149  
 
Biotin-alkyne 
Propargylamine (2.91 µL, 66 µmol) was added to a solution of biotin-NHS 
(Sigma) (25 mg, 73 µmol) in DMSO (659 µL) and the mixture was rotated 
overnight at room temperature. A solution of 2 M Tris-HCl, pH 7.5 (300 µL) was 
added to block unreacted biotin-NHS and the mixture was rotated for 1 hour at 
room temperature. LRMS (ESI+, m/z) [M+H]+ calculated for C13H20N3O2S: 282.1; 
found: 282.1. 
 
Transglutaminase-catalyzed crosslinking of HspB6 
Reactions were performed in a volume of 50 µL containing 25 µM HspB6, 250 
µM acyl acceptor substrate, 5 µg guinea pig transglutaminase 2 (TG2, Sigma-
Aldrich), 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 20% glycerol and 5 mM CaCl2. 
Either 5-azidopentylamine or 5-(biotinamido)pentylamine (Invitrogen) was used 
as acyl acceptor substrate. Reactions were incubated for 2 hours at 37 °C.  
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Cell culture and preparation of lysates 
HeLa cells were cultured in Dulbecco’s modified Eagle’s medium (Invitrogen) 
and supplemented with 10% Fetal Bovine Serum Gold (PAA Laboratories). Cells 
were harvested using trypsin (Sigma-Aldrich). Cells were washed twice with 
phosphate-buffered saline (PBS) and resuspended in ice-cold lysis buffer (25 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP40, Complete EDTA-free Protease Inhibitor 
Cocktail (Roche)). Lysates were incubated on ice for 15 minutes, sonicated at 0 °C 
and centrifuged at 15,700 × g for 10 minutes at 4 °C. Protein concentrations of the 
supernatants were determined using the Pierce BCA Protein assay (Thermo 
Scientific). Lysates were either used directly for labeling with biotinylated alkynes 
or stored at −20 °C. 
 
Labeling with biotinylated alkynes 
The labeling reaction was performed in a PBS solution with a final volume of 
15 µL containing 100 µM of the appropriate alkyne and either 10 µg cell lysate 
proteins or 1 µg HspB6 crosslinked with 5-azidopentylamine. For Cu(I)-dependent 
cycloadditions 1.5 µL 10× freshly prepared working solution was added, 
containing 10 mM CuSO4, 10 mM sodium ascorbate and 10 mM tris((1-((O-
ethyl)carboxymethyl)-(1,2,3-triazole-4-yl))methylamine (triazole ligand). The 
reaction mixtures were incubated at 4 °C for 1 hour, after which 4× sample buffer 
(8% SDS, 20% -mercaptoethanol, 40% glycerol, 0.12% bromophenol blue and 1 
M Tris-HCl, pH 6.8; for the non-reducing condition -mercaptoethanol was 
omitted.) was added and reaction products were analyzed by SDS-PAGE and 
western blotting as described below.  
 
SDS-PAGE and western blot analysis 
Sodium dodecyl sulfate polyacrylamide gelelectrophoresis (SDS-PAGE) was 
performed according to standard procedures unless stated otherwise. Protein 
staining was performed according to standard protocols using Coomassie Brilliant 
Blue G 250 (Serva). Proteins were transferred to nitrocellulose membranes (GE 
Healthcare) by electroblotting. The membranes were incubated with primary 
antibodies (rabbit polyclonal anti-HspB6, mouse monoclonal anti--tubulin (GTU-
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88, Abcam)) or with NeutrAvidin DylightTM 800 (Pierce Biotechnology), which was 
used to detect biotinylated proteins. Bound antibodies were detected by 
incubation with IRDye 680CW-conjugated polyclonal goat anti-mouse or goat anti-
rabbit antibodies (Li-Cor) and visualized using an Odyssey Infrared Imaging System 
(Li-Cor). 
 
 
Results and discussion  
 
Reactivity of alkynes towards cellular proteins 
The reactivity of the strained alkynes DIBO, DIBAC and BCN and a terminal 
alkyne toward cellular proteins was evaluated by incubating the biotinylated 
alkynes with a HeLa cell lysate. The terminal alkyne was incubated together with 1 
mM CuSO4, 1 mM sodium ascorbate and 1 mM triazole ligand to mimic conditions 
required for CuAAC. Labeling was analyzed by SDS-PAGE followed by western 
blotting and detection of biotinylated polypeptides with labeled NeutrAvidin 
(Figure 2). Conjugation to cellular proteins was observed for all alkynes. The 
labeling pattern resembled the total protein pattern, indicating that the reactivity 
is largely directed against proteins in general, although some polypeptides 
appeared to be preferentially labeled. All cyclooctynes showed higher reactivities 
than observed for the terminal alkyne, suggesting that additional instability 
introduced by the ring-strain and/or the increased hydrophobicity enhances the 
efficiency by which they react with proteins. BCN and DIBAC resulted in more 
intense signals than DIBO, which fits with the previously reported observation 
showing a higher azide-independent cell-surface labeling for BCN than for DIBO.148 
 
Effect of IAM on the reactivity of alkynes towards cellular proteins 
 A likely candidate responsible for the azide-independent labeling of cellular 
proteins is the thiol group of reduced cysteines. In polymer chemistry the thiol- 
yne addition is often used as a radical reaction, which needs to be enhanced by 
light or a photoinitiator.150 However, spontaneous addition of cyclooctynes to 
thiols  may  occur  under  certain  conditions.113,151  To  investigate  if  alkynes  can 
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Figure 2. Reactivity of biotinylated alkynes 
with proteins in HeLa cell lysates. HeLa cell 
lysates were incubated for 1 hour without 
(-) or with a terminal alkyne or the strain-
promoted alkynes DIBO, DIBAC or BCN, all 
conjugated to biotin. Protein biotinylation 
was monitored by western blotting using 
labeled NeutrAvidin (upper panel), 
whereas total protein patterns were 
visualized by Coomassie Brilliant Blue 
(CBB) staining (lower panel). 
 
 
 
indeed react with peptidylcysteine side chains, thiol groups were blocked with 
iodoacetamide (IAM) (Figure 3A).152 HeLa cell lysates were pre-incubated with 1 or 
5 mM IAM for 30 minutes at room temperature and subsequently incubated with 
the biotinylated alkynes. After separation by SDS-PAGE, the proteins were 
analyzed by western blotting for biotin conjugation using labeled NeutrAvidin. As 
a loading control -tubulin was visualized (Figure 3B). Preincubation with IAM 
reduced the amount of proteins labeled by the cyclooctynes on average by 70-
80%, indicating that they are indeed mainly reactive with the free thiol group of 
peptidylcysteines. IAM treatment did not completely abolish labeling of proteins, 
which may be due to either incomplete alkylation of reduced cysteines or to 
reactivity of the cyclooctynes toward other functionalities in the proteins. Since 
protein biotinylation is not further repressed by increasing concentrations of IAM, 
the latter explanation seems more plausible. After the IAM treatment, DIBAC and 
BCN still gave the most profound labeling, suggesting that the more activated 
cyclooctynes are not only more reactive toward thiols, but also toward other 
functionalities in proteins. IAM treatment does not decrease labeling of proteins 
by the terminal alkyne, suggesting that only strained alkynes are reactive toward 
peptidylcysteines.  
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Figure 3. Reactivity of alkynes with 
HeLa cell proteins containing 
alkylated thiols. (A) Putative reaction 
of a thiol with a cyclooctyne and 
reaction of a thiol with 
iodoacetamide (IAM). (B) HeLa cell 
lysates were pre-incubated without 
or with 1 and 5 mM IAM and 
subsequently incubated with the 
biotinylated alkynes as indicated. 
Protein biotinylation was monitored 
by western blotting using labeled 
NeutrAvidin (upper panel). As a 
loading control -tubulin was 
detected by immunoblotting using a 
monoclonal antibody (lower panel). 
 
 
Reactivity of cyclooctynes toward thiols 
To confirm that thiols are the main reactive functionalities in proteins, we 
used heat shock protein 20 (HspB6) as a model. HspB6 contains one cysteine and 
in purified recombinant HspB6, which assembles into an oligomeric complex, this 
cysteine residue forms an intermolecular disulfide bridge with the cysteine of a 
neighboring subunit.153 The reactivity of the alkynes toward oxidized, reduced and 
alkylated HspB6 was determined to establish the contribution of the 
peptidylcysteine to biotin conjugation. Reduced HspB6 was obtained by 
incubating 1 mg/mL (56 µM) purified recombinant (oxidized) HspB6 with 1 mM 
dithiothreitol (DTT) for 30 minutes followed by dialysis to remove the remaining 
DTT. Alkylated HspB6 was obtained by incubating the reduced HspB6 with 1 or 5 
mM of IAM for 30 minutes. The resulting preparations of HspB6 were incubated 
with the alkynes, separated by non-reducing SDS-PAGE and analyzed by western 
blotting to detect both total levels of HspB6 isoforms and their biotinylation 
(Figure 4A). All cyclooctynes appeared to be reactive with the reduced HspB6, but 
not  or  to  a  much  lesser  extent  with  the  oxidized  or  alkylated  HspB6.  For  the 
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Figure 4. Reactivity of cyclooctynes towards thiols. (A) Oxidized (- DTT), reduced (+ DTT), 
and alkylated (1 and 5 mM IAM) HspB6 were incubated with the biotinylated terminal and 
ring-strained alkynes, separated by non-reducing SDS-PAGE and analyzed by western 
blotting using either labeled NeutrAvidin (upper panel) or antibodies to HspB6 (lower 
panel). The positions of the isoforms of HspB6 are indicated on the right. (B) Reduced 
HspB6 (4 µM) was incubated with the biotinylated cyclooctynes DIBO, DIBAC and BCN (0.1 
mM) in the presence of different concentrations of thiol-containing compounds. The thiol 
concentrations used for -mercaptoethanol (BME), dithiothreitol (DTT) and glutathione 
(GSH) were 0, 0.01, 0.1, 1, and 10 mM and for bovine serum albumin (BSA) 0, 0.001, 0.01, 
and 0.1 mM. Reduced HspB6 was included as a control (C). Polypeptides were separated by 
SDS-PAGE and analyzed by western blotting using either labeled NeutrAvidin or antibodies 
to HspB6. 
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terminal alkyne no labeling could be detected, regardless of the state of HspB6. 
These data substantiate the reactivity of the strained cyclooctynes with thiols in 
proteins. Labeled monomeric HspB6 migrated slightly slower than the non-labeled 
monomer, which is most likely due to the mass increase resulting from biotin-
cyclooctyne conjugation. The appearance of a single sharp band for the labeled 
HspB6 monomer is consistent with the presence of a single cysteine in this 
protein. Furthermore, all cyclooctynes, but DIBAC and BCN in particular, showed a 
weak labeling of oxidized and alkylated HspB6 (Figure 4A), indicating that labeling 
can occur via other functionalities, although free peptidylcysteines are clearly 
preferred. This result fits with the observation that the labeling of the lysate 
proteins was not completely abolished by preincubation with IAM (Figure 3).  
Cyclooctynes have a hydrophobic nature which may contribute to non-specific 
interactions with proteins. Such interactions may favor reactivity toward 
peptidylcysteines over non-peptidyl thiols. To investigate this possibility reduced 
HspB6 was incubated with the cyclooctynes for 1 hour at 4 C in either the 
absence or the presence of increasing concentrations of -mercaptoethanol 
(BME), DTT, glutathione (GSH) or bovine serum albumin (BSA), which contains one 
free thiol (peptidylcysteine). Due to gel loading limitations the highest 
concentration used for BSA (0.1 mM) was 100-fold lower than that for the small 
thiol-containing molecules. The results of the western blot analysis (Figure 4B) 
showed that a 250- and 2500-fold excesses of BME, DTT and GSH compared to the 
peptidyl thiol of HspB6 reduced the labeling of HspB6. At 25-fold excess weak 
competition could be observed for BSA as well as for BME, DTT and GSH, showing 
that the peptidylcysteine in BSA competes as well as a non-peptidyl thiol, 
indicating that cyclooctynes do not have a preference for peptidyl thiols.  
 
Effect of thiol-yne addition on the selectivity of SPAAC  
To show that the reaction of cyclooctynes with azides is much more efficient 
than with thiol groups competition experiments were performed between benzyl 
azide and L-glutathione with BCN and DIBAC and analyzed by NMR (Figure S1 and 
S2). After a complete reaction only SPAAC products could be detected and no 
thiol-yne products. Also DIBO has been shown to be highly reactive towards 
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azides but not toward thiols.110 However, these results cannot be extrapolated to 
the labeling of azido-functionalized proteins, not only because the ratios between 
azides, thiols and cyclooctynes are different, but also because detection of 
cyclooctyne labeling by western blotting is much more sensitive than by NMR.  
To test whether the cyclooctynes also specifically undergo SPAAC when 
incubated with an azido- and thiol-containing protein, HspB6 was functionalized 
with an azide using transglutaminase 2 (TG2). TG2 catalyzes the formation of 
isodipeptide bonds between the -amino group of peptidyllysine or small primary 
amine substrates and the -carboxamide group of peptidylglutamine.3 This 
crosslinking activity is generally monitored with labeled acyl acceptor substrates, 
such as 5-(biotinamido)pentylamine (BPA), which can be covalently attached to a 
subset of acyl donor substrate proteins by TG2. Here, the azido-functionalized 
pentylamine (Figure 5A) was used as a TG2 acyl acceptor substrate to label 
recombinant HspB6, which is an excellent acyl donor substrate (Figure 5B).45,149 
Reduced HspB6 was incubated with either 5-azidopentylamine or the directly 
biotinylated substrate BPA in the presence or absence of active TG2. Reactions 
with 5-azidopentylamine were incubated with or without IAM (1 mM) for 30 
minutes at room temperature and subsequently biotinylated via SPAAC using 
either DIBO, DIBAC or BCN. Reaction products were separated by SDS-PAGE and 
analyzed by western blotting for biotinylated proteins and HspB6 (Figure 5C). TG2-
catalyzed intermolecular crosslinking leads to the formation of di- and multimeric 
isoforms of HspB6.45,149 When the enzymatic reaction was performed in the 
presence of BPA, TG2-dependent labeling of the different forms of HspB6 was 
observed. When the enzymatic reaction was performed in the presence of 5-
azidopentylamine followed by incubation with the biotinylated cyclooctynes, a 
comparable biotinylated polypeptide pattern was obtained. This indicates that the 
TG2-dependent introduction of an azide handle in HspB6 and the subsequent 
cyclooctyne-mediated biotinylation proceeds efficiently. However, additional 
bands (Figure 5C, indicated by arrowheads) were observed at the monomer and 
dimer positions, the appearance of which was repressed by pre-incubation with 
IAM. More slowly migrating TG2 reaction products, representing HspB6 
multimers, also became less intense, suggesting that these products were labeled 
Chapter 3 
___________________________________________________________________ 
70 
 
 
Figure 5. Effect of IAM on SPAAC-based detection of transglutaminase-catalyzed labeling 
of HspB6. (A) Structures of the biotinylated and azido-functionalized transglutaminase acyl 
acceptor substrates. (B) Introduction of an azide handle in HspB6 with the TG2-catalyzed 
acyl-transfer reaction and 5-azidopentylamine. (C) 5-azidopentylamine was crosslinked to 
reduced HspB6 by TG2 and subsequently incubated with or without 1 mM IAM for 30 
minutes, followed by incubations with biotinylated DIBO, DIBAC or BCN. Incubations 
without alkyne and/or TG2 were used as negative controls. The biotinylated TG2 substrate 
BPA was used as positive control for TG2 activity. HspB6 isoforms were separated by SDS-
PAGE and analyzed by western blotting using either labeled NeutrAvidin (upper panel) or 
antibodies to HspB6 (lower panel). The monomeric and dimeric HspB6 azide-independent 
and azide-dependent reaction products are indicated by arrowheads and asterisks, 
respectively. 
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both in an azide-dependent and -independent manner. The ratio between azide-
dependent and -independent labeling could not be improved by reducing 
incubation time and/or lowering the cyclooctyne concentration (data not shown). 
These results show that although the cyclooctynes are much more reactive 
toward azides, their selectivity may be limited in proteins containing free thiols. 
However, it should be noted that free thiols are relatively uncommon in proteins 
exposed to non-reducing conditions, such as extracellular proteins. Importantly, 
IAM treatment did not reduce the intensity of the bands of the monomer and 
dimer products that were solely labeled via the incorporated 5-azidopentylamine 
(Figure 5C, indicated by asterisks). Hence, IAM treatment improves the specificity 
of SPAAC and thereby results in a higher signal-to-noise ratio.  
 
Identification of the thiol-cyclooctyne conjugate 
To identify the reaction product of the thiol-yne addition we used biotinylated 
BCN and GSH, thereby assuming that a vinyl sulfide would be formed by direct 
addition of the thiol to the alkyne triple bond (Figure 6A). The two compounds 
were incubated either separately or as a mixture for 72 hours at 4 C and 
subsequently analyzed by LC-MS. When incubating BCN and GSH together, a 
product was generated as indicated by the altered chromatographic elution 
profile (Figure 6B). The product shows an m/z of 902.6 in the positive mode 
(Figure 6C), which corresponds to the mass (M+H) of the predicted compound for 
thiol-yne addition (Figure 6A). Furthermore, beside the single adduct also a 
double adduct formed by a tandem thiol-yne/thiol-ene reaction could be 
observed by MS analysis when incubating non-labeled BCN with cysteine methyl 
ester (Figure S3). 
Thiol-yne addition was further examined by 1H NMR analysis of the purified 
reaction product formed by the incubation of non-labeled BCN with cysteine in 
D2O. The NMR spectrum was consistent with the direct addition of the thiol to the 
alkyne leading to the corresponding vinyl sulfide (Figure S4). Additionally, a partial 
protonation was observed (approximately 13%) instead of deuteration of the 
double bond of the resulting vinyl sulfide. This suggests a radical-based 
mechanism: a purely nucleophilic mechanism involving attack of thiolate anion  
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Figure 6. (on the left page) Analysis of the reaction product of BCN and glutathione (GSH). 
(A) The putative reaction of BCN with GSH. (B) 1 mM BCN and 1 mM GSH were incubated 
separately or together for 72 hours at 4 °C and analyzed by electrospray LC-MS. Ion 
chromatograms (positive mode) show the elution profiles of the starting materials (#) and 
the reaction products (the main product is marked with an asterisk). (C) Mass spectrum 
(positive mode) at the retention time of the main reaction product (*).  
 
onto the triple bond of the alkyne would generate an intermediate vinyl sulfide 
anion, expected to instantaneously abstract deuterium from D2O. In contrast, a 
radical-based mechanism would involve an intermediate vinyl sulfide radical that 
is likely to abstract (to some extent at least) a hydrogen radical from a (non-
deuterated) thiol. Moreover, a radical-based mechanism, facilitated by reactive 
oxygen species, has also been suggested previously for the spontaneous addition 
of thiols to alkynes.151 However, no detectable reduction of the azide-
independent labeling of cellular proteins by DIBO, DIBAC or BCN was observed 
when adding up to 5 mM of sodium ascorbate (data not shown). The latter 
suggests that the reaction mechanism might be dependent on the experimental 
conditions that are used. 
Our results clearly demonstrate that cyclooctynes are susceptible to thiol-yne 
addition with peptidylcysteines. These conjugation reactions are responsible for 
the majority of the undesired azide-independent labeling when performing SPAAC 
with a cell lysate. Although other investigators report differently,154 we observed a 
strong IAM-dependent repression of thiol-yne addition, and as a consequence a 
significantly enhanced specificity of labeling via SPAAC. While being compatible 
with SPAAC itself, IAM treatment is therefore favored when labeling azido-
modified proteins in a cell lysate, for example with fluorescent or biotin tags for 
visualization or with biotin or epitope tags for purification.  
When cyclooctynes are applied in living cells or animals, pre-incubation with 
IAM is undesired since this reagent will interfere with biological processes. 
However, in case of in vivo labeling of extracellular proteins with a membrane-
impermeable cyclooctyne the background problem will be limited, because most 
extracellular peptidylcysteines are in the oxidized state and thus do not react. 
Nevertheless, when injected into mice, cyclooctynes have been reported to react 
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in an azide-independent manner with serum albumin, which contains in contrast 
to BSA two reduced cysteines.132 Due to the very high abundance of albumin, the 
non-specific binding may severely reduce the availability of the cyclooctyne at the 
sites where the azide functionalities are present and in this way may indirectly 
affect the efficiency of azide detection.  
Alternatively, variants of cyclooctynes may be designed that are less prone to 
thiol-yne addition and thereby may display more selective labeling. The 
cyclooctynes investigated here indeed show considerable variation in their 
reactivity toward thiols, thus giving space for improvements. Also a variation in 
reactivity toward thiol was shown for the cell-permeable difluorinated 
cyclooctyne and the less reactive mono- or non-fluorinated variants.113 While 
more reactive cyclooctynes are usually favored for their superior azide-dependent 
labeling, their possible reactivity toward thiols should be taken into consideration 
when highly specific labeling is required. 
  
 
Conclusions 
Cysteine thiols are the major reactive functionalities responsible for azide-
independent labeling of proteins with cyclooctynes. Our data indicate that thiols 
in general are susceptible to thiol-yne addition, since no clear preference for 
specific peptidylcysteines was observed. Alkylation of peptidylcysteines with IAM 
results in a strong reduction of the azide-independent labeling of proteins by 
cyclooctynes. Since IAM is compatible with SPAAC, pre-incubation with this 
reagent is recommended to achieve a more specific azide-dependent labeling.  
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Figure S1. Competition between benzyl azide and L-glutathione with BCN. A solution of 
BCN (2.3 mg, 0.015 mmol) in CD3CN/D2O 1:2 (1 mL) was added to a solution of benzyl azide 
(BnN3, 4.2 mg, 0.030 mmol) and L-glutathione (GSH, 9.2 mg, 0.030 mmol) in CD3CN/D2O 
1:2 (2 mL). The progress of the reaction was checked with 
1
H NMR. BCN completely reacted 
within 2 hours (BCN -CH2-OH at  3.57, indicated by #). The peak corresponding to BnN3 
decreased in time (BnN3 PhCH2N3 at  4.30, indicated by open arrowheads), while peaks 
corresponding to GSH remained unchanged (GSH at  3.83 and 3.65, indicated by closed 
arrowheads). Furthermore, only formation of the triazole product of BCN and BnN3 could 
be observed (triazole -CH2-OH at  3.52, indicated by asterisks). Peaks at  3.75 (BCN 
spectrum) and 4.43 (BCN + BnN3/GSH spectra) correspond to D2O. 
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Figure S2. Competition between benzyl azide and L-glutathione with DIBAC. (A) 
Competition experiment between benzyl azide and L-glutathione with DIBAC. A solution of 
DIBAC (4.8 mg, 0.015 mmol) in CD3CN/D2O 1:2 (4 mL) was added to a solution of benzyl 
azide (BnN3, 4.2 mg, 0.030 mmol) and L-glutathione (GSH, 9.2 mg, 0.030 mmol) in 
CD3CN/D2O 1:2 (2 mL). The progress of the reaction was checked with 
1
H NMR. DIBAC 
completely reacted within 7 minutes (DIBAC -CH2-N- at  5.03, indicated by #). (B) To show 
that the formation of thiol-yne addition products are very inefficient, a solution of DIBAC 
(4.8 mg, 0.015 mmol) and L-glutathione (23.1 mg, 0.075 mmol, 5 equiv.) in CD3CN/D2O 1:1 
was stirred at rt. The progress of the reaction was checked with 
1
H NMR. Even after 20 
days, no thiol-yne addition products could be detected while DIBAC was still present (DIBAC 
-CH2-N- at  5.03, indicated by #), indicating that DIBAC is highly stable in the presence of 
GSH.  
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Figure S3. Formation of BCN-L-(+)-cysteine methyl ester adducts. A solution of BCN (15 mg, 
0.10 mmol) and L-(+)-cysteine methyl ester.HCl (51 mg, 0.30 mmol) in deoxygenated 
CH3CN/H2O (1:1, 200 μL) was stirred at rt and progress of the reaction was checked by 
LCQ. After 2 hours, mass spectrometry indicated the formation of a significant amount of 
the mono thiol-yne adduct (m/z M+1: 286), as well as the formation of a double adduct, 
formed by a tandem thiol-yne/thiol-ene reaction (m/z M+1: 421).  
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Figure S4. (on the left page) Characterization of BCN-L-(+)-cysteine adduct by (A) MS and 
(B) 
1
H-NMR. A solution of BCN (30 mg, 0.20 mmol) and L-(+)-cysteine (73 mg, 0.600 mmol) 
in CD3CN/D2O (ratio 1:2, total 2.25 mL) was stirred at rt for 1 week. Solvents were 
evaporated under reduced pressure and the residue was purified by silica gel column 
chromatography (CH3CN/H2O=7:3) to afford the thiol-yne adduct as a 87:13 mixture of two 
compounds, containing either deuterium (D) or hydrogen (H) at the olefinic position 
(combined 20 mg, 37%). (A) HRMS (ESI+) m/z calculated for C13H21DNO3S (M + H)
+
: 
273.1383, found: 273.1378. (B) 
1
H NMR (D2O, 400 MHz):  6.11-6.06 (m, 0.13H), 3.90 (dt, J 
= 9.0, 3.7 Hz, 1H), 3.74 (d, J = 7.2 Hz, 2H), 3.47-3.36 (m, 1H), 3.03 (ddd, J = 30.2, 14.9, 9.1 
Hz, 1H), 2.77-2.68 (m, 1H), 2.53-2.43 (m, 1H), 2.40-2.12 (m, 3H), 2.07-1.96 (m, 1H), 1.71-
1.55 (m, 2H), 1.18-1.00 (m, 3H).  
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Abstract 
Transglutaminase 2 (TG2) is a Ca2+-dependent enzyme able to catalyze the 
formation of (-glutamyl)-lysine crosslinks between polypeptides, resulting in 
high molecular mass multimers. We have developed a bioorthogonal chemical 
method for the labeling of TG2 glutamine-donor proteins. As amine-donor 
substrates we used a set of azide- and alkyne-containing primary alkylamines that 
allow, after being crosslinked to glutamine-donor proteins, specific labeling of 
these proteins via the azide-alkyne cycloaddition. We demonstrate that these 
azide- and alkyne-functionalized TG2 substrates are cell permeable and suitable 
for specific labeling of TG2 glutamine-donor substrates in HeLa and Movas cells. 
Both the Cu(I)-catalyzed and strain promoted azide-alkyne cycloaddition proved 
applicable for subsequent derivatization of the TG2 substrate proteins with the 
desired probe. This new method for labeling TG2 substrate proteins introduces 
flexibility in the detection and/or purification of crosslinked proteins, allowing 
differential labeling of cellular proteins. 
 
 
Introduction 
Transglutaminase 2 (TG2) catalyzes an acyl-transfer reaction between the -
carboxamide functionality of a peptidylglutamine (Q) and either the -amino 
functionality of a peptidyllysine (K), leading to protein crosslinking, or a primary 
alkylamine such as putrescine, spermidine and spermine, leading to the formation 
of different monosubstituted -amides.3,4,133 Beside the crosslinking activity, TG2 
also displays GTPase,155 ATPase156 and protein disulfide isomerase157 activity. The 
crosslinking activity of TG2 is a two-step reaction that is tightly regulated by 
calcium and GTP.15 The reaction starts with a nucleophilic attack by the thiol of 
the active-site cysteine on the -carboxamide of the amine-acceptor 
peptidylglutamine, leading to the formation of a thiolester intermediate and the 
release of ammonia. In the second step, the acyl group is transferred to the amine 
donor.3,40 While TG2 is very restrictive toward the amine-acceptor glutamine 
residue, a wide variety of amine donors can be utilized.3,4,43 Under certain 
conditions, the amine can even be replaced by water and alcohols, leading to 
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deamidation and esterification, respectively.41,158 The crosslinking activity of TG2 is 
involved in a wide variety of processes including apoptosis, cell motility, cell 
differentiation, formation and remodeling of the extracellular matrix and wound 
healing.3,4 Furthermore, posttranslational modifications introduced by TG2 have 
also been associated with various pathological conditions, such as deamidation of 
gluten peptides in celiac disease159 and crosslinking, polyamination and 
deamidation of aggregated proteins in neurodegenerative diseases.133 
To gain more insight in the role of TG2-catalyzed crosslinking in cellular and 
pathological processes, various methods for monitoring TG2 activity have been 
developed.84,85 Since TG2 is less restrictive towards the amine donor, these assays 
are often based on labeled primary alkylamine substrates such as 
dansylcadaverine and 5-(biotinamido)pentylamine (BPA), which can be detected 
via western blotting, ELISA, or immunocytochemistry. To further improve these 
detection methods, we developed a method based on the bioorthogonal chemical 
reporter strategy.117,119 In this approach, the amine donor is functionalized with a 
small chemical handle, which, after being incorporated in the amine-acceptor 
substrate protein by activated TG2, can be labeled via a bioorthogonal chemical 
ligation reaction. The advantage of this approach is that the introduced chemical 
handle is smaller than a conventional label, and therefore, may allow crosslinking 
to structurally less accessible amine-acceptor glutamine residues as well. In this 
way, amine-acceptor sites that exclusively allow incorporation of small (naturally 
occurring) polyamines may be revealed. Furthermore, the chemical ligation step 
increases the flexibility of the method, since the handle allows conjugation to a 
probe containing any desired label, enabling biotinylation, fluorescent labeling 
and covalent linkage to a solid support. 
Only a few reactions, often collectively termed click chemistry,98 have the 
characteristics required for efficient and specific labeling of tagged molecules in 
complex systems. These click reactions need to be fast, selective, high yielding 
and proceed in water. A prototypical click reaction is the Cu(I)-catalyzed azide-
alkyne cycloaddition (CuAAC), which is a triazole-forming reaction between an 
alkyne and an azide.99,100 Over the last decade, this reaction has proven to be 
extremely well suitable for the labeling of posttranslationally modified 
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biomolecules including protein glycosylation,136 lipidation126 and prenylation.128 
Recently, CuAAC has been applied for the detection of the active form of TG2 
using azide- or alkyne-containing inhibitors.92 In order to circumvent the use of 
the toxic Cu(I) catalyst, which significantly reduced in vivo applicability, also highly 
strained cyclooctynes can be used for reactions with azides.101,119,135 This strain-
promoted azide-alkyne cycloaddition (SPAAC) has been successfully applied to 
label biomolecules in living cells109 or animals.131,132 
Here, we demonstrate that azide-functionalized amine-donor substrates are 
efficiently crosslinked by TG2 in living cells and that their subsequent labeling can 
be performed effectively via either CuAAC or SPAAC. Furthermore, we show that 
the azido group of the amine-donor substrate can be replaced by an alkynyl group 
allowing detection of the crosslinked product via conjugation with a labeled azide. 
With this two-step approach crosslinked TG2 substrates can be functionalized 
with one or more labels depending on the purpose of the experiment. 
 
 
Materials and methods 
Reagents and solvents were used as commercially provided, unless stated 
otherwise. Biotin-azide and Alexa555-azide were purchased from Invitrogen. The 
TG2 inhibitor Z006 was purchased from Zedira. ESI-MS analyses were performed 
using a Thermo Scientific Advantage LCQ linear-ion trap (LRMS). HPLC was 
conducted on a Shimadzu system (DGU-20A5, LC-20AT, SIL-20A, CMB-20A and 
CTO-20A) equipped with UV-Vis (SPD-20A) and evaporative light scattering 
detector (Alltech ELSD 200ES). For both LC-MS and HPLC analysis a Reprosil 100 
C18, 3 µm, 150 mm × 3 mm analytical column (Screening Devices) was used and 
applied with the following mobile phase gradient profile: 0-5 minutes 5% 
acetonitrile/95% water, 5-30 minutes gradient to 95% acetonitrile/5% water, 30-
40 minutes 95% acetonitrile/5% water. The mobile phase was supplemented with 
0.1% formic acid and trifluoroacetic acid for LC-MS and HPLC measurements, 
respectively. Fluorescent imaging of fixed cells was performed using the Leica-
DMRA microscope equipped with COHU CCD camera and QFluoro 1.2 software. 
The biotinylated terminal alkyne (Chapter 3) and the cyclooctynes DIBO,110 
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DIBAC114 and BCN,148 were synthesized as previously described. Expression and 
purification of recombinant rat HspB6 was performed as previously described.149 
 
Q-peptide 
Biotin-GQEPVR was synthesized on solid support (Wang resin) using standard 
Fmoc-based peptide synthesis methods and commercially available Fmoc amino 
acids. LRMS (ESI+, m/z) [M+H]+ calculated for C38H63N12O12S: 911.5; found: 911.5. 
 
K-peptide  
Biotin-GNEPVK was synthesized analogously to 9. LRMS (ESI+, m/z) [M+H]+ 
calculated for C37H60N10O12S: 869.4; found: 869.5. 
 
Transglutaminase-catalyzed crosslinking of HspB6 
Reactions were performed in a solution of 50 mM Tris-HCl, pH 7.5, 150 mM 
NaCl, 20% glycerol and 5mM CaCl2. The crosslinking reactions of substrate 1-3 
with the Q-peptide were performed in a total volume of 1200 µL containing 1 mM 
Q-peptide, 1 mM of the appropriate amine-donor substrate and 13 µg/mL gpTG2 
(≥1.5 U/mg, Sigma). Reactions were incubated at 37°C and at the indicated time-
points 190 µL of each reaction was mixed with 10 µL 0.5 M EDTA and subjected to 
HPLC or LC/MS analysis. The crosslinking reactions with HspB6 were performed in 
a total volume of 50 µL containing 25 µM HspB6, 250 µM of the appropriate 
primary amine substrate and either no or 50 µg/mL gpTG2. Reactions were 
incubated for 2 hours at 37°C followed by labeling with biotinylated probes and 
SDS-PAGE and western blot analysis (see below). 
 
Transfection 
TG2 specific siRNAs (TG2 siRNA1 and TG2 siRNA2) and a control siRNA (GFP 
siRNA) were purchased from Eurogentec. The sequences of TG siRNA1, TG2 
siRNA2 and GFP siRNA are 5’-GCGUCGUGACCAACUACAAdTdT-3’, 5’-
ACCUUCUCAUCGAGUACUUdTdT-3’ and 5’-CCAUGUAACCGUAAGAAUAdTdT-3’, 
respectively. pIRES-HspB6 construct has been described before.149 Approximately 
24 hours prior to siRNA or DNA transfection HeLa cells were plated in DMEM with 
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10% fetal calf serum in six-well plates. HeLa cells were transfected either with 20 
µM siRNA using OligofectamineTM reagent (Invitrogen), or with a total of 1 µg of 
pIRES-HspB6 DNA per well using FuGENE6TM (Roche), both in accordance with the 
manufacturer’s instructions. HeLa cells were labeled with primary amine 
substrates approximately 24 hours posttransfection (see below). 
 
Labeling of HeLa cells with primary amine substrates 
Approximately 3 × 105 HeLa cells were plated in DMEM with 10% fetal calf 
serum in six-well plates. After 24 hours, HeLa cells were incubated as indicated 
with 250 µM of the appropriate substrates, 10 µM A23187 and/or 50 µM Z006. 
After 2 hours cells were harvested either by scraping or by removing the 
supernatant medium, incubating with 200 µL Non-enzymatic Cell Dissociation 
Solution (Sigma) and recombining with the supernatant medium. Cells were 
washed twice with PBS and resuspended in ice-cold lysis buffer [25 mM Tris-HCl, 
pH 7.5, 150 mM NaCl, 1% NP40, Complete EDTA-free Protease Inhibitor Cocktail 
(Roche)]. Lysates were incubated on ice for 15 minutes, sonicated (5 times 30 
seconds at 0°C) and centrifuged at 13,000 rpm for 10 minutes at 4°C. Protein 
concentrations were determined using the Pierce BCA Protein assay (Thermo 
scientific). Lysates were used for immunoprecipitation or directly for labeling with 
biotinylated probes (see below). 
 
Immunoprecipitation 
For each immunoprecipitation, 2 µL of rabbit polyclonal anti-HspB6 antibody 
was coupled to 10 µL protein A-agarose beads (Kem-En-Tec Diagnostics) by 
rotating end-over-end for 1 hour at 4°C in IPP500 (500 mM NaCl, 10 mM Tris-HCl, 
pH 8.0, 0.05% NP40). Beads were washed trice with IPP500 and once with IPP150 
(150 mM NaCl, 10 mM Tris-HCl, pH 8.0, 0.05% NP40). The lysate of (labeled) 
pIRES-HspB6 transfected HeLa cells was added to the beads and rotated end-over-
end overnight at 4°C in IP150. Beads were washed twice with IPP500 and once 
with PBS followed by labeling with biotinylated probes (see below). 
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Labeling with biotinylated probes 
The labeling reactions were performed in PBS containing 0.1 mM of the 
appropriate biotinylated probe (terminal alkyne, DIBO, DIBAC, BCN or azide) and 
either 10 µg cell lysate proteins, 1 µg (TG2 treated) HspB6 or 10 µL beads 
containing the immunoprecipitated proteins. The reactions in solution were 
performed in a final volume of 15 µL and the reactions on the beads in 100 µL. 
When applying SPAAC, the lysate proteins were pre-incubated for 30 minutes 
with 1 mM Iodoacetamide (IAM) to reduce azide-independent labeling (see 
Chapter 3). For Cu(I)-dependent cycloadditions 10× concentrated freshly prepared 
working solution was added, containing 10 mM CuSO4, 10 mM sodium ascorbate 
and 10 mM tris((1-((O-ethyl)carboxymethyl)-(1,2,3-triazole-4-yl))methylamine 
(triazole ligand). All reaction mixtures were incubated at 4 °C for 1 hour, after 
which the beads were washed once with PBS. Sample buffer was subsequently 
added to a final concentration of 2% SDS, 5% -mercaptoethanol, 10% glycerol, 
0.03% bromophenol blue and 0.25 M Tris-HCl, pH 6.8 and incubated for 5 minutes 
at 95°C. Samples were analyzed by SDS-PAGE and western blot (see below). 
 
SDS-PAGE and western blot analysis 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed according to standard procedures. Proteins were transferred to 
nitrocellulose membranes (GE Healthcare) by electroblotting for western blot 
analysis. The membranes were incubated with primary antibodies (rabbit 
polyclonal anti-HspB6, mouse monoclonal anti--tubulin (GTU-88, Abcam) and 
mouse monoclonal anti-TG2 (CUB 7402 + TG100, Neomarkers)) or with IRDye 
800CW Streptavidin (Li-Cor) to detect biotinylated proteins. Bound antibodies 
were detected by incubation with IRDye 680CW-conjugated polyclonal goat anti-
mouse or goat anti-rabbit antibodies (Li-Cor) and visualized using an Odyssey 
Infrared Imaging System (Li-Cor). 
 
Fluorescent imaging 
Approximately 24 hours prior to the labeling 1 × 105 Movas cells (ATCC CRL-
2797) were plated in DMEM supplemented with 10% fetal calf serum in 24-well 
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plates with 12 mm round glass coverslips. The cells were incubated with or 
without 250 µM substrate 4 and 50 µM FITC-cadaverine for 24 hours. The cells 
were rinsed twice with PBS and incubated for 15 minutes in DMEM with 10% fetal 
calf serum, allowing diffusion of non-crosslinked substrates, which otherwise 
cause background labeling,138 into the medium. The cells were rinsed twice with 
PBS, fixed with 2% paraformaldehyde solution for 10 minutes, and rinsed twice 
with PBS. For each coverslip, 100 µL PBS containing 1 mM CuSO4, 1 mM NaAsc, 1 
mM triazole ligand and 25 µM Alexa555-Azide was pipetted on parafilm in a 
humidified incubation chamber. The coverslips were inverted, placed on top of 
this solution and incubated for 1 hour at room temperature. Coverslips were 
transferred to a 24-well plate and washed 4 times with PBS and once with water. 
Coverslips were agitated for 3 minutes between washes. Coverslips were dried, 
mounted on slides using Mowiol 4-88 mounting medium containing 0.02% of 
NaN3 and imaged by fluorescence microscopy. 
 
 
Results and discussion 
 
Azido substrates and biotinylated alkynyl probes 
We have synthesized three azide-functionalized amine-donor substrates for 
TG2 (Figure 1A). All three substrates contain a pentylamine that mimics the -
amino group of a peptidyllysine, which is essential for effective recognition by 
TG2.86,87 Substrate 1 is the smallest TG2 substrate, in which the azide is directly 
conjugated to the pentylamine. In substrates 2 and 3, a linker region is included 
consisting of an amide bond, which in substrate 3 is extended with a small 
hydrophobic alkyl chain. For the detection of the azide-functionality of substrates 
1-3 after their incorporation into TG2 substrate proteins a panel of different 
alkynyl probes are available, consisting of one terminal alkyne and three strained 
cyclooctynes, i.e. dibenzocyclooctyne (DIBO),110 azadibenzocyclooctyne (DIBAC)114 
and bicyclo[6.1.0]nonyne (BCN)148 (Figure 1B). To allow comparison with the 
labeling via BPA (Figure 1A), which has previously been demonstrated to be a 
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good TG2 substrate,87 these alkynes were all biotin-conjugated, as depicted in 
Figure 1B. 
 
 
Figure  1.  Structures  of  TG2  substrates  and  biotinylated  alkynes  used  in  this  study.  
(A) Biotinylated and azide-functionalized TG2 amine-donor substrates. (B) Biotinylated 
terminal and ring-strained alkynes. 
 
TG2-catalyzed crosslinking of azide-functionalized amine-donor substrates 
To investigate whether the amine-donor substrates 1-3 can be crosslinked by 
TG2 to an amine-acceptor substrate, a synthetic Q-containing peptide (biotin-
GQEPVR, 1 mM) was incubated with substrates 1, 2 or 3 (1 mM) in the presence of 
TG2. As a positive control, BPA was used. Crosslinking reactions were followed in 
time by analyzing small aliquots with HPLC, revealing the formation of a single 
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reaction product for each amine-donor substrate. The amount of which was 
plotted versus reaction time (Figure 2). For substrate 2, MS analysis confirmed 
that the mass of the product corresponds to the expected -glutamyl-monoamine 
crosslink product (Figure S1), proving that substrate 2 is indeed recognized as 
amine-donor substrate by TG2. The crosslinking of substrates 1, 2 and 3 to the Q-
peptide followed a similar time-course, showing that the way the azido group is 
linked to the pentylamine has no major influence on the substrate behavior of the 
molecules. Moreover, the crosslinking efficiencies are comparable to BPA, 
indicating that TG2 recognizes these substrates equally well as BPA. 
Figure 2. Analysis of TG2-catalyzed crosslinking of azide-functionalized amine-donor 
substrates. Substrate 1, 2, 3 and BPA (1 mM) were incubated with the amine-acceptor 
peptide biotin-GQEPVR (1 mM) after which the amount of -glutamyl-monoamine crosslink 
product was monitored by HPLC and plotted versus time. 
 
Detection of TG2-catalyzed crosslinking of heat shock protein B6 (HspB6) 
In order to evaluate whether substrates 1-3, after being crosslinked by TG2, 
can be labeled via CuAAC we used HspB6 as a model system. HspB6 is an excellent 
amine-donor and acceptor substrate for TG245,149 and its CuAAC-mediated 
biotinylation can easily be visualized via SDS-PAGE followed by western blot 
analysis. TG2-catalyzed crosslinking was performed by incubating substrate 1, 2, 3 
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or BPA (250 µM) with HspB6 (25 µM) for 2 hours at 37°C in the presence or 
absence of active TG2. After the crosslinking reaction, the incorporated azide-
handles were biotinylated via the CuAAC by incubating the (crosslinked) HspB6 
(1.7 µM) with biotin-alkyne (0.1 mM) for 1 hour at 4°C in the presence of CuSO4, 
sodium ascorbate and triazole ligand (1 mM each). Reaction products were 
separated by SDS-PAGE followed by western blotting to detect all isoforms of 
HspB6 (Figure 3A, lower panel) and the biotin-conjugated isoforms (Figure 3A, 
upper panel). HspB6 contains both amine-donor and acceptor sites allowing the 
TG2-catalyzed formation of an intramolecular and a variety of intermolecular 
crosslinked products.45,149 Labeling of the HspB6 isoforms via the CuAAC is 
observed only when substrate 1, 2 or 3 was present during the crosslinking 
reaction (Figure 3A, upper panel lanes 6, 8, 10). Furthermore, labeling is 
completely eliminated when TG2 was omitted (Figure 3A, upper panel lanes 5, 7, 
9). The labeled monomeric HspB6 appeared to migrate slightly slower than the 
unlabeled monomer (Figure 3A, lower panel compare e.g. lane 5 and 6), which is 
likely due to the mass increase resulting from the substrate together with the 
biotinylated probe. The intensity of labeling observed for substrate 1-3 is 
comparable to that of BPA (Figure 3A, upper panel compare lanes 6, 8 and 10 with 
lane 12), indicating that these substrates are crosslinked with similar efficiencies 
and that a (nearly) complete conversion of the introduced azides was achieved 
during the CuAAC. These results show that TG2 is able to crosslink the azide-
containing substrates to HspB6 and that the introduced azide-moieties can be 
efficiently converted into the corresponding biotinylated triazole derivatives via 
CuAAC. 
To evaluate labeling via SPAAC, the probes DIBO, DIBAC and BCN were used to 
label the crosslinked substrate 2. Therefore, HspB6 crosslinked to substrate 2 was 
incubated with the biotinylated derivatives of DIBO, DIBAC or BCN (0.1 mM) for 1 
hour at 4°C. Labeling via CuAAC and crosslinking with BPA, both performed as 
described above, were included as a control. Reactions were separated by SDS-
PAGE and analyzed by western blotting for the HspB6 isoforms and biotinylated 
forms (Figure 3B). All cyclooctynes showed efficient labeling, which was 
comparable to the labeling with the terminal alkyne and BPA (Figure 3B, compare 
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Figure 3. Detection of TG2-catalyzed crosslinking of HspB6 via CuAAC and SPAAC. (A) 
Substrates 1, 2 and 3 were crosslinked by TG2 onto HspB6 and subsequently biotinylated 
via CuAAC using biotin-alkyne. (B) Substrate 2 was crosslinked by TG2 onto HspB6 and 
subsequently biotinylated via CuAAC, using biotin-alkyne, and SPAAC, using DIBO, DIBAC 
and BCN. As negative controls, TG2, the azide-containing substrate and/or biotin-alkyne 
were omitted. The biotinylated TG2 substrate BPA was used as a positive control for TG2 
activity. HspB6 isoforms were separated by SDS-PAGE and analyzed by western blotting 
using either labeled streptavidin to detect biotinylated proteins (upper panels) or 
antibodies directed to HspB6 (lower panels). The positions of HspB6 monomers, dimers and 
multimers are indicated on the right. Intramolecular crosslinked HspB6 monomers are 
indicated with i. The size and position of the protein markers are indicated on the left. 
 
lanes 10, 14 and 18 with lanes 6 and 20). This implicates that under these 
conditions SPAAC results in a (nearly) complete conjugation of the cyclooctynes to 
the crosslinked substrate 2. Labeling via SPAAC was also highly specific, since 
hardly any labeling was observed when TG2 and/or substrate 2 was omitted 
(Figure 3B, upper panel lanes 7-9, 11-13, 15-17). Only DIBAC and BCN showed 
weak azide-independent labeling of monomeric HspB6 (Figure 3B, upper panel 
lanes 11, 13, 15 and 17). This azide-independent labeling is mainly caused by mild 
reactivity of the cyclooctynes towards the thiol of the reduced peptidylcysteine 
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present in HspB6, which can be avoided by pre-incubating the (crosslinked) HspB6 
with iodoacetamide (IAM) (see Chapter 3). 
 
Detection of crosslinked substrates in HeLa cells 
The efficiency by which the azide-containing substrates can be crosslinked by 
TG2 in vivo was determined by using HeLa cell cultures. The cells were incubated 
for 2 hours with substrate 1, 2, 3 or BPA (250 µM). The endogenous HeLa cell TG2 
was activated through elevating intracellular Ca2+-levels either by harvesting the 
cells with a cell scraper, leading to a short elevation due to membrane damage,160 
or by incubating with Ca2+-ionophore A23187 for 2 hours, leading to a continuous 
elevation. Lysates were prepared and the introduced azide-handles were 
biotinylated via CuAAC by incubating the lysate proteins (10 µg) with biotin-alkyne 
(0.1 mM) for 1 hour at 4°C. As a negative control, the CuAAC was also applied to 
lysates derived from cells without substrate incubation. Lysates were separated 
by SDS-PAGE followed by western blot analysis for biotinylated proteins. -Tubulin 
was used as a loading control (Figure 4A). A clear labeling of proteins was 
observed when HeLa cells were treated with ionophore in the presence of 
substrate 1, 2, 3 or BPA (Figure 4A, lanes 9, 12, 15, 18), indicating that the 
substrates, as BPA, are incorporated into a wide range of proteins upon 
ionophore-treatment, and that the CuAAC can be applied for biotinylation of the 
introduced azide-moieties in cell lysate proteins. However, the terminal alkyne 
also reacted mildly with cellular proteins in an azide-independent manner (Figure 
4A, lanes 4-6). This background staining was also encountered by other 
investigators in reactions where the alkyne is used as the probe.128,130 The azide-
independent labeling could not be prevented by preincubation with IAM, 
indicating that it is not caused by a reaction with reduced cysteines. Also different 
concentrations for the alkyne, ligand, reducing agent and copper(I)-source, did 
not reduce this azide-independent labeling (data not shown).161 The background 
staining limits the sensitivity of the assay, as exemplified by the hardly detectable 
mild TG2 activity induced by scraping (Figure 4A, compare lane 7 and 8, 10 and 11, 
13 and 14, 16 and 17). This means that in a cell lysate efficient but not completely 
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specific labeling of azide-modified proteins can be achieved via the CuAAC, 
allowing only sufficiently strong signals to be detected. 
 
 
Figure 4. Detection of TG2 substrate proteins in HeLa cells. (A) HeLa cells were cultured for 
2 hours without (-) or with substrate 1, 2, or 3 after which the lysates were labeled via 
CuAAC using biotin-alkyne. (B) HeLa cells were cultured for 2 hours without (-) or with 
substrate 2 and subsequently biotinylated via CuAAC, using biotin-alkyne, and SPAAC, 
using DIBO, DIBAC or BCN. TG2 was either not activated (-), mildly activated through 
harvesting by scraping (S) or strongly activated through incubating with Ca
2+
-ionophore 
A23187 (I). The biotinylated TG2 substrate BPA was used as a positive control for TG2 
activity. Protein biotinylation was monitored by western blotting using labeled streptavidin 
(upper panels). As a loading control -tubulin was used (lower panels). The size and 
position of the protein markers are indicated on the left. 
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Next it was determined whether azide-modified TG2-substrate proteins in a 
cell lysate could be biotinylated using SPAAC. First, lysates were prepared of HeLa 
cells which were labeled with substrate 2 or BPA as described above. Prior to 
biotinylation via SPAAC, lysates were pre-incubated with IAM (1 mM) for 30 
minutes at room temperature to reduce azide-independent labeling by strained 
alkynes (see Chapter 3). Note that in contrast to CuAAC, the strained probes used 
for SPAAC did lead to IAM-sensitive background signals. The lysates were 
incubated with the biotinylated derivatives of the terminal alkyne, DIBO, DIBAC or 
BCN (0.1 mM) for 1 hour at 4°C. After separation by SDS-PAGE, the biotinylated 
proteins were analyzed by western blotting. As a loading control -tubulin was 
visualized (Figure 4B). In this experiment, the labeling with substrate 2 was more 
efficient than in the previous one (Figure 4, compare lanes 10-12 in panel A with 
7-9 in panel B). The reason for this variation in TG2 activation is not clear, but 
might be due to a variation in the condition of the HeLa cells. All strained alkynes 
showed highly efficient labeling comparable to the terminal alkyne and BPA 
(Figure 4B, compare lanes 15, 21 and 27 with lanes 9 and 30). Only a low level of 
azide-independent labeling was observed which is in the same range as for CuAAC 
(Figure 4B, compare lanes 10-12, 16-18 and 22-24 with lanes 4-6). These data 
show that in a cell lysate labeling of azide-modified proteins can be achieved via 
SPAAC with a similar efficiency and specificity as with CuAAC. 
 
Specificity of TG2 activity detection 
To confirm that TG2 is indeed responsible for the crosslinking of the azide-
containing substrates 1-3 in HeLa cells, TG2 was either inhibited using the specific 
irreversible active-site inhibitor Z006, which is based on a 6-diazo-5-oxo-
norleucine reactive group,162,163 or downregulated using siRNAs directed against 
the TG2 mRNA. HeLa cells were incubated with Z006 for 2 hours simultaneously 
with the azide-containing substrate. The siRNA transfections were performed 1 
day prior to the substrate labeling using two different siRNAs directed against TG2 
and one control siRNA directed against the green fluorescent protein (GFP). The 
labeling experiment was performed as described above using substrate 2 and 
CuAAC. Lysates were separated by SDS-PAGE and analyzed by western blotting for 
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biotinylated proteins, TG2 and -tubulin (Figure 5). When substrate 2 was applied 
in the presence of Z006, ionophore-induced labeling was completely abolished 
(Figure 5, compare lanes 3 and 6). Furthermore, ionophore-induced labeling was 
reduced in cells transfected with the TG2 siRNAs compared to cells transfected 
with the control siRNA (Figure 5, compare lanes 12 and 15 with lane 9) due to a 
partial downregulation of TG2. These results indicate that the labeling of HeLa cell 
proteins with substrate 2 is indeed TG2-mediated. Since all azide-functionalized 
substrates show similar biotinylated protein patterns (Figure 4A), it is likely that 
the labeling with substrate 1 and 3 is also dependent on TG2. 
 
 
Figure 5. TG2-dependency of substrate crosslinking. HeLa cells were transfected with 
siRNAs directed against TG2 (TG2 siRNA 1 or 2) or GFP (negative control) and, after 1 day, 
incubated with substrate 2. In addition, untransfected cells were incubated without (-) or 
with TG2 inhibitor Z006 during the incubation with substrate 2. The proteins crosslinked 
with the substrate were labeled with biotin-alkyne and analyzed by western blotting using 
labeled streptavidin to detect biotinylated proteins (upper panel) or antibodies directed 
against TG2 (middle panel) or -tubulin (lower panel). The size and position of the protein 
markers are indicated on the left. 
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Labeling with an alkyne-functionalized amine-donor substrate 
Next, we tested if TG2 can also crosslink an alkyne-containing substrate. The 
advantage of such a substrate is that the labeling step with an azide- instead of 
alkyne-containing probe may produce less background staining when performing 
CuAAC in a cell lysate.128,130 For this reason, the alkyne-containing substrate 4 was 
synthesized, which can be labeled with a biotinylated azide (Figure 6A). Its CuAAC-
based labeling was compared with the azide-containing substrate 2, which is 
structurally most closely related. The substrates were crosslinked to HspB6 by TG2 
and subsequently labeled via CuAAC (Figure 6B). Substrate 2 again showed highly 
specific and efficient labeling comparable to BPA. Labeling via the alkyne-
containing substrate 4 was also highly specific, but slightly less efficient (Figure 6B, 
compare lane 10 with lane 6 and 12). Prolonged incubation with biotin-azide did 
not increase the labeling efficiency (data not shown), indicating that substrate 4 is 
a good TG2 substrate, but gives somewhat less efficient labeling. 
Next, we compared the labeling of substrate 2, 4 and BPA in HeLa cells 
followed by biotinylation of the introduced azides or alkynes via CuAAC (Figure 
6C). In line with previous experiments, crosslinking of substrate 2 to cellular 
proteins followed by biotinylation via the CuAAC is highly efficient, but not 
completely specific due to azide-independent labeling of the terminal alkyne. 
When the alkyne-containing substrate 4 is crosslinked followed by biotinylation 
via the CuAAC, protein labeling is less intense (Figure 6C, compare lane 15 with 
lane 9 and 18), however, the biotinylated azide shows a much lower background 
labeling (Figure 6C, lanes 10-12). As a result, the signal-to-noise ratio, based on 
the ionophore results (Figure 6C, lanes 6, 9, 12, 15), was approximately 1.5 times 
higher with the alkyne-bearing substrate 4 than with the azide-bearing substrate 2.   
Figure 6. (on the right page) Detection of TG2 activity with an alkyne-functionalized 
amine-donor substrate. (A) Structures of alkyne-containing substrate 4 and the 
corresponding biotinylated azide. (B) Substrates 2 and 4 were crosslinked by TG2 onto 
HspB6 and subsequently biotinylated via CuAAC using the appropriate probe. The analysis 
was performed as described for Figure 3. (C) TG2 substrate proteins in HeLa cells were 
labeled with substrate 2 and 4 followed by biotinylation via the CuAAC using the 
appropriate probe. The analysis was performed as described for Figure 4. 
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This means that in case the background is relatively high a better signal-to-noise 
ratio might be obtained using an azide-containing probe instead of an alkyne-
containing probe for the labeling step. These results are in good agreement with 
earlier reports.128,130 
 
Cell permeability of azide- and alkyne-functionalized TG2 substrates 
TG2 has been reported to be localized both in the intracellular and in the 
extracellular space.29 This means that the azide- and alkyne-containing substrates 
not necessarily had to enter the cells in order to be crosslinked to proteins, 
although the scraping and ionophore treatment most likely only activate the 
cytosolic TG2. To confirm that the substrates can pass the cell membrane HspB6 
was used, which is an excellent intracellular TG2-substrate. HeLa cells were 
transfected with pIRES-HspB6 DNA and incubated for 2 hours with substrates 1-4. 
BPA, which is a cell permeable substrate,164,165 was used as a positive control and 
the synthetic K-containing peptide (biotin-GNEPVK), which is a cell impermeable 
amine-donor substrate, as a negative control. TG2 activity was induced either by 
treatment with the Ca2+-ionophore A23187 or by scraping; only the latter disrupts 
the plasma membrane and thereby enables intracellular labeling by cell 
impermeable substrates. The cells were lysed and HspB6 was immunoprecipitated 
from the cell lysates, after which the incorporated azide- or alkyne-moieties were 
biotinylated via the CuAAC. The biotinylated and the total amount of precipitated 
HspB6 were analyzed by western blotting (Figure 7). When TG2 was activated by 
scraping, all substrates were crosslinked to HspB6 to varying extents (Figure 7, 
lanes 4-6 and 8-10). However, when TG2 was activated by ionophore-treatment 
only substrates 1-4 as well as BPA showed a strong labeling intensity, in contrast 
to the cell impermeable K-peptide (Figure 7). These results indicate that 
substrates 1-4 can indeed pass the cell membrane. This is in line with the cell 
penetrating properties observed for other small amine-donor substrates138,164,165 
and indicates that the azide or alkyne present in the substrates do not prevent 
entering cells. 
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Figure 7. Analysis of the membrane permeability of substrates 1-4. HeLa cells were 
transfected with pIRES-HspB6 and, after 24 hours, incubated with no substrate (-), 
substrate 1, 2, 3, 4, the membrane permeable BPA or the membrane impermeable K-
peptide. TG2 was activated by incubating with Ca
2+
-ionophore A23187, enabling labeling 
of HspB6 by cell permeable substrates only, or by scraping, enabling labeling of HspB6 
regardless of the substrate permeability. HspB6 was isolated from the lysates of the 
treated cells by immunoprecipitation and biotinylated via CuAAC using the appropriate 
alkynyl and azido probes. The analysis was performed by western blot analysis using 
labeled streptavidin to detect biotinylated proteins (upper panel) or antibodies to HspB6 
(lower panel). 
 
Fluorescent imaging of TG2-substrate proteins 
We next employed the alkyne-containing substrate 4 for fluorescent imaging 
of TG2 substrate proteins in cells. For this experiment, we used the smooth 
muscle cell line Movas, which has a high extracellular TG2 activity (see Figure 1A 
of Chapter 6). Movas cells were incubated simultaneously with substrate 4 and 
the fluorescently labeled amine-donor substrate FITC-cadaverine.138 After 24 
hours, cells were fixed, labeled via CuAAC using an Alexa555-conjugated azido 
probe and analyzed by fluorescence microscopy. As a negative control, both 
substrates were omitted (Figure 8). Cells treated with alkyne-containing substrate 
4, but not the control cells, showed specific labeling with the fluorescent azide of 
a subset of the Movas cells. This labeling completely colocalized with the 
incorporated FITC-cadaverine, which shows that TG2-substrate proteins can be 
visualized in cell cultures using click chemistry. 
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Figure 8. Visualization of fluorescently 
labeled TG2 substrates in Movas cells. 
Movas cells were incubated for 24 hours 
without substrate (left panel) or with 
azido substrate 4 together with FITC-
cadaverine (right panel). Cells were 
fixed, stained with Alexa555-azide for 1 
hour and subsequently analyzed by 
fluorescence microscopy for bright field 
(BF, first row), FITC-cadaverine (FITC, 
second row) and Alexa555-azide (Alexa555, 
third row). Overlays are composed of all 
three channels (merge, fourth row). 
 
 
 
 
 
Conclusions 
In this study, we demonstrated that azide- and alkyne-containing 
pentylamines are efficiently crosslinked to amine-acceptor substrate proteins in a 
TG2-dependent manner. These tagged pentylamines are membrane permeable, 
allowing labeling of intracellular amine-acceptor substrate proteins in intact cells. 
After fixation or cell lysis, the introduced azide- or alkyne-handles can be labeled 
via CuAAC, allowing detection by western blotting or fluorescence microscopy. 
Under CuAAC conditions, the azido probe shows, compared to the alkynyl probe, 
a somewhat lower non-specific reactivity towards proteins and therefore, the 
former might be preferred when a high signal-to-noise ratio is needed. 
Furthermore, SPAAC could be applied successfully to biotinylate azide-modified 
TG2 substrate proteins, thereby avoiding the need for toxic copper ions. 
Overall, the click chemistry-based method may be an attractive alternative 
method for the detection of TG2 activity and/or substrates because of the 
advantage of the relatively small size of the amine-donor substrate and the 
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introduction of a flexible labeling step after the crosslinking of the substrate, 
allowing differential labeling of cellular proteins. This new method may therefore 
help to shed more light on the role of TG2 in different cellular and/or pathological 
processes. 
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Figure S1. MS analysis of 
TG2-catalyzed crosslinking 
of azido substrate 2 and 
the Q-peptide. (A) Mass 
spectrum (positive mode) 
of the reaction mixture 
without incubation at 37°C 
shows the mass 
corresponding to Q-
peptide (m/z calculated for 
C38H62N12O12S (M+H)
+
: 
911.4, found 911.6) (B) 
Mass spectrum (positive 
mode) of the reaction 
mixture after incubating 
20.5 hours at 37°C shows 
the mass corresponding to the expected -glutamyl-monoamine crosslink product of the Q-
peptide and substrate 2 (m/z calculated for C45H74N16O13S (M+H)
+
: 1079.5, found 1079.6) 
and the deamidated Q-peptide (m/z calculated for C38H61N11O13S (M+H)
+
: 912.4, found 
912.6).  
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Abstract 
While inward remodeling of small arteries in response to low blood flow, 
hypertension, and chronic vasoconstriction depends on type 2 transglutaminase 
(TG2), the mechanisms of action have remained unresolved. We studied the 
regulation of TG2 activity, its (sub) cellular localization, substrates, and its specific 
mode of action during small artery inward remodeling. We found that inward 
remodeling of isolated mouse mesenteric arteries by exogenous TG2 required the 
presence of a reducing agent. The effect of TG2 depended on its crosslinking 
activity, as indicated by the lack of effect of mutant TG2. The cell-permeable 
reducing agent DTT, but not the cell-impermeable reducing agent TCEP, induced 
translocation of endogenous TG2 and high membrane-bound transglutaminase 
activity. This coincided with inward remodeling, characterized by a stiffening of 
the artery. The remodeling could be inhibited by a TG2 inhibitor and by the nitric 
oxide donor, SNAP. Using a pull-down assay and mass spectrometry, 21 proteins 
were identified as TG2 crosslinking substrates, including fibronectin, collagen and 
nidogen. Inward remodeling induced by low blood flow was associated with the 
upregulation of several anti-oxidant proteins, notably glutathione-S-transferase, 
and selenoprotein P. In conclusion, these results show that a reduced state 
induces smooth muscle membrane-bound TG2 activity. Inward remodeling results 
from the crosslinking of vicinal matrix proteins, causing a stiffening of the arterial 
wall. 
 
 
Introduction 
Small arteries represent the main site of resistance in the vascular system, 
and as such, have a large impact on tissue perfusion and blood pressure. Inward 
remodeling of small arteries occurs after a reduction in blood flow, but is also 
associated with high blood pressure.166-168 It is a hallmark of essential 
hypertension and a strong predictor of cardiovascular events.169 Previous work 
from our group showed that transglutaminases, in particular type 2 
transglutaminase (TG2), play a crucial role in the inward remodeling of small 
arteries after reduced blood flow and hypertension in vivo, and chronic 
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vasoconstriction in vitro.170-176 The mechanism by which TG2 contributes to 
vascular remodeling however, remains poorly understood.  
One reason for the elusive role of TG2 in remodeling may relate to its wide 
range of actions. Its best known function is the stabilization of matrix proteins 
through the formation of a specific crosslink, the Nε(γ-glutamyl)lysine isopeptide 
bond, which is the result of a transamidation reaction.66 This reaction is regulated 
by several factors including calcium, GTP, nitric oxide and the redox potential.5,29 
The isopeptide bond provides mechanical strength and resistance to proteolytic 
degradation in tissues. Recent work from Santhanam et al.177 showed that the 
crosslinking action of TG2 is highly relevant for human cardiovascular pathology. 
Thus, these authors showed that the formation of crosslinks by TG2 relates to the 
stiffening of large arteries that is associated with aging. Besides the formation of 
isopeptide bonds within and between proteins,66 TG2 promotes cell adhesion via 
its binding to fibronectin, integrin 51 and heparan sulfate proteoglycans.
36,178 In 
addition, TG2 acts as protein disulfide isomerase,157 functions as a G-protein179 
and aids in the regulation of cytoskeletal structure and cell contractility.180-182 
Of great potential relevance for cardiovascular pathology, Stamnaes et al.27 
recently showed that TG2 contains a triad of cysteine residues that act as a redox 
sensor, which could regulate the crosslinking activity of TG2 in the extracellular 
environment. In the present study we investigated the activation, (sub) cellular 
localization, and substrates of TG2 during the inward remodeling of small arteries. 
Besides the regulation of TG2 by calcium and nitric oxide, we focused on the 
redox state of TG2 using reducing agents with different properties regarding 
cellular permeability. We report that TG2 is translocated to the surface of smooth 
muscle cells (SMCs) upon intracellular reduction. In a reduced state TG2 acts as a 
membrane-bound crosslinking enzyme in SMC, which coincides with inward 
remodeling. Using mass spectrometry, we identified several matrix proteins as 
TG2 substrates. Taken together, these data elucidate the regulation, secretion and 
substrates of TG2 in the process of vascular remodeling.  
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Materials and methods 
 
Mice and vessel isolation  
Four months old male C57Bl/6 mice (Harlan) were anesthetized using 
isoflurane and sacrificed by cervical dislocation. Then, the abdomen was opened 
and the mesentery was excised and placed in cold MOPS buffer. First and second 
order arteries were isolated from the mesenteric vasculature. Arteries were cut in 
equal-sized pieces where one segment was randomly assigned as control and the 
other segments subjected to various interventions. This approach allowed for 
pair-wise statistics and drastically decreased variability which results from 
anatomical variation in vessel caliber. All protocols consisted of a 24-hour 
incubation period at 37 0C, where the vessels were placed in 100 μL buffer 
containing Leibovitz medium with 10% fetal bovine serum (Gibco), a mix of 
antibiotic-antimycotic solution (Gibco), and additional compounds, depending on 
the specific protocol. All experiments were approved by the Committee for 
Animal Experiments of the Academic Medical Center Amsterdam (permissions 
101221 and 101555). TG2 knockout mice were obtained from Prof. G. Melino 
(Rome, Italy) and bred at our local facility.  
  
Pressure myograph and remodeling 
To determine remodeling of the arteries, segments were cannulated in a 
pressure myograph system after the incubation period and inner diameters were 
recorded as described previously.170 After checking for leaks, a passive pressure- 
diameter relationship was determined in calcium-free MOPS buffer, 
supplemented with papaverine (0.1 mmol/L) to rule out influences of vasomotor 
tone.  
 
Exogenous recombinant TG2 
In this set of experiments, vessels were exposed to recombinant human TG2 
(Zedira, T002) or crosslinking deficient C277S-TG2 (Zedira, T018), with or without 
the membrane-impermeable reducing agent tris(2-carboxyethyl)phosphine 
hydrochloride (TCEP, 1 mmol/L). Control experiments were included were 
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segments only were exposed to TCEP. In all experiments, recombinant TG2 was 
administered at 50 μg/mL. 
 
Activation of endogenous TG2 
In this set of experiments, vessels were incubated with calcium ionophore 
A23187 (Sigma, C7522: 1 μmol/L). Alternatively, vessels received 2 mmol/L DTT 
(Sigma, 43816), which is membrane-permeable. In the latter experiment, TG2 
activity was blocked using either the TG2 active-site inhibitor L682777 (Zedira, 
T101: 10 μmol/L, also known as R283) or the NO donor SNAP (Sigma, N3398: 1 
mmol/L).  
The effect of DTT on vessel viability was assessed in a separate set of vessels. 
Here, the contractile response to the thromboxane/prostaglandin agonist U46619 
(Sigma, D8174: 1 μmol/L) was measured after a 24-hour incubation with 2 mmol/L 
DTT. 
 
Localization of TG2 activity 
In vessels stimulated with calcium ionophore or DTT, TG2 activity was 
visualized using the pseudo-substrate cadaverine, linked to either FITC (AnaSpec, 
81504; 100 μmol/L) or AlexaFluor594 (Invitrogen, A-30678;10 μmol/L). In 
experiments where SNAP was used to inhibit TG2 activity, cadaverine was added 
>30 min after SNAP. SNAP was used at 10-4 mol/L with calcium ionophore and at a 
concentration of 10-3 mol/L with DTT. Vessels were fixed with formalin, mounted 
on glass slides using Vectashield/DAPI (Vector Laboratories H-1500) and imaged 
on a confocal microscope (Leica TCS SP2). TG2 activity was quantified by spatial 
integration of FITC or AlexaFluor594 signal in ImageJ. Data were corrected for 
vessel size and depicted in arbitrary units.  
 
Immunostaining of TG2 
The effect of DTT on the translocation of TG2 was assessed by 
immunofluorescent staining of extracellular TG2 on cultured mouse smooth 
muscle cells (MOVAS, ATCC CRL-2797). Cells were grown in microscopic culture 
chambers (BD Falcon 354102, untreated glass) that were coated with fibronectin. 
The redox state of TG2 controls arterial remodeling 
___________________________________________________________________ 
111 
 
After a culture period of 24 hours in DMEM with 10% FCS, 0.1 mmol/L DTT was 
added for 2 hrs. Then cells were washed 3 times with warm PBS and fixated with 
cold formalin. After blocking with BSA/goat serum, the non-permeabilized cells 
were stained with a rabbit polyclonal TG2 antibody Ab-4 (Neomarkers RB-060-P, 
1:10; 1 hr at room temperature) followed by anti-rabbit Cy3 (Brunschwig 111-165-
144, 1:200; 1 hr at room temperature) as secondary antibody, and slides were 
mounted in Vectashield/DAPI (Vector Laboratories H-1500). 
 
Substrates of transglutaminase in smooth muscle cells 
The substrates for transamidation catalyzed by TG2 were determined using a 
mouse smooth muscle cell line (MOVAS, ATCC CRL-2797). Cells were cultured in 
DMEM with 10% FCS for 96 hours in T75 flasks. Then either BPA (biotinylated 
pentylamine, Invitrogen A1594, 1 mmol/L) or Q-peptide (Biotin-GQEPVR, 
synthesized using standard Fmoc-based solid phase peptide synthesis, 0.25 
mmol/L) were added to function as lysine and glutamine donors respectively,89 
while a control group was left without competitive substrate. All groups received 
0.1 mmol/L DTT to increase the amount of active TG2 in the extracellular matrix. 
After a 24 hrs incubation period, the cultures were washed 3 times with warm PBS 
to remove non-bound BPA and Q-peptide. Then the lysates were collected in a 1% 
SDS solution and boiled for 5 minutes at 95C to denature the proteins. For each 
group, the material from 2 T75 flasks was pooled and stored at -20C until further 
use. 
Lysates were sonicated (5 times 30 seconds at room temperature) and 
dialysed against 1% SDS (3 times 500 mL for 1 hour at room temperature) to 
further decrease the amount of non-bound BPA and Q-peptide. Then lysates were 
centrifuged at 15.700 g for 10 minutes at room temperature and 13 mL buffer 
containing 100 mmol/L NaCl, 50 mmol/L Tris HCl pH 7.5, 1 mmol/L EDTA, 0.5% 
NP40 was added to 1.2 mL supernatant. Streptavidin-Agarose (50 L, Sigma 
S1638) was added and the mixture was rotated end-over-end at room 
temperature for 20 hours. The agarose-beads were washed with 100 mmol/L 
NaCl, 50 mmol/L Tris HCl pH 7.5, 1 mmol/L EDTA, 0.05% NP40 (3 times 5 minutes 
end-over-end at room temperature) and taken up in 2x sample buffer (4% SDS, 
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10% -mercaptoethanol, 20% glycerol, 0.06% bromophenol blue and 0.5 mol/L 
Tris HCl pH 6.8). 
For Western blot analysis 2% of each pull-down was loaded on a 12% SDS-
PAGE gel and after blotting stained with IRdye 800CW Streptavidin (li-Cor), rabbit 
polyclonal anti-Fibronectin (GIBCO 1A0540) and rabbit polyclonal nidogen-1 
(Immun Diagnostik AP1003.1). 
For MS analysis 20% of each pull-down was loaded on a 12% SDS-PAGE gel 
and stained with colloidal Coomassie Brilliant Blue. The biotin containing region 
(~30 kDa and up) from each Coomassie stained lane was sliced into 16 equal 
parts. Proteins in the slice were reduced with DTT, alkylated with iodoacetamide 
and digested with trypsin using the Proteineer DP digestion robot (Bruker, 
Bremen, Germany), adapted in house to accommodate larger gel pieces. The 
tryptic peptides were extracted from the gel, lyophilized, dissolved in 95/3/0.1 
v/v/v water/acetonitril/formic acid and subsequently analyzed by on-line 
nanoHPLC MS/MS using a1100 HPLC system (Agilent Technologies), as previously 
described.183 Peptides were trapped at 10 µL/min on a 15-mm column (100-µm 
ID; ReproSil-Pur C18-AQ, 3 µm, Dr. Maisch GmbH) and eluted to a 200 mm column 
(50-µm ID; ReproSil-Pur C18-AQ, 3 µm) at 150 nL/min. All columns were packed in 
house. The column was developed with a 120-min gradient from 0 to 30% 
acetonitrile in 0.1% formic acid. The end of the nanocolumn was drawn to a tip (ID 
~5 µm), from which the eluent was sprayed into a 7-tesla LTQ-FT Ultra mass 
spectrometer (Thermo Electron). The mass spectrometer was operated in data-
dependent mode, automatically switching between MS and MS/MS acquisition. 
Full scan MS spectra were acquired in the FT-ICR with a resolution of 25,000 at a 
target value of 3,000,000. The two most intense ions were then isolated for 
accurate mass measurements by a selected ion monitoring scan in FT-ICR with a 
resolution of 50,000 at a target accumulation value of 50,000. Selected ions were 
fragmented in the linear ion trap using collision-induced dissociation at a target 
value of 10,000. In a post-analysis process, raw data were first converted to peak 
lists using Bioworks Browser software v 3.2 (Thermo Electron), then submitted to 
the SwissProt database version 51.6 using Mascot v. 2.2.04 
(www.matrixscience.com) for protein identification and finally sorted and 
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compared using Scaffold software version 3.0.1 (www.proteomesoftware.com). 
Mascot searches were with 2 ppm and 0.8 Da deviation for precursor and 
fragment mass, respectively, and trypsin as enzyme. Scaffold filtered for identified 
proteins with at least 2 peptides with 95% confidence. Collision-induced 
dissociation spectra were also manually inspected. Common contaminants were 
removed manually from the list. 
 
Regulators of redox balance during inward remodeling 
The expression of redox regulating enzymes in inwardly remodeling vessels 
was investigated using a microarray approach published previously by Wesselman 
et al.184 In short, flow-modifying surgery was performed on rat first-order 
mesenteric arteries. This leads to a flow reduction in ligated vessels to 
approximately 10% of control, and a doubling of flow in adjacent high flow 
vessels. Animals were sacrificed after 1, 2, or 4 days and for each time point 
vessels from 4 animals were pooled. cDNA from either low or high flow vessels 
linked to a Cy5 probe was hybridized onto 2 different microarrays in the presence 
of Cy3-labeled cDNA from control vessels. Up- or down regulation of a number of 
redox regulating enzymes with decreased flow was then normalized to control 
values. If genes were present more than once in the 2 arrays employed, their 
values were averaged. 
 
Statistics 
Data are shown as mean ± SEM. For all measurements of P,d-curves, 
differences in diameter between groups were tested at each pressure level using 
a paired T-test with Bonferroni correction when appropriate. Distensibility was 
calculated as the lumen diameter of the artery at 120 mmHg divided by the 
diameter at 5 mmHg. For quantification of fluorescence, 3 images were averaged 
per vessel. In all figures, P-values smaller than 0.05 resp. 0.01 are indicated by 
single or double symbols (e.g. * and **). 
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Results 
 
Vascular remodeling by recombinant TG2 requires a reducing agent 
Small mesenteric arteries were incubated for 24 hours under various 
conditions. After the incubation period, vascular remodeling of these vessels was 
determined by cannulation and recording of a passive pressure-diameter (P,d) 
relationship. Incubation of mesenteric arteries with exogenous recombinant TG2 
had no effect on the P,d-curve as compared to untreated control arteries (Figure 
1A). Distensibility of the arteries, determined as the ratio of the diameter at 120 
mmHg divided by the diameter at 5 mmHg, was unchanged: 1.98 ± 0.14 vs. 1.93 ± 
0.10 for control and TG2 respectively. Administration of 1 mmol/L TCEP, a cell-
impermeable reducing agent, also did not affect the P,d curve (Figure 1B). 
Distensibility was unchanged: 2.01 ± 0.12 vs. 2.03 ± 0.11 for control and TCEP 
respectively. However, when TG2 was added together with TCEP, vessel diameter 
was significantly reduced at higher pressure levels (Figure 1C). This resulted in a 
significant decrease in distensibility from 1.95 ± 0.04 to 1.76 ± 0.14 for TCEP vs. 
TCEP + TG2 (p=0.01). When the catalytically inactive TG2 mutant Cys-277 was 
used instead of recombinant TG2, inward remodeling was again absent (Figure 
1C). Distensibility was similar to TCEP alone: 1.92 ± 0.08 (NS). These data 
therefore show that inward remodeling by TG2, characterized by a reduction in 
distensibility, depends on its crosslinking action and requires the presence of a 
reducing agent. 
 
A cell-permeable reducing agent activates endogenous TG2 
In order to test if endogenous TG2 could be activated by a cell-permeable 
reducing agent, vessels were incubated with dithiothreitol (DTT). As indicated by 
FITC-cadaverine incorporation, DTT induced a profound increase in TG2 activity in 
the vessel wall (Figure 2A). This activity was completely abolished in vessels 
incubated with the TG2 inhibitor L682777 (Figure 2, panels A-B). The activation of 
endogenous TG2 with DTT caused a highly significant inward remodeling, which 
was almost completely prevented by L682777 (Figure 2C). The effect of 
endogenous TG2 on vascular remodeling was similar to that of exogenous TG2, 
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with a reduction in vessel diameter at higher distending pressures only (Figure 
2C). Thus, distensibility decreased from 2.00 ± 0.12 to 1.71 ± 0.08 for control and 
DTT respectively (p<0.01).  
 
Figure 1. Microvascular remode-
ling by transglutaminase requires 
a reducing agent and cross-
linking activity. Passive pressure-
diameter relationships (P,d curve) 
of isolated, cannulated arteries 
were measured to reveal 
remodeling. (A) Exogenous TG2 
had no effect on vessel properties 
in the absence of a reducing 
agent. (B) The cell-impermeable 
reducing agent TCEP did not 
induce remodeling by itself. (C) 
When exogenous TG2 was 
combined with TCEP, inward 
remodeling was observed. This 
effect was absent with 
recombinant TG2, defective in 
crosslinking. Data were averaged 
over 6 vessels obtained from 3 
mice.  
 
** TCEP vs. TG2+TCEP: P<0.01. 
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Figure 2. Activation of endoge-
nous TG2 by the cell-permeable 
reducing agent DTT. (A-B) 
Exposure to DTT induces TG2 
activity in the medial layer of the 
vessel, as shown by the 
incorporation of FITC cadaverine. 
(C) TG2 activation with DTT 
induces inward remodeling, as 
indicated by a downward shift of 
the P,d-curve. This was blocked 
with a site-specific TG2 inhibitor 
(L682777). Data were averaged 
over 6 vessel  obtained from 3 
mice, with 3 images per vessel;  
 
scalebar = 75 μm.  
* non-stimulated vs. DTT: P<0.05, 
** P<0.01,  
# DTT vs. L682777+DTT: P<0.05, 
## P<0.01. 
 
 
 
 
 
 
 
 
 
When small mesenteric arteries from TG2 knockout mice were exposed to 
DTT, inward remodeling was observed also, albeit to a lesser extent as compared 
to vessels from C57BL/6 mice. Distensibility decreased significantly from 2.10 ± 
0.08 to 1.95 ± 0.08 for control and DTT respectively (p<0.001). In this case 
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however, the TG2 inhibitor L682777 was ineffective. Distensibility was not altered 
as compared to DTT: 1.97 ± 0.11 (NS). These data suggest that in the TG2 
knockout mice other mechanisms are activated by DTT which induce remodeling 
(Figure S1).  
In subsequent experiments we tested if remodeling induced by DTT could also 
be counteracted by nitric oxide. Transglutaminase activity was strongly reduced 
by the NO donor SNAP, as indicated by the incorporation of Alexa Fluor-
594/cadaverine (Figure 3, panels A-B). This was paralleled by an almost complete 
inhibition of the remodeling (Figure 3C). Distensibility decreased significantly by 
treatment with DTT from 1.96 ± 0.10 to 1.64 ± 0.13 (p<0.01), but was reversed by 
SNAP to 1.86 ± 0.06 (p=0.01). Control experiments showed that SNAP alone did 
not affect vessel properties (Figure S2). Hence, these results show that a shift of 
the intracellular redox balance to a more reduced state activates a TG2-
dependent inward remodeling and, in addition, this remodeling can be inhibited 
by nitric oxide (NO). 
 
Calcium ionophore A23187 stimulates TG2 activity but does not induce inward 
remodeling 
Calcium triggers a conformational change in TG2, providing access of 
substrates to TG2’s active site.29 Normally, under physiological conditions the level 
of intracellular calcium is too low to induce crosslinking activity by TG2. However, 
after exposure to vasoconstrictor substances, or under pathological conditions, 
the level of intracellular calcium may rise considerably. To test the role of calcium 
we analyzed the effect of the calcium ionophore A23187 on TG2 activity and 
arterial remodeling. Administration of the ionophore increased TG2 activity in the 
vessel wall about 3-fold, as demonstrated by the incorporation of FITC-cadaverine 
(Figure 4, panels A,B). This calcium-induced intracellular activity could be inhibited 
by 1 mmol/L of the NO donor SNAP (Fig 4, panels A,B). Despite the increase in TG2 
activity, the calcium ionophore did not induce small artery inward remodeling, as 
reflected by an unchanged P-d curve after incubation of cannulated arteries with 
1 μmol/L A23187 (Figure 4C). Distensibility was also unchanged: 1.90 ± 0.14 vs. 
1.94 ± 0.13 for control and A23187 respectively (NS).  
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Figure 3. DTT-induced activation 
of TG2 can be counteracted with 
the NO donor SNAP. (A-B) 
Incorporation of AlexaFluor594 
/cadaverine was significantly 
inhibited with SNAP. (C) SNAP 
abolished the inward remode-
ling induced by DTT. Data were 
averaged over 6 vessels 
obtained from 3 mice, with 3 
images per vessel.  
 
Scalebar = 75 μm.  
* non-stimulated vs. DTT: 
P<0.05 , ** P<0.01, 
 # DTT vs. SNAP+DTT: P<0.05 , 
## P<0.01. 
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Figure 4. Incubation with 
calcium ionophore (A23187) 
induces transglutaminase 
activity without remodeling. (A-
B) Exposure to A23187 
stimulates the incorporation of 
FITC cadaverine. TG2 activity 
can be inhibited by the NO 
donor SNAP. (C) A23187 does 
not induce inward remodeling. 
Data were averaged over 6 
vessels obtained from 3 mice, 
with 3 images per vessel.  
 
Scalebar = 75 μm.  
* non-stimulated vs. A23187: 
P<0.05,  
# A23187 vs. A23187+SNAP: 
P<0.05. 
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Localization of TG2 activity is stimulus-dependent 
While activation of intracellular TG2 with DTT caused significant inward 
remodeling, this was absent for activation by the calcium ionophore A23187. We 
tested whether this difference is related to localization of TG2 activity. In the 
adventitia, TG2 activity was virtually absent (data not shown). The incorporation 
of FITC-cadaverine around endothelial cells was also relatively low. In contrast, 
TG2 activity following stimulation with A23187 or DTT was prominent in the 
medial layer. The subcellular staining pattern in the SMCs was strongly dependent 
on the stimulus for TG2 activation. Following stimulation with the calcium 
ionophore, TG2 activity appeared throughout the cytosol, while cellular 
boundaries remained clearly visible (Figure 5). On the other hand, DTT induced 
TG2 activity at the cell membrane, producing a mirror image of the activation 
pattern with A23187. In addition to the TG2 activity at the membrane, patches of 
high TG2 activity were observed at the interface of the endothelium and smooth 
muscle layers (data not shown). Thus, a clear difference was observed in the 
localization of TG2 activity with A23187 and DTT. 
 
 
Figure 5. Differential localization of transglutaminase activity. (A) When vessels were 
incubated with the cell-permeable reducing agent DTT, FITC cadaverine was crosslinked at 
the cell membrane of smooth muscle cells. (B) When vessels were incubated with the 
calcium ionophore A23187, FITC cadaverine appeared throughout the cytosol. Vascular 
remodeling occurred with DTT treatment, but not with the calcium ionophore.  
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Intracellular reduction increases TG2 protein at the cell surface 
The confocal images showed a membrane-bound TG2 activity upon 
stimulation with DTT, but did not provide sufficient resolution to determine 
whether the activity is intra- or extracellular. We therefore studied the presence 
of TG2 on non-permeabilized smooth muscle cells with immunocytochemistry. 
Cultured SMCs were stimulated with a low dose of DTT and stained for 
extracellular TG2. This revealed a strong increase in the level of extracellular TG2 
as compared to untreated control cells (Figure 6). Hence, these data suggest that 
a reduced state triggers translocation of TG2 from the cytosol to the cell surface.  
 
Figure 6. Intracellular reduction increases cell 
surface TG2. Incubation of cultured smooth 
muscle cells with DTT (0,1 mmol/L) increased 
the amount of extracellular TG2 (shown in 
red), as visualized by immunostaining of non-
permeabilized cells. Fluorescence intensity 
was integrated per cell and averaged over 35-
37 cells per group.  
 
Scalebar = 20 μm.  
** non-stimulated vs. DTT: P<0.01. 
 
 
 
 
 
 
Substrates of TG2 
As TG2 activity at the smooth muscle cell membrane was associated with 
inward remodeling, we next investigated the extracellular substrates of TG2 using 
cultured SMCs that were stimulated with DTT. Labeling of TG2 substrates with the 
lysine donor biotinylated pentylamine (BPA) or a specifically designed Q-peptide 
(glutamine donor) was followed by a pull down assay and mass spectrometry. This 
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revealed a number of proteins as substrate for TG2 (Table 1). Fibronectin was the 
major extracellular substrate, crosslinked both to BPA and Q-peptide. In addition, 
BPA identified the ECM components collagen, fibulin-2 and nidogen-1 as 
glutamine donors for transamidation. Both fibronectin and nidogen-1 were 
subsequently confirmed as TG2 substrates in western blots (Figure S3). 
Furthermore, a number of cytoskeletal and other intracellular proteins were 
identified.  
 
Table 1. Identification of TG2 substrates in cultured smooth muscle cells. Cultured smooth 
muscle cells were incubated with BPA and Q-peptide, which were used as lysine and 
glutamine donor respectively. Samples were purified by a streptavidin pull down assay and 
bands were analyzed by mass spectrometry. Values represent the number of unique 
peptides found for each protein and give an indication of the abundance of the protein in 
the sample. 
  control BPA Q-peptide  known 
Extracellular Matrix      substrate
1 
fibronectin precursor   63 47  yes 
collagen alpha-1 chain 
precursor 
  4 1  yes 
fibulin-2 precursor   2   no 
nidogen-1 precursor   2   yes 
       
Cytoskeleton & Cell 
Membrane 
      
vimentin  6 14 13  yes 
actin  3 14 12  yes 
tubulin alpha-1  1 7 5  no 
tubulin beta-5   7 3  yes 
moesin   4 2  no 
WD repeat protein 1   2   no 
annexin A1    2  no 
V-CAM1   3   no 
       
Cell Metabolism       
alpha-enolase  1 10 2  yes 
L-lactate dehydrogenase  2 10 6  no 
pyruvate kinase   9 2  no 
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GAPDH  4 4 6  no 
aldehyde dehydrogenase, 
mitochondrial 
  2 1  no 
voltage-dependent anion-
selective channel 
  2 1  no 
transketolase   2   no 
       
DNA, RNA & Protein Synthesis       
elongation factor 1   7 4  yes 
histone H1.2   5   yes 
THO complex  4 3 4  no 
initiation factor 4A-I  1 3 3  no 
ribosomal protein 53-A   2 3  no 
elongation factor 2   1 3  no 
       
Various       
heat shock protein 90   7 4  yes 
guanine nucleotide-binding 
protein 
  5 3  no 
serum albumin precursor   1 4  no 
multifunctional protein ADE2    2  no 
       
1
Database used: http://genomics.dote.hu/wiki/index.php/Category:Tissue_transglutaminase 
 
Regulators of redox balance during in vivo remodeling 
The activation of TG2 by DTT proved to be a strong stimulus for inward 
remodeling, but represents an artificial means of manipulating the redox state. 
Therefore, the expression of several enzymes capable of reducing thiol groups on 
proteins was studied in vessels remodeling in vivo. The mRNA expression was 
assessed in vessels stimulated to remodel inwardly by reducing blood flow in vivo. 
In arteries undergoing inward remodeling, selenoprotein P upregulation peaked 
after 2 days (Table 2). Glutathione transferase was already increased 80% after 24 
hrs, followed by a gradual decline of expression. In outward remodeling vessels on 
the other hand, these enzymes were downregulated after 1 and 2 days (data not 
shown). 
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Table 2. Changes in mRNA of redox regulating enzymes during inward remodeling. Inward 
remodeling was induced by a surgically imposed decrease in blood flow in rat mesenteric 
arteries. Vessels were harvested at several time points and mRNA expression was 
determined by microarray analysis. Data represent changes in mRNA expression as 
percentage from control. An increased expression of several redox regulating enzymes was 
found. For each time point, vessels from 4 animals were pooled. Some genes were present 
several times on the microarray. 
   Day   repetitions 
  1 2 4  on arrays 
Glutathione Reductase  40 30 10  1 
Glutathione Synthetase  10 7 30  3 
Glutathione Transferase T1  80 50 -20  2 
Macrophage Migration Inhibitory Factor  57 13 70  3 
Protein Disulphide Isomerase  0 -10 20  1 
Selenoprotein P  28 174 62  5 
Thioredoxin  -30 -70 0  1 
Thioredoxin Reductase  20 20 20  1 
Xanthine Dehydrogenase  73 90 47  3 
 
 
 
Discussion 
Vascular remodeling of small arteries after reduced blood flow, hypertension, 
and exposure to vasoconstrictors depends on TG2.170,171,173 In large arteries TG2 is 
involved in vascular calcification, and atherosclerotic plaque development and 
stability.185-189 Recently, also large artery stiffening associated with aging was 
shown to be dependent on TG2.177 While many studies have contributed to the 
understanding of the regulation and functions of TG2,5 the actual role of TG2 in 
vascular remodeling remained largely unknown. In our previous work we 
identified a strong relationship between vascular tone and remodeling. We 
reported that persistent vasoconstriction induces inward remodeling in several 
types of arteries.170,190,191 This remodeling could be inhibited or reversed by 
vasodilator compounds such as the calcium channel inhibitors verapamil191 or 
amlodipine.173 As constriction and dilation mechanisms act partly through 
modulation of intracellular calcium levels, we herein tested the hypothesis that 
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elevation of intracellular calcium triggers TG2 activity and remodeling. The 
calcium ionophore indeed increased intracellular transglutaminase crosslinking 
activity, but remodeling was completely absent. Thus, although intracellular 
proteins might have been crosslinked, this did not affect vessel caliber (Figure 4). 
Thus, these results suggested that other mechanisms of TG2 activation than 
elevation of intracellular calcium operate during vascular remodeling. 
We found that the redox state of TG2 is a critical determinant in small artery 
remodeling. DTT induced a strong inward remodeling response, which was 
inhibited by the TG2 inhibitor (Figure 2). The data on remodeling by exogenous 
recombinant TG2 (Figure 1) underline the need for a reduced environment. As the 
cell-impermeable reducing agent TCEP did not change blood vessel diameter, the 
remodeling most likely stems from activation of an intracellular source of TG2. 
Since transglutaminase activity associated with remodeling was located at the 
surface of smooth muscle cells, we inferred that upon intracellular reduction, TG2 
is excreted but remains bound to the cell membrane. This was substantiated by 
specific staining of extracellular TG2, using cultured SMCs. Similar mechanisms 
may exist in endothelial cells.177 We speculate that after translocation to the cell 
membrane, TG2 activity is fully uncovered by the high extracellular calcium 
concentration.  
The reversible formation of disulfide bridges, S-nitrosylation and S-
glutathiolation of key cysteines are increasingly recognized as crucial mediators of 
protein activation and function.192-194 TG2 is a good example of such regulation. It 
contains 18 sulfhydryl residues which can potentially be oxidized to form disulfide 
bridges, thereby impairing TG2 function.27,195,196 The active site cysteine (Cys-277) 
was shown not to be easily prone to form disulfide bridges, probably due to the 
low accessibility of the active cysteine.27,195,197,198 However, disulfide bonds formed 
using cysteine residues from other parts of TG2 have been shown to strongly 
reduce crosslinking activity as well.14,195,197 Recently, a crucial cysteine pair at 
amino acids 370-371, controlled by Cys-230, was identified.27 It has been 
hypothesized that these disulfide bridges impede the calcium-triggered 
conformational change that is required for activation.27,195 Thus, a reduced state is 
necessary for TG2 to allow its crosslinking action. Generally speaking, the 
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intracellular compartment is relatively reduced, whereas the extracellular 
environment is more oxidized.199 More detailed studies have revealed that the 
redox balance is further controlled at the subcellular level.199-201 In addition, the 
redox state of proteins can be individually regulated.202 The cell-permeable 
reductant DTT that we used is known to activate in situ transamidation without 
affecting other TG2 functions.203 We recognize that DTT is a non-specific reducing 
agent that might exert toxic effects. However, incubation with DTT did not affect 
vessel viability, assessed by its ability to contract (Figure S4). Hence, DTT did not 
have an overt detrimental effect on the used ex vivo vessels. In addition, the 
concentration of DTT that was used appears relatively high, but one needs to keep 
in mind that intracellular reducing compounds such as glutathione are present in 
the millimolar range.29  
The observation that a reduced state of TG2 is essential for its crosslinking 
activity, seems to contradict a report that TG2 is activated by oxidative stress via 
reactive oxygen species (ROS).204 However, UV irradiation or administration of 
exogenous H2O2 did not potentiate in vitro TG activity in a large number of cell 
types.29,205 Therefore, TG2 activity in response to ROS may be a secondary effect, 
possibly linked to calcium leakage over the damaged cell membrane or increased 
TG2 expression in apoptosis-prone cells.29,206,207 Indeed, cytosolic ROS were 
reported to trigger an increase in cytosolic calcium.199 In addition, generation of 
ROS was reported to inhibit TG2 degradation.208 
In addition to disulfide formation, TG2 crosslinking activity can be regulated 
by nitrosylation of cysteines.196 Here, the redox balance plays an important role as 
well: cationic nitric oxide causes S-nitrosylation, but anionic NO leads to formation 
of a disulfide bridge.209 In the present study, we showed that activation of TG2 
within the vessel wall, either by reduction or elevated intracellular calcium is 
inhibited by NO. The inhibition of TG2 activity fully prevented inward remodeling. 
As the nitric oxide level falls in several physiological and pathological conditions, 
such as low blood flow, hypertension and aging, this may be an important 
determinant in transglutaminase activity in vivo. Indeed, we previously showed 
that inhibition of NO synthesis results in TG2 dependent inward remodeling.167,210 
In further support, recent work by Santhanam et al.177 showed that vascular 
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stiffening associated with aging depends on TG2 activity and a reduction in nitric 
oxide levels. 
The substrates of TG2 in small artery remodeling have not been previously 
studied. We identified fibronectin as both a lysine and glutamine donor (Table 1). 
Another relevant extracellular substrate is fibulin-2, which is active in tissue 
remodeling by crosslinking several elements in the pericellular matrix.211 The 
confocal images showed high TG2 activity at the interface between smooth 
muscle cells and endothelial cells (Video S2). This layer, the internal elastic lamina, 
contains laminin-nidogen complexes and collagen type IV, which are both known 
substrates for TG2.212,213 We confirmed nidogen-1 as substrate for SMC-derived 
TG2 using BPA. Regarding the collagen family, the alpha-1 chain of collagen type I 
was detected as TG2 substrate. Thus, although we identified a number of proteins 
that are crosslinked and known to determine extracellular matrix properties, the 
actual substrate(s) responsible for remodeling remains to be determined. Also, 
the relevance of the intracellular substrates, including cytoskeletal proteins and 
glycolytic enzymes, warrants further investigation.  
An important question is how reduction of specific proteins such as TG2 is 
achieved in vivo. We addressed this question by studying mRNA expression of 
redox-related proteins using a micro-array approach. Here we found several 
reducing enzymes to be quickly upregulated in vessels undergoing inward 
remodeling (Table 2). Glutathione transferase (GST), which catalyzes the 
conjugation of reduced glutathione to substrate proteins, was strongly 
upregulated after 1 and 2 days, together with glutathione reductase. Interestingly, 
a broad protein interaction study identified GST as the 2nd most important 
interaction partner of immobilized TG2,213 a finding confirmed in several 
pathological conditions.44,214,215 Thioredoxin is expressed amongst others in 
endothelial and SMCs, was detected in plasma216,217 and is involved in protein 
denitrosylation.192 Surprisingly, thioredoxin was downregulated in inward 
remodeling vessels, although its corresponding reductase was slightly upregulated 
at all time points. On the other hand, the expression of selenoprotein P, which is 
structurally closely related to thioredoxin reductase, was elevated 174% after 2 
days. Although protein disulfide isomerase was reported to act as reductase at the 
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cell membrane of SMCs,218 its expression level was unchanged. Macrophage 
migration inhibitory factor, which plays a role during inflammation but also in 
redox regulation at the cell membrane,219 was upregulated at all time points. 
Taken together, the upregulation of a panel of reducing enzymes was identified in 
vessels in the process of inward remodeling. These enzymes could provide a more 
reduced state necessary for TG2 crosslinking activity.  
In summary, using the Cys-277 mutant of TG2 and an active-site inhibitor, we 
showed that the crosslinking action of TG2 is necessary to induce inward 
remodeling of small arteries. Importantly, TG2 needs to be kept in a reduced state 
to fulfill its action. Within the vessel wall, we found that smooth muscle cells 
respond to intracellular reduction with a strong increase in TG2 activity at the cell 
membrane. This localized transglutaminase activity was associated with inward 
remodeling. Of physiological and pathological relevance, TG2 activity and 
remodeling could be inhibited by addition of a NO-donor. A schematic overview of 
the results is given in Figure S5. Using mass spectrometry, we identified a number 
of proteins as substrates for TG2 that could be responsible for the change in 
vessel caliber. Finally, we found several reducing enzymes that were strongly 
upregulated in vessels undergoing inward remodeling induced by low blood flow. 
These enzymes could help to provide a more reduced state during inward 
remodeling in vivo. 
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Figure S1. Effect of DTT on arteries from TG2 knockout mice. Passive pressure-diameter 
relationships of isolated, cannulated arteries from TG2 knockout mice that were exposed 
to DTT showed inward remodeling. In contrast to arteries from C57BL/6 mice, the 
remodeling of arteries from TG2 knockout mice was not sensitive to the TG2 inhibitor 
L682777.  
*** Indicates P<0.001 for control vs. DTT.  
 
 
 
 
Figure S2. SNAP does not alter vessel properties. Passive pressure-diameter relationships 
of isolated, cannulated arteries were not altered after 24 h exposure to the nitric oxide 
donor SNAP (n=5).  
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Figure S3. Fibronectin and nidogen-1 are substrates for TG2 in DTT treated smooth muscle 
cells. TG2 substrates were labeled with BPA or Q-peptide and subsequently purified by 
streptavidin pull down. Control cells were treated with DTT only. (A) Coomassie staining of 
the total lysates and pull downs (* indicates streptavidin band). (B) Western blot stained 
with antibodies against fibronectin and nidogen-1 shows specific labeling of both proteins 
with the lysine donor BPA. For fibronectin an additional high molecular weight product can 
be observed which is labeled with both the lysine and the glutamine donor substrate. 
 
 
 
 
Figure S4. Effect of DTT on vessel reactivity. Treatment with DTT did not significantly alter 
the vessel response to the thromboxane analogue U46619. After incubating vessels for 24 
hrs with 2 mmol/L DTT, maximal contraction to U46619 was unchanged. Data are 
expressed as percentage of vessel diameter at full relaxation. 
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Figure S5. Schematic overview of experimental results. Exogenous, recombinant TG2 
required a reducing agent to induce inward remodeling, which was accomplished by cross-
linking. Only a cell-permeable reducing agent activates a pool of endogenous TG2 that can 
induce inward remodeling. Intracellular TG2 translocates to the cell surface and 
subsequently crosslinks a number of proteins. This can be prevented with a site-specific 
inhibitor of TG2 or an NO donor. Exposure to calcium ionophore increases intracellular 
transglutaminase activity, which also can be counteracted with SNAP. In this case, 
however, inward remodeling is absent.  
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Abstract 
Extracellular transglutaminase 2 (TG2) activity plays an important role in cell 
migration. Changes in extracellular TG2 activity have been linked to various 
pathological conditions with deregulated cell migration, including cancer 
metastasis and invasiveness and abnormal wound healing. Here we show that 
inhibition of extracellular TG2 with Z006 reduces the ability of Movas cells to 
migrate. HeLa cells, which have no detectable extracellular TG2 activity, do not 
show a reduced migration upon incubation with the TG2 inhibitor. Paradoxically, 
activation of the extracellular TG2 by the cell impermeable reducing agent TCEP 
does not enhance, but also inhibits HeLa cell migration. Our data show that active 
extracellular TG2 is involved in cell migration, but its effect on cell migration may 
depend on whether activation is global or localized at specific sites of the cell 
surface.  
 
 
Introduction 
Tissue transglutaminase or transglutaminase 2 (TG2) is a multifunctional 
protein that catalyzes the formation of N,ε(-glutamyl)lysine isopeptide bonds 
between a peptidyllysine and a peptidylglutamine. TG2 can also modify 
peptidylglutamines by amine incorporation and deamidation.3,4 Besides its 
crosslinking activity, TG2 may also bind and hydrolyze guanosine triphosphate 
(GTP) and adenosine triphosphate (ATP). This G protein function of TG2 is 
involved in transmembrane signaling.6 Furthermore, TG2 has been suggested to 
function as a protein disulfide isomerase157 and a protein kinase.220 Functions of 
TG2 are tightly regulated by calcium and GTP.15 Calcium ions are required for its 
crosslinking activity and induces a conformational change required to expose the 
active site to the substrate.14 In contrast, binding of GTP or ATP induces a closed 
conformation.16 The latter lacks the crosslinking activity and acts as a G protein 
instead.6 In the intracellular environment, the normally low calcium and high 
nucleotide concentrations prevent TG2-catalyzed crosslinking. Although calcium 
and nucleotide conditions in the extracellular environment favor the open active 
conformation, most extracellular TG2 does not display crosslinking activity under 
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normal conditions.31 This is most likely explained by the presence of a redox 
sensitive cysteine triad in TG2 that, under oxidative conditions, facilitates the 
formation of a disulfide bond and thereby induces an open but inactive 
conformation.16,27 The latter is in agreement with the in Chapter 5 described 
activation of extracellular TG2 by reducing agents. 
Depending on the (sub)cellular localization, TG2 can be involved in a wide 
variety of cellular processes.29 TG2 localized on the cell surface or in the 
extracellular matrix (ECM) plays an important role in the interactions of cells with 
the surrounding ECM, thereby facilitating adhesion, spreading and motility of 
cells.36,68 TG2 may affect cell migration both in a crosslinking-dependent and -
independent manner.72 Active TG2 may affect cell-ECM interactions by 
crosslinking various ECM proteins including fibronectin, collagen and fibrinogen.66 
On the other hand, inactive TG2 also directly interacts with fibronectin, integrins 
and heparan sulphates and thereby may affect cell-ECM interactions.221,222 These 
aspects of TG2 have been suggested to play an important role in various 
pathological processes, such as abnormal wound healing,67,69 inflammation and 
cancer progression.83  
Here we investigate the influence of activating extracellular TG2 by a reducing 
agent on cell migration. We demonstrate that inhibition of naturally occurring 
active extracellular TG2 in MOVAS cells reduces cell migration, but that global 
activation of extracellular TG2 in HeLa cells with the help of a reducing agent also 
reduces cell migration. Our data suggest that the localization of active TG2 may 
have an important effect on cell migration.  
 
 
Materials and methods 
 
Fluorescent imaging 
Approximately 24 hours prior to the labeling 1 × 105 MOVAS cells or HeLa cells 
were plated in DMEM supplemented with 10% fetal calf serum in 24-well plates 
with 12 mm round glass coverslips. The cells were incubated with 50 µM FITC-
cadaverine (AnaSpec) for 24 hours. The cells were rinsed twice with PBS and 
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incubated for 15 minutes in DMEM with 10% fetal calf serum, to remove non-
crosslinked substrates.138 The cells were rinsed again twice with PBS, fixed with 
2% paraformaldehyde solution for 10 minutes, and rinsed twice with PBS and 
once with water. Coverslips were agitated for 3 minutes between washes. 
Coverslips were dried, mounted on slides using Mowiol 4-88 mounting medium 
containing 0.02% of NaN3 and imaged by fluorescence microscopy using the Leica-
DMRA microscope equipped with COHU CCD camera and QFluoro 1.2 software. 
 
Cell migration assay 
Culture inserts (Ibidi) were placed in a 24-well plate after which 2 × 104 HeLa 
or MOVAS cells were seeded on both sides of the barrier and grown for 15 to 23 
hours in DMEM supplemented with 10% fetal calf serum. The confluent 
monolayer of cells was washed twice with PBS and incubated with DMEM with 
10% fetal calf serum containing the indicated concentrations of tris(2-
carboxyethyl)phosphine (TCEP) and/or 50 µM Z006 (Zedira). The culture inserts 
were removed, resulting in a cell-free gap of 500 μm ± 50 μm, and time lapse 
imaging was performed in a microscope stage incubator (Oko-Lab) on a Nikon 
DiaPhot microscope equipped with a Hamamatsu C8484-05G digital camera. 
Images were taken every hour for the indicated time using TimeLapse software 
(Oko-Lab). Images were analyzed using Tscratch software223 to determine the gap 
size.  
 
Cell viability assay 
The relative number of adherent viable cells was determined using the crystal 
violet assay. Approximately 3 × 104 HeLa or MOVAS cells were seeded in a 96-
wells plate in DMEM supplemented with 10% fetal calf serum and grown for 
approximately 24 hours. To prevent evaporation of the growth medium, no cells 
were seeded in the outer wells, to which PBS was added instead. The cells were 
incubated for 24 hours with DMEM with 10% fetal calf serum containing the 
indicated concentrations of reducing agent and/or 50 µM Z006. The cells were 
rinsed twice with PBS and incubated for 30 minutes at room temperature with 
100 μL 20% methanol containing 0.5% crystal violet (Merck). The 96-wells plate 
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was washed with water, dried and 100 μL methanol was added to each well. After 
1 hour shaking, the absorption at 540 nm was measured using a Tecan Sunrise 
ELISA reader.  
 
Labeling of TG2 substrates with biotinylated Q-peptide 
Approximately 3 × 105 HeLa cells were plated in DMEM with 10% fetal calf 
serum in 6-well plates. After 24 hours, HeLa cells were incubated as indicated with 
250 µM Q-peptide (Biotin-GQEPVR-OH) in the presence of varying concentrations 
of reducing agent. After 24 hours cells were rinsed trice with PBS and lysed in 200 
μL 2% SDS. Lysates were incubated at 95°C for 5 minutes, sonicated (5 times 30 
seconds at 0°C) and protein concentrations were determined using the Pierce BCA 
Protein assay (Thermo scientific). Sample buffer was subsequently added to a final 
concentration of 2% SDS, 5% -mercaptoethanol, 10% glycerol, 0.03% 
bromophenol blue and 0.25 M Tris-HCl, pH 6.8. The biotinylated proteins were 
analyzed by SDS-PAGE and western blot (see below). 
 
SDS-PAGE and western blot analysis 
SDS-PAGE (Sodium dodecyl sulphate polyacrylamide gelelectrophoresis) was 
performed according to standard procedures. Proteins were transferred to 
nitrocellulose membranes (GE Healthcare) by electroblotting for western blot 
analysis. Biotinylated proteins were detected by incubating the membranes with 
IRDye 800CW Streptavidin (Li-Cor) and -tubulin was detected by incubating with 
mouse monoclonal anti--tubulin (GTU-88, Abcam) followed by IRDye 680CW 
conjugated polyclonal goat anti-mouse (Li-Cor). Bound streptavidin or secondary 
antibodies were visualized using an Odyssey Infrared Imaging System (Li-Cor). 
 
Statistical analysis 
Results are given as mean ± standard error of the mean (s.e.m.). Data were 
analyzed using an unpaired T-test to assess statistical significance. P-values 
smaller than 0.05 and 0.01 are indicated either in the figure or given in the figure 
legend.  
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Results 
 
The effect of TG2 inhibition on the migration of MOVAS cells 
To establish the presence and localization of active TG2 in MOVAS cells, we 
applied the fluorescent TG2 substrate FITC-cadaverine.138 MOVAS cells were 
cultured for 24 hours in the presence of FITC-cadaverine (50 μM), fixed and 
analyzed by fluorescence microscopy (Figure 1A). A few cells showed a 
homogenous staining pattern (Figure 1A, indicated with arrowheads). The 
morphological changes of these cells indicated that the stained cells represent 
dying cells, which are known to have high intracellular TG2 activity.224 Most of the 
cells showed heterogeneous incorporation of FITC-cadaverine in structures 
located around the edges of the cells (Figure 1A, indicated with asterisks). This 
represents the TG2 activity in majority of the MOVAS cells which appears to be 
located at the cell surface or in the extracellular matrix.  
To determine whether the TG2 activity plays a role in the migration of MOVAS 
cells, we used the TG2-specific irreversible active-site inhibitor Z006.163 Migration 
of a population of cells does not only depend on their motility, but also on their 
proliferation and survival rates. Therefore, we first performed a crystal violet 
assay to show that Z006 (50 μM) does not affect proliferation and/or does not 
induce cell death in MOVAS cell (Figure 1B). Next, confluent MOVAS cell 
monolayers were allowed to migrate across a gap in the presence or absence of 
Z006. Cell migration was monitored by time lapse imaging for 15 hours. For both 
conditions representative phase-contrast microscopy pictures are shown after 0 
and 10 hours (Figure 1C). The relative gap sizes were determined for both 
conditions and plotted as a function of time (Figure 1D). The non-treated control 
cells reached confluency in approximately 11 hours. However, when treated with 
Z006, MOVAS cells migrated significantly slower reaching confluency in 
approximately 14 hours. Combined with the observation that Z006 does not 
interfere with MOVAS cell viability, these data suggest that the TG2 activity 
associated with MOVAS cells is directly involved in cell migration.  
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Figure 1. (on the left page) Involvement of TG2 activity in the migration of MOVAS cells. 
(A) MOVAS cells were incubated with the TG2 substrate FITC-cadaverine for 24 hours 
followed by fixation and analysis by fluorescence microscopy for bright field (BF, upper 
panel) and FITC (middle panel). Overlays are composed of both channels (merge, lower 
panel). Cells showing a homogenous cellular staining are indicated with arrowheads and 
cells surrounded with a lattice-shaped staining are indicated with asterisks. Scale bar: 20 
µm. (B) Effect of the TG2 inhibitor Z006 on the viability of MOVAS cells. Cells were cultured 
in the presence or absence of Z006 for 24 hours after which the relative cell density was 
measured using crystal violet assay. Data represent mean + s.e.m. of 5 measurements per 
condition. (C) The effect of the TG2 inhibitor Z006 on the migration of MOVAS cells. 
Confluent monolayers of MOVAS cells were allowed to migrate across a gap in the 
presence (Z006) or absence (control) of Z006 for 15 hours. Representative phase contrast 
microscopy pictures were taken with an interval of 1 hour and are shown after 0 (left 
panels) and 10 hours (right panels). (D) The relative gap area was quantified for all 
conditions and time points and plotted against time. The relative gap area was determined 
by dividing it through the initial gap area at 0 hours, which was set at 100%. Data 
represent mean ± s.e.m. of 6 measurements per condition/time point. P < 0.01 from 2 to 12 
hours. 
 
The effect of TG2 inhibition on the migration of HeLa cells 
We evaluated the TG2 activity present in the HeLa cell line using the same 
approach as described for the MOVAS cell line (Figure 2A). Again, homogeneous 
TG2 activity was only observed in a few cells, which based on their morphology 
are likely dying cells (indicated with arrowheads). In contrast to the MOVAS cells, 
no additional TG2 activity was detected, indicating that under normal conditions 
extracellular TG2 activity in HeLa cells is very low or absent.  
We subsequently tested whether Z006-treatment affects the migration of 
HeLa cells. The crystal violet assay showed that Z006 did not affect the viability of 
HeLa cells (Figure 2B). Confluent monolayers of HeLa cells were incubated with or 
without Z006 and allowed to migrate across a gap for 23 hours. The migration was 
monitored by time lapse imaging, after which the relative gap sizes were 
quantified. Representative phase-contrast microscopy pictures are shown after 0 
and 20 hours (Figure 2C). Compared to MOVAS cells, which reached confluence in 
approximately  11  hours,  HeLa  cells  migrated  slower  reaching  near  confluency  
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Figure 2. (on the left page) Involvement of TG2 activity in the migration of HeLa cells. (A) 
Visualization of the TG2 activity in HeLa cells. The analysis was performed as described for 
Figure 1A. Cells showing a homogenous cellular staining are indicated with arrowheads. 
Scale bar: 20 µm. (B) The effect of the TG2 inhibitor Z006 on the viability of HeLa cells. The 
analysis was performed as described for Figure 1B. (C) The effect of the TG2 inhibitor Z006 
on the migration of HeLa cells. Confluent monolayers of HeLa cells were allowed to 
migrate across a gap in the presence (Z006) or absence (control) of Z006 for 23 hours. 
Representative phase contrast microscopy pictures are shown after 0 (left panels) and 20 
hours (right panels). (D) Time course of the migration of HeLa cells in the absence or 
presence of Z006. The analysis was performed as described for Figure 1D. 
 
after 20 hours (Figure 2D). No difference was observed between non-treated and 
Z006-treated cells. These data indicate that, in contrast to MOVAS cells, HeLa cells 
do not display extracellular TG2 activity and, in agreement with this, the TG2 
inhibitor does not affect their migration rate. 
 
Activation of extracellular TG2 by a reducing agent 
Since the redox state has been shown to be a regulator of extracellular TG2 
activity,27 we investigated whether a reducing agent could activate the 
extracellular TG2 of HeLa cells. Extracellular TG2 activity was detected by 
incubation with a cell-impermeable biotinylated Q-donor substrate peptide 
(Biotin-GQEPVR-OH). Cells were incubated for 24 hours with the biotinylated Q-
peptide and different concentrations of the reducing agents dithiothreitol (DTT) or 
tris(2-carboxyethyl)phosphine (TCEP), after which the biotinylated proteins were 
detected by western blot analysis (Figure 3). -Tubulin was used as a loading 
control. When HeLa cells were incubated solely with the biotinylated Q-peptide, 
already some crosslinking to HeLa proteins was observed (Figure 3A, compare 
lane 1 and 2). This background staining was most likely due to TG2 activity present 
in the dying HeLa cells which have lost their membrane integrity (see Figure 2A). 
Increased crosslinking of the biotinylated Q-peptide to HeLa proteins was 
observed upon incubation with 0.5 and 1.0 mM of the reducing agents DTT and 
TCEP, and was most pronounced for the cell-permeable DTT (Figure 3). The 
increased labeling is most clearly visible for high molecular weight protein 
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complexes that are unable to migrate through the gel (Figure 3A, indicated with 
arrowhead). These data indicate that both TCEP and DTT are able to activate 
extracellular TG2 of HeLa cells.  
 
 
Figure 3. The effect of the reducing agents DTT and TCEP on the HeLa cell TG2 activity. 
Cells were incubated with a concentration series of the reducing agents (0.1, 0.5, 1 mM) 
for 24 hours in the presence of the cell impermeable biotinylated TG2 Q-donor substrate 
peptide. Protein biotinylation was monitored by western blotting using labeled streptavidin 
(upper panels). As a loading control -tubulin was detected using a monoclonal antibody 
(lower panels). The molecular weights and positions of the protein markers are indicated 
on the left. Heavily labeled high molecular weight protein complexes at the top of the 
stacking gel are indicated with an arrowhead. 
 
Effect of reducing conditions on HeLa cell migration 
Before investigating the effect of the reducing agents on HeLa cell migration, 
we first analyzed the effect of the reducing agents on HeLa cell viability. Using the 
crystal violet assay it was found that DTT significantly reduced cell viability (Figure 
4A). TCEP did not significantly affect HeLa cell viability, even in combination with 
Z006. Therefore, only TCEP was used to activate TG2 in the cell migration assay. 
Confluent HeLa cell monolayers were allowed to migrate across a gap for 23 hours 
during which the relative gap sizes were quantified and plotted against time. 
Representative phase-contrast microscopy pictures are shown in Figure 4B. 
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Remarkably, cell migration was significantly reduced by applying 0.5 mM and 1.0 
mM TCEP (Figure 4C). Since the relative number of viable HeLa cells was not 
affected by TCEP, these results suggest a direct effect of TCEP on the motility of 
HeLa cells. In agreement with the results of previous experiments, treatment with 
Z006 alone did not change HeLa cell migration (Figure 4C, compare Z006 with 
control for 0.0 mM TCEP). However, when Z006 was applied in the presence of 
TCEP, the reduced migration due to TCEP-treatment was partially rescued. These 
data show that TCEP treatment reduces the motility of HeLa cells via a mechanism 
that is at least partially dependent on the activation of TG2. 
 
 
Discussion 
Cell migration plays an important role in various physiological as well as 
pathological conditions such as inflammation, wound healing, fibrosis and tumor 
metastasis. A significant body of evidence implicates both the crosslinking-
dependent and -independent functions of extracellular TG2 in cell 
migration.35,72,76,225,226 Interestingly, extracellular TG2 generally shows no activity 
in vivo under normal conditions, but becomes active during tissue injury or 
inflammation.31 Although the role of TG2-mediated crosslinking under these 
conditions has been well documented, the mechanism that regulates this activity 
in vivo remains unclear. Recently, a redox sensitive cysteine triad has been 
identified which likely regulates its activity in the extracellular environment. The 
oxidative conditions may facilitate the formation of a vicinal disulfide bond that 
induces an open but inactive conformation.16,27  
In the present study we investigated the role of active TG2 in cell migration. 
As model systems, we used HeLa carcinoma and MOVAS smooth muscle cell lines. 
In contrast to HeLa cells, MOVAS cells showed under normal conditions TG2 
activity on the cell surface and/or in the ECM. The observed activity with MOVAS 
cells was unexpected, because extracellular TG2 is considered to be catalytically 
inactive without stimulation of the cells.31 Since the oxidative inactivation of TG2 
appeared to be relatively slow,227 it is possible that MOVAS cells maintain 
detectable levels of activated extracellular TG2 due to a relatively high export rate 
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Figure 4. (on the left page) The effect of reducing agents on the viability and migration of 
HeLa cells. (A) The viability of HeLa cells was determined in the presence of 0.0, 0.5 and 1.0 
mM DTT and TCEP in the absence (control) or presence (Z006) of Z006. The analysis was 
performed as described for Figure 1B. DTT-treated control vs. non-treated control: * P < 
0.05, ** P < 0.01. (B) The effect on HeLa cell migration was determined for TCEP using 
precisely the same conditions as for the cell viability assay. The analysis was performed as 
described for Figure 2C. Representative phase contrast microscopy pictures are shown at 
the start of the experiment (0 hr.) for 0.0 mM TCEP (first column) and after 20 hours for all 
TCEP concentrations (0.0 mM, second column, 0.5 mM, third column and 1.0 mM, fourth 
column). (C) Time course of HeLa cell migration. The analysis was performed as described 
for Figure 1D. Data represent mean ± s.e.m. from 3 measurements per condition/time 
point. The migration was significantly rescued by co-treatment with Z006 both at 0.5 mM 
TCEP (P < 0.05 from 8 to 12 hours) and at 1.0 mM TCEP (P < 0.05 from 10 to 20 hours). 
 
of reduced TG2. Also the expression of specific heparan sulfate proteoglycans on 
the cell surface may contribute to the enhancement of extracellular TG2 
activity.228 Alternatively, MOVAS cells may create a reducing extracellular 
microenvironment by secreting factors able to reduce the disulfide bond of the 
vicinal cysteine residues of TG2, such as thioredoxin,227 and thereby avoiding 
oxidation of TG2. By using the inhibitor Z006 we have demonstrated that the 
extracellular TG2 activity positively affects the mobility of MOVAS cells. In 
agreement with the lack of extracellular TG2 activity on HeLa cells, their mobility 
was not affected by the TG2 inhibitor. This is consistent with previously published 
data showing that in rich medium the migration of HeLa cells is independent on 
TG2 activity.225 Although it is not exactly known how active extracellular TG2 
stimulates cell migration, several mechanisms can be envisaged. TG2 may locally 
crosslink ECM proteins, such as fibronectin, fibrinogen and collagen, thereby 
allowing a cell-ECM interaction that is more suitable for cell migration by 
stabilizing the extracellular matrix.229 Alternatively, TG2 may affect other plasma 
membrane proteins that are involved in cell migration, such as matrix 
metalloproteinase 9.230 Further investigations are needed to clarify how active 
TG2 influences cell migration.  
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TCEP is a cell impermeable agent with sufficient reducing capacity to activate 
oxidized TG2. Treatment of HeLa cells with TCEP reduced the motility of HeLa 
cells, which appeared to be partially depending on the activation of TG2. A 
completely TG2-dependent mechanism is unlikely since other proteins involved in 
cell migration, such as matrix metalloproteinase 1, are also known to be redox-
regulated.231 Paradoxically, TCEP-induced TG2 activation reduced HeLa cell 
migration, whereas active TG2 associated with MOVAS cells appeared to stimulate 
cell migration. Furthermore, active TG2 has been shown to enhance the migration 
of HeLa cells when it is localized at the leading edges.225,226 These discrepancies 
might be explained by the global activation of TG2 in the presence of TCEP, 
whereas cell migration requires the local activation of extracellular TG2 at specific 
sites on the cell surface. The more uniformly distributed TG2 activity likely 
increases cell adhesion not only at the leading edges, but also at sites where cell-
ECM contacts need to be broken, resulting in the observed inhibition of cell 
motility. In an attempt to determine the localization of TCEP-induced TG2 activity, 
we used the fluorescent TG2 substrate FITC-cadaverine. However, no 
incorporation of FITC-cadaverine could be detected (data not shown), which 
might due to the lack of localized activation resulting in a diffuse signal too low to 
be detected.  
Overall, we show a potential redox-dependent mechanism for TG2 activation 
during cell migration. Our findings suggest that the subcellular localization of the 
TG2 activity is physiologically relevant. Since TG2 overexpression and/or aberrant 
activation have been noted in a significant percentage of the more aggressive 
tumors, TG2 inhibitors have been tested for the efficacy to limit their aggressive 
behaviour.59 Our results show that not only TG2 inhibitors but also non-specific 
activators could potentially be important in therapeutic intervention against 
human malignancies whose aggressive phenotype is coupled to TG2 expression.  
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General discussion 
 
Tissue transglutaminase, also called transglutaminase 2 (TG2), is a 
multifunctional protein that may function as a protein crosslinker, G protein and 
an adaptor protein.29 The focus of this thesis is on the crosslinking activity of TG2, 
which is a Ca2+-dependent transamidation reaction by which N,ε(-glutamyl)lysine 
isopeptide bonds are formed between a peptidyllysine and a peptidylglutamine. 
TG2 may also use primary amines or water instead of peptidyllysine, which leads 
to amine incorporation or deamidation of peptidylglutamines.3,4 The crosslinking 
activity of TG2 plays an important role in various cellular processes ranging from 
apoptosis, cell differentiation, adhesion and migration. Not surprisingly, TG2 
activity has been implicated in a wide variety of diseases including various 
inflammatory diseases, (neurodegenerative) protein folding diseases and cancer. 
Despite extensive research, the exact role of TG2 in many of these cellular and 
pathological processes remains unknown. The research presented in this thesis 
was performed to gain more insight in the role of TG2-catalyzed crosslinking.  
To better understand the role of TG2-catalyzed crosslinking, it is crucial to 
have sophisticated tools that allow detection of TG2 activity and/or substrates. In 
the last decades, much effort has been spent to improve existing methods, for 
example by designing isoform-specific substrate peptides for TG2, which enables 
to discriminate between the different transglutaminase isozymes.86 The first part 
of this thesis (Chapter 2 – 4) describes how recent developments in the field of 
click chemistry have been exploited to develop a novel detection method for TG2 
activity and/or substrates. The advantage of this new approach is the relative 
small size of the amine-donor substrates and the flexibility provided by the 
chemical ligation step. The second part of this thesis focuses on the functional 
aspects of TG2 and addresses the role of extracellular TG2 activity both in inward 
remodeling of small arteries (Chapter 5) and in cell migration (Chapter 6). Here, I 
specifically focus on the role of redox-dependent regulation of TG2 activity in 
these physiological processes. The redox state is a recently discovered third 
regulatory mechanism of TG2 activity and is believed to be responsible for the 
regulation of extracellular activity of TG2 in vivo.27 In this chapter the most 
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important findings of this thesis will be summarized and discussed. Finally, I will 
speculate about potential future directions. 
 
Synthesis and characterization of clickable amine-donor substrates for TG2 
The detection method for TG2 activity described in this thesis is based on the 
bioorthogonal chemical reporter strategy (see also paragraph 2.5 of Chapter 1). In 
this approach, we used a set of azide- and alkyne-containing amine-donor 
substrates that allow, after being crosslinked to glutamine-donor proteins by TG2, 
specific labeling of these proteins via the azide-alkyne cycloaddition (also known 
as the click reaction). This method is characterized by the smaller size of the 
amine-donor substrates compared to standard substrates such as BPA and 
biotinylated peptide, and by the more flexible way of labeling substrate proteins 
allowing several different applications after the crosslinking step (Figure 1). 
Although similar approaches have been applied to study other enzymatic activities 
or posttranslational modifications, this study was the first to describe a click 
chemistry-based method for the detection of TG2 activity and for the 
identification of its substrates. A panel of four azide- or alkyne-containing amine-
donor substrates for TG2 have been synthesized as described in chapter 2. These 
substrates can easily be obtained via a straightforward synthetic route which only 
consists of 3 or 4 steps. All four substrates consist of a pentylamine, which is 
efficiently recognized by TG2, conjugated to either an azide- or alkyne-handle via 
a variable linker region. With the exception of rarely used radiolabeled substrates 
like 14C- or 3H-labeled putrescine,232 these clickable TG2 substrates are much 
smaller compared to other labeled TG2 substrates, which contain for example a 
biotin or fluorescent moiety. This has the advantage that these substrates may 
reveal novel amine-acceptor sites that are structurally less accessible and 
therefore exclusively allow incorporation of small (naturally occurring) amines. 
Possibly, novel substrates may be identified in a proteomics-based analysis where 
the azide or alkyne moieties may be conveniently used as a handle for 
purification.  
The applicability of the clickable TG2 substrates depends on several factors 
including the efficiency and specificity by which TG2-catalyzed crosslinking occurs, 
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but also other characteristics such as membrane permeability. The research 
presented in chapter 4 deals with these aspects. Both in vitro and in vivo studies 
show that the efficiencies by which TG2 incorporates the different azide- and 
alkyne-containing substrates into acceptor peptides or proteins are comparable, 
suggesting that the addition of a small hydrophobic alkyl chain does not increase 
the reactivity of TG2 towards these pentylamines. Furthermore, the crosslinking 
efficiencies also resemble those observed for the commonly used TG2 substrates 
5-(biotinamido)pentylamine (BPA) and FITC-cadaverine. Although we could not 
detect significant differences in crosslinking efficiencies, it remains possible that a  
 
Figure 1. Schematic representation of the labeling of transglutaminase substrate proteins 
via BPA (upper reaction), a biotinylated peptide (middle reaction) and an azide-containing 
substrate (lower reaction). The azide-conjugated substrate proteins can be labeled via the 
click reaction in several different ways.  
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limited number of substrate proteins with lesser accessible glutamines do have a 
preference for a specific TG2 substrate. Indeed, others did report an increased 
affinity of TG2 towards cadaverine when adding a hydrophobic moiety such as a 
dansyl group.137,139 The high crosslinking efficiencies of the clickable substrates are 
important because this also allows detection of relatively low levels of TG2 
activity. For example, a very short activation of TG2 by a temporal elevation of the 
intracellular calcium, which occurs during harvesting of HeLa cells with a cell 
scraper, could still be detected. Furthermore, we show that the incorporation of 
the clickable substrates into HeLa cell proteins is indeed TG2-mediated. This could 
be confirmed by inhibition of TG2 activity using the irreversible active-site 
inhibitor Z006 and by downregulation of TG2 using two different siRNAs directed 
against TG2. However, it should be noted that TG2 is the only type of 
transglutaminase highly expressed in HeLa cells. Small amine-donors are not 
considered to be specific for one transglutaminase isoform and can also be 
crosslinked by other types of transglutaminases. For example, the amine-donor 
substrate BPA has also been used to detect the crosslinking activities of TG1233 
and factor XIII.234 To our knowledge, only certain glutamine-donor peptides have 
been reported that enable to differentiate between the activity of different 
transglutaminases.48,88 Therefore, it is to be expected that the clickable amine-
donor substrates can be applied to monitor the total crosslinking activity of most, 
if not all transglutaminase isoforms.  
Since TG2 is predominantly a cytoplasmic protein, it was important to find out 
whether or not the azide- and alkyne-functionalized substrates could pass the cell 
membrane. This was investigated by treating HeLa cells with a low dose of 
calcium-ionophore (10 µM), which results in elevated intracellular calcium levels 
without disrupting the plasma membrane. In these experiments, a TG2 peptide 
substrate, unable to pass the cell membrane, was used as a negative control. 
Under these conditions, all clickable substrates were efficiently incorporated into 
a variety of HeLa cell proteins. Also the cytosolic substrate protein HspB6, which 
was overexpressed in HeLa cells, was efficiently labeled, indicating that all four 
substrates are indeed able to pass the cell membrane. Overall, we conclude that 
the azide- and alkyne-containing pentylamines are excellent substrates for TG2 
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and are widely applicable for the specific and efficient detection of 
transglutaminase activity, not only in the extracellular but also in the intracellular 
environment.  
 
Specificity of the azide-alkyne cycloaddition 
A crucial factor that determines the applicability of any approach based on 
the bioorthogonal chemical reporter strategy is the efficiency and specificity by 
which the chemical ligation step takes place. In the last decade, much effort has 
been spent in the development of different reaction types that proceed efficiently 
under physiological conditions while being inert to other biomolecules. Especially 
the azide-alkyne cycloaddition has proven to be extremely well suited for the 
specific labeling of tagged biomolecules in complex systems and has been applied 
for the detection of various types of posttranslational modifications including 
protein glycosylation,136 lipidation,126 acetylation,127 and methylation.129 We 
applied both the copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC), which 
occurs between an azide and a terminal alkyne in the presence of catalytic 
amounts of copper(I), and the strain-promoted azide-alkyne cycloaddition 
(SPAAC), which occurs between an azide and a more activated strained 
cyclooctyne under physiological conditions without the need for a toxic copper(I)-
catalyst. Although the azide-alkyne cycloaddition is considered to be 
bioorthogonal, we show that azide-independent labeling of proteins by alkynes 
may occur to a certain extent, thereby limiting the sensitivity of the assay 
(Chapter 3). In particular the more activated strained cyclooctynes react in an 
azide-independent manner with proteins in a cell lysate. As also reported by 
others,113 we demonstrate that azide-independent labeling by cyclooctynes 
mainly occurs via thiol-yne addition with reduced peptidylcysteines, which can be 
prevented by alkylating the thiol group of reduced peptidylcysteines with 
iodoacetamide (IAM). Since IAM is compatible with SPAAC itself, pre-treatment of 
azido-modified proteins with IAM may significantly enhance the specificity of 
SPAAC-based labeling. When labeling proteins in a cell lysate via SPAAC, 
preincubation with IAM reduces the azide-independent labeling with 
approximately 70-80%, resulting in comparable background levels as observed for 
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CuAAC. The remaining azide-independent labeling by cyclooctynes most likely 
occurs via other functionalities in proteins than thiols. Also terminal alkynes, 
which are not reactive towards reduced cysteines, do show a mild reactivity 
towards other functional groups present in proteins. Further investigations are 
required to find out which functionalities, besides thiols, may react with (strained) 
alkynes and how these reactions can be prevented.  
In contrast to terminal as well as strained alkynes, the azide-moiety appeared 
to be truly bioorthogonal as it did not show any reactivity towards native proteins 
in a cell lysate. This allowed us to detect TG2 activity in a completely specific 
manner by using an alkyne- instead of azide-containing TG2 substrate, which 
could be detected with a biotinylated azide via CuAAC (Chapter 4). Detection of 
TG2 activity via the alkyne-functionalized substrate was achieved with an 
improved signal-to-noise ratio, which may be particularly useful when monitoring 
low levels of TG2 activity. Unfortunately, the terminal alkyne cannot be detected 
in vivo due to the toxic copper(I)-catalyst required for the click reaction. However, 
pentylamines containing a mildly activated cyclooctyne variant, which is relatively 
stable in the presence of thiol groups, might be used for in vivo detection of TG2 
activity.  
The research described in this thesis shows that specific labeling of tagged 
proteins in a cell lysate can be achieved via CuAAC and, after preincubation with 
IAM, also via SPAAC. Unfortunately, both Cu(I) and IAM are, due to their toxicity, 
restricted to ex vivo applications such as the detection and/or purification of 
azido-modified proteins in a cell lysate or visualization of azido-modified proteins 
in fixed cells. In vivo labeling has been reported to be possible in experiments 
applying membrane-impermeable cyclooctynes such as DIBO and BCN.110,148 
Presumably this is because most extracellular peptidylcysteines are in the oxidized 
state and thus do not react. Interestingly, the in vivo labeling of extracellular 
proteins resulted in higher signal-to-noise ratios when using more activated 
cyclooctynes, which is in contrast to what is observed for the labeling of cell lysate 
proteins.148 The specificity by which different cyclooctynes react thus clearly 
depends on the experimental conditions. Further experiments will be required to 
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answer the question whether intra- and/or extracellular TG2 activity can be 
detected via SPAAC in vivo.  
Overall, it can be concluded that the most optimal experimental approach, 
either CuAAC with an azide- or alkyne-containing probe, or SPAAC with or without 
IAM-treatment using either mildly or strongly activated cyclooctynes, depends on 
the type of experiment and the research question addressed. When using the 
appropriate conditions, the chemical ligation step can be advantageous since it 
provides a more flexible way to specifically and efficiently label TG2 substrate 
proteins without the need for a large probe during the enzymatic labeling step. 
 
Effect of reducing conditions on extracellular TG2 activity and physiological 
implications 
Although high calcium and low GTP levels in the extracellular environment are 
in favor of the open active conformation of TG2, the majority of extracellular TG2 
proved to be inactive under normal physiological conditions.31 Recently, Stamnaes 
et al. showed that under oxidative conditions, a disulfide bond is formed between 
cysteines 230 and 370 of TG2, which subsequently facilitates the formation of a 
vicinal disulfide bond between cysteines 370 and 371, resulting in an open but 
inactive conformation.27 This third allosteric regulatory mechanism is most likely 
responsible for the oxidative inactivation of extracellular TG2. Since oxidative 
inactivation of TG2 is a reversible process, changes in the extracellular redox state 
may directly lead to activation of extracellular TG2. Thus, besides the transient 
activation of reduced TG2 upon secretion into the extracellular environment, this 
may very well be an important regulatory mechanism for extracellular TG2 activity 
in vivo. For this reason the second part of this thesis is focused on the effect of the 
redox state on extracellular TG2 activity as well as its potential role in different 
physiological processes, including arterial remodeling (Chapter 5) and cell 
migration (Chapter 6). 
TG2 has previously been reported to play a crucial role in the inward 
remodeling of small arteries after reduced blood flow and hypertension.170,172 
However, the mechanism by which TG2 contributes to vascular remodeling 
remains poorly understood. In Chapter 5 we show that the redox state of TG2 is 
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an important factor in small artery remodeling. It was shown that the cell-
permeable reducing agent dithiothreitol (DTT), but not the cell-impermeable 
reducing agent tris(2-carboxyethyl)phosphine (TCEP), induces translocation of 
endogenous TG2 to the cell surface and high membrane-bound TG2 activity, 
resulting in inward remodeling. However, TCEP was also capable of inducing 
inward remodeling in the presence of exogenous recombinant TG2, indicating 
that activated extracellular TG2 is responsible for the arterial remodeling. 
Importantly, no remodeling was observed when using either a catalytically 
inactive TG2 mutant or a TG2 specific inhibitor, demonstrating that the observed 
extracellular TG2 activity is indeed required. Interestingly, these results indicate 
that arterial remodeling does not only depend on activation of extracellular TG2, 
but also on the translocation of intracellular TG2 to the cell surface. The latter 
requires intracellular reduction and occurs via a yet unknown mechanism.  
Another important function of extracellular TG2 is the regulation of 
interactions between cells and the extracellular matrix (ECM), which are crucial 
for the adhesion, spreading and motility of cells.36,68 Both the crosslinking-
dependent and -independent functions of TG2 have been implicated in cell 
migration.72 While inactive TG2 may directly interact with multiple adhesion 
molecules including fibronectin, integrins and heparan sulphates,221,222 active TG2 
may affect cell-ECM interactions by crosslinking various extracellular proteins 
including collagen, fibrinogen and fibronectin.66 However, the exact mechanisms 
involved in these processes remain unclear. Therefore, the potential role of TG2 in 
cell migration was studied by alterations of the redox state (Chapter 6). In 
contrast to DTT, the cell-impermeable TCEP did not affect HeLa cell viability and 
was therefore found to be more suitable to study the effect of extracellular TG2 
activity on HeLa cell migration. It was shown that treatment of HeLa cells with 
TCEP reduced the motility of HeLa cells in a partially TG2-dependend manner. A 
completely TG2-dependent mechanism is unlikely since TCEP is a nonspecific 
reducing agent and will therefore also affect other redox-regulated proteins 
involved in cell migration, such as matrix metalloproteinase 1.231 Interestingly, 
TCEP-induced extracellular TG2 activity reduces cell motility, while active 
extracellular TG2 present in MOVAS cells appears to stimulate cell migration. 
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These discrepancies might be explained by the global activation of TG2 in the 
presence of TCEP, whereas cell migration requires the local activation of 
extracellular TG2 at specific sites on the cell surface. This is in line with the 
observation that active TG2 promotes HeLa cell migration when localized at the 
leading edges.225,226 Our data thus suggest that activation of extracellular TG2 
occurs locally in case of the stimulation of cell migration. However, more studies 
need to be performed to determine the effect of the localization of active TG2 on 
cell adhesion and motility. 
The studies described in this thesis clearly show that the redox state affects 
extracellular TG2 activity and its associated physiological functions. However, 
activation has only been demonstrated under artificial conditions using reducing 
agents. Therefore, the question remains unanswered whether or not extracellular 
TG2 may indeed be activated by reduction in vivo. Proteins involved in redox 
regulatory processes would be the most likely candidates to facilitate the 
activation of extracellular TG2 in vivo. Interestingly, various reducing enzymes, 
including gluthathione transferase (GST) and selenoprotein P, proved to be 
upregulated during inward remodeling of rat mesenteric arteries. In addition, 
human thioredoxin (Trx), which can be secreted into the extracellular 
environment during inflammation, has recently been shown to specifically 
recognize and reduce the disulfide bond of TG2.227 These findings suggest that 
activation of extracellular TG2 via reduction may indeed be an important 
regulatory mechanism in various physiological and possibly also pathological 
processes that occur in vivo.  
 
Concluding remarks and future perspectives 
The click chemistry-based method described in the first part of this thesis may 
be an attractive alternative method for the detection of TG2 activity and/or the 
identification of substrate proteins. The most significant advantages are the 
relatively small size of the amine-donor substrate and the introduction of a 
flexible bioorthogonal labeling step. With this in mind, one can speculate about its 
potential future applications. As mentioned earlier, a proteomics-based analysis 
using the clickable pentylamines would be particularly interesting since it may 
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lead to the identification of novel TG2 substrate proteins. Other studies already 
demonstrated the advantage of combining a click-chemistry based strategy with a 
proteomic approach when identifying new substrate proteins, for example for 
protein glycosylation.235 In addition, a proteomics study may also reveal 
differences in specificity by which TG2 conjugates various amine-donors to 
specific peptidylglutamines. Additionally, it would be interesting to find out how 
these clickable substrates behave not only in living cells, but also in animal model 
systems.  
The click chemistry-based strategy may also be useful for mimicking small 
primary biogenic monoamines (PBMAs) such as serotonin, norepinephrine, 
histamine and dopamine.236 Until recently, PBMAs were considered only as 
natural inhibitors for TG2-catalyzed crosslinking. However, recent findings suggest 
that conjugation of these PBMAs to proteins plays an important role in multiple 
physiological as well as pathological processes.236 Since the isolation and 
subsequent identification of modified target proteins remains challenging, little is 
known about the functional role of these posttranslational modifications. Possibly, 
novel substrate proteins containing PBMA-acceptor glutamines may be revealed 
when using a PBMA analogue containing a small azide- or alkyne handle instead of 
a more commonly used label such as biotin.  
In the last decades, the crosslinking activity of TG2 has also been employed to 
achieve site-selective labeling of proteins. In this way, a protein of interest may be 
visualized by conjugation to a fluorescent probe.237 In addition, site-selective 
PEGylation of therapeutic proteins by TG2 may alter the pharmacokinetics, water 
solubility and immunogenicity of these proteins.238,239 In such an approach, the 
flexibility may also be increased by introducing a bioorthogonal labeling step. 
Interestingly, this strategy has recently also been proposed by others.240  
The second part of this thesis shows that redox-induced activation of 
extracellular TG2 might be an important regulatory mechanism for its 
physiological functions in vivo. Here, we show that both cell migration and arterial 
remodeling depend on the redox state of TG2. However, it can be envisioned that 
the redox state of TG2 may affect many more physiological as well as pathological 
processes associated with extracellular TG2 activity, as for example fibrosis, 
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wound healing and cancer. Future studies will clarify whether or not endogenous 
factors may indeed activate extracellular TG2 by reduction, which exact 
mechanisms are involved and to what extent these processes may affect the 
functions of extracellular TG2 in vivo.  
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Summary 
 
Transglutaminase 2 (TG2) is a multifunctional protein that catalyzes the 
formation of isopeptide bonds between the -amino group of a peptidyllysine (the 
amine-donor) and the -carboxamido group of a peptidylglutamine (the amine-
acceptor), leading to intra- or intermolecular protein crosslinking. The crosslinking 
activity of TG2 plays an important role in various cellular processes including 
apoptosis, cell differentiation and migration. Furthermore, deregulated TG2 
expression and/or activity has been associated with several inflammatory diseases 
(e.g. celiac disease and multiple sclerosis), protein folding diseases (e.g. 
Alzheimer’s disease and Parkinson’s disease) and cancer. However, the 
mechanism by which TG2 contributes to many of these (pathological) processes 
remains poorly understood. To gain more knowledge about TG2, it is crucial to 
have sophisticated tools that allow detection of TG2 activity and/or identification 
of its protein substrates. The main objective of this study was to develop an 
improved detection method for TG2 activity and/or substrates. In addition, we 
aimed at elucidating the effect of the redox state on the activity and functional 
role of extracellular TG2, thereby focussing on arterial remodelling and cell 
migration.  
Chapter 1 gives an overview of our current knowledge on TG2 and the tools 
available for the detection of TG2 activity and for the identification of its substrate 
proteins. In this chapter I describe the recent developments in the field of click 
chemistry, a term which refers to a set of highly specific and efficient reaction 
types that ‘spontaneously’ mediate the covalent linkage of two molecules. The 
azide-alkyne cycloaddition, which is considered as the prototypical click reaction, 
is employed in the TG2 activity detection method presented in this thesis.  
The synthesis and characterization of a panel of four clickable amine-donor 
substrates for TG2 is described in Chapter 2. The relatively straightforward 
synthetic route consists of only 3 or 4 steps and results in substrates with purities 
above 90%. The clickable substrates are characterized by a pentylamine, which is 
required for efficient TG2-catalyzed crosslinking onto amine-acceptor proteins, 
and an azide- or alkyne-moiety, which allows detection of the crosslinked TG2 
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substrate proteins via the azide-alkyne cycloaddition. The advantage of this two-
step approach is that it eliminates the need for a large probe during the enzymatic 
labeling step, while simultaneously more flexibility is introduced during the 
chemical ligation step.  
The specificity of the azide-alkyne cycloaddition is crucial for the sensitive 
detection of azide- or alkyne-tagged TG2 substrate proteins. The results in 
Chapter 3 show that in particular strained alkynes react with proteins in a 
nonspecific manner, which occurs mostly through thiol-yne addition with reduced 
peptidylcysteines. This undesired side-reaction could be prevented by alkylating 
peptidylcysteines with iodoacetamide (IAM). Since IAM is compatible with the 
azide-alkyne cycloaddition itself, azide-dependent labeling with increased 
specificity was achieved by pre-incubating proteins containing reduced cysteines 
with IAM.  
In the experiments described in Chapter 4 the optimized click reaction was 
applied to validate the click chemistry-based detection of TG2 activity. Both in 
vitro and in vivo studies show that all four azide- or alkyne-containing 
pentylamines are efficiently crosslinked to amine-acceptor substrate proteins in a 
TG2-dependent manner. Furthermore, these substrates are membrane 
permeable, allowing labeling of intracellular amine-acceptor substrate proteins in 
intact cells. After fixation or cell lysis, the introduced azide- or alkyne-handles can 
be labeled via the azide-alkyne cycloaddition, allowing detection by western 
blotting or fluorescence microscopy. These results emphasize the applicability and 
potential advantages of this method. 
TG2 has been found both in cells and in the extracellular space. Extracellular 
TG2 is catalytically inactive under normal conditions, which is probably due to 
oxidative inactivation of TG2. In Chapters 5 and 6 we studied the role of the redox 
state on the activity and physiological functions of extracellular TG2. In Chapter 5 
we propose that the redox state of TG2 plays a crucial role in the inward 
remodeling of small arteries, which is a strong predictor of cardiovascular events 
such as heart and renal failure. Here we show that small arteries undergo inward 
remodeling under reducing conditions and that the strong activation of 
extracellular TG2 appears to be essential in this process.  
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Extracellular TG2 activity also plays an important role in cell migration. 
Changes in extracellular TG2 activity have been linked to various pathological 
conditions with deregulated cell migration, including cancer metastasis and 
invasiveness and abnormal wound healing. The results in Chapter 6 suggest a 
potential redox-dependent mechanism for TG2 activation during cell migration. 
Furthermore, our findings indicate that the effect of extracellular TG2 activity on 
cell migration may strongly depend on its subcellular localization.  
In Chapters 7 the results presented in this thesis are discussed in a more 
general context and I speculate about potential future directions.  
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Samenvatting 
 
Transglutaminase 2 (TG2) is een multifunctioneel eiwit dat crosslinks kan 
vormen tussen specifieke eiwitten (de zogenaamde substraateiwitten). De 
crosslinks of verbindingen worden gevormd tussen de aminozuren lysine en 
glutamine, welke deel uitmaken van de substraateiwitten. De crosslink-activiteit 
van TG2 speelt een belangrijke rol bij verschillende processen in lichaamscellen, 
bijvoorbeeld apoptose (celdood), celdifferentiatie en celmigratie. Ook bestaat er 
een verband tussen abnormale TG2 expressie en/of activiteit en verschillende 
inflammatoire ziekten (bijvoorbeeld coeliakie en multiple sclerosis), 
eiwitvouwingsziekten (bijvoorbeeld de ziekte van Alzheimer en de ziekte van 
Parkinson) en kanker. Over de manier waarop TG2 bijdraagt aan veel van deze 
(pathologische) processen is echter nog weinig bekend. Geavanceerde methoden 
voor de detectie van TG2 activiteit en de betrokken eiwitsubstraten zijn cruciaal 
om hier meer inzicht in te krijgen. Het primaire doel van deze studie was om een 
verbeterde methode te ontwikkelen voor de detectie van TG2 activiteit en de 
betrokken eiwitsubstraten. Verder werd getracht de invloed van de redox status 
op de activiteit en de functie van TG2 te achterhalen, waarbij de nadruk werd 
gelegd op celmigratie en de remodellering van bloedvaten.  
In Hoofdstuk 1 wordt een overzicht gegeven van de huidige kennis over TG2 
en de methoden voor de detectie van TG2 activiteit en de identificatie van 
substraateiwitten. Hier worden bovendien de recente ontwikkelingen op het 
gebied van de klikchemie beschreven, een term die verwijst naar een aantal zeer 
specifieke en efficiënte reacties welke spontaan twee moleculen aan elkaar 
klikken. De azide-alkyn cycloadditie, welke wordt beschouwd als de prototypische 
klikreactie, vormt de basis voor de detectiemethode voor TG2 activiteit 
beschreven in dit proefschrift. 
De synthese en karakterisatie van vier verschillende ‘klikbare’ substraten voor 
TG2 staat beschreven in Hoofdstuk 2. De relatief eenvoudige synthetische route 
bestaat uit slechts 3 of 4 stappen en resulteert in substraten met zuiverheden 
boven de 90%. De klikbare substraten worden gekenmerkt door twee chemische 
groepen, namelijk een pentylamine en een azide- of alkyngroep. De pentylamine 
 
___________________________________________________________________ 
194 
 
bootst een deel van het aminozuur lysine na, waardoor deze klikbare substraten 
door TG2 gecrosslinkt kunnen worden aan substraateiwitten. Hierdoor bevatten 
de gecrosslinkte substraateiwitten plotseling een azide- of alkyngroep, welke in 
een tweede stap bijvoorbeeld zichtbaar gemaakt kan worden door er een 
fluorescerende groep aan te klikken. Het voordeel van deze twee-staps aanpak is 
dat deze klikbare substraten geen grote detecteerbare groep bevatten welke kan 
storen bij de TG2-gekatalyseerde crosslinkreactie. Bovendien biedt deze methode 
extra flexibiliteit doordat tijdens de klikreactie iedere gewenste functionele groep 
geïntroduceerd kan worden.  
De specificiteit van de azide-alkyn cycloadditie is cruciaal voor de gevoelige 
detectie van azide- of alkyn-gelabelde TG2 substraateiwitten. De resultaten in 
Hoofdstuk 3 laten zien dat met name door ringspanning geactiveerde alkynen 
aspecifiek met eiwitten kunnen reageren. Deze reactie vindt voornamelijk plaats 
via het aminozuur cysteine wanneer deze gereduceerd is. Deze ongewenste 
zijreactie kan voorkomen worden door eiwitten met gereduceerde cysteines 
vooraf met joodaceetamide (IAM) te alkyleren. IAM is compatibel met de azide-
alkyn cycloadditie en het voorbehandelen van eiwitten met IAM leidt hierdoor tot 
een specifiekere labeling van de aan eiwitten gecrosslinkte azides.  
De experimenten die beschreven staan in Hoofdstuk 4 zijn bedoeld om na te 
gaan of TG2 activiteit gemeten kan worden met behulp van de klikbare substraten 
en de geoptimaliseerde condities voor de klikreactie. Hieruit blijkt dat alle vier de 
azide- of alkynsubstraten efficiënt gecrosslinkt worden aan substraateiwitten en 
dat dit proces inderdaad afhankelijk is van TG2. Bovendien zijn deze substraten in 
staat om het celmembraan te passeren, waardoor het mogelijk is om 
intracellulaire substraateiwitten te labelen in levende intacte cellen. Na het 
fixeren of lyseren van deze cellen kunnen de geïntroduceerde azide- of 
alkyngroepen gelabeld worden via de klikreactie, waardoor de substraateiwitten 
gedetecteerd kunnen worden via bijvoorbeeld western blotting of fluorescentie 
microscopie. Deze resultaten laten zien dat de crosslinkactiviteit van TG2 via 
klikchemie gedetecteerd kan worden en wat de mogelijke voordelen hiervan zijn. 
TG2 bevindt zich zowel in cellen als in de extracellulaire ruimte. Extracellulair 
TG2 is onder normale omstandigheden katalytisch inactief, wat waarschijnlijk 
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komt door de oxidatieve inactivatie van TG2. Hoofdstuk 5 en 6 gaan in op de rol 
van de redox status bij de activiteit en de fysiologische functie van TG2. In 
Hoofdstuk 5 stellen we dat de redox status van TG2 een belangrijke rol speelt bij 
de inwaartse remodellering van kleine bloedvaten, hetgeen leidt tot een verhoogd 
risico op cardiovasculaire aandoeningen zoals hart- en nierfalen. Hier laten we 
zien dat kleine bloedvaten inwaarts remodelleren onder reducerende 
omstandigheden en dat een sterkte activatie van extracellulair TG2 essentieel is in 
dit proces.  
Extracellulaire TG2 activiteit speelt ook een belangrijke rol in celmigratie. 
Veranderingen in extracellulaire TG2 activiteit zijn kenmerkend voor diverse 
pathologische aandoeningen met ontregelde celmigratie, bijvoorbeeld kanker en 
abnormale wondgenezing. De resultaten in Hoofdstuk 6 wijzen op een potentieel 
redox-afhankelijk mechanisme voor TG2 activatie tijdens celmigratie. Verder laten 
we zien dat het effect van TG2 op celmigratie waarschijnlijk sterk afhankelijk is 
van zijn subcellulaire lokalisatie. 
In Hoofdstuk 7 worden de belangrijkste resultaten bediscussieerd in een wat 
bredere context. Tenslotte wordt er kort ingegaan op de mogelijkheden voor 
vervolgonderzoek.  
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geweest! Beste Floris, het leek ons in eerste instantie een leuk idee voor de cursus 
Chemical Biology om klikchemie en transglutaminase 2 te combineren, maar dit 
heeft uiteindelijk de basis gevormd voor een belangrijk deel van mijn proefschrift, 
bedankt voor jouw hulp hierbij. Ik ben blij dat ik bij SynAffix de kans heb gekregen 
om verder te werken aan klikchemie, dit is voor mij de ideale nieuwe uitdaging. 
Mark en Marjoke, jullie inzet en positieve resultaten hebben aanleiding gegeven 
om zelf ook verder te gaan met de klikchemie, bedankt hiervoor en succes met 
jullie eigen promotieonderzoek. Door deze wending in mijn onderzoek stond ik 
opeens zelf ook weer op het lab bij Organische Chemie, wat wel even wennen 
was. Dennis, Hans en Morten, bedankt voor jullie hulp hierbij!  
 
Beste Erik en Jeroen, fijn dat ik een bijdrage mocht leveren aan jullie 
interessante onderzoek naar de rol van transglutaminase in de bloedvaten! 
Gelukkig heeft dit geleid tot een mooi artikel wat ook terug te vinden is in 
hoofdstuk 5 van mijn proefschrift. Peter en George, jullie natuurlijk ook bedankt 
voor deze fijne samenwerking. Ook wil ik alle transglutaminase-collega’s 
bedanken voor de leuke en leerzame meetings. Het was altijd heel interessant om 
te zien en te horen wat er verder allemaal gedaan werd op dit gebied. Benjamin, 
Micha en Robin, ik heb met veel plezier met jullie samengewerkt om de 
modificaties van α-synucleïne bij Parkinson patiënten verder op te helderen. 
Helaas bleek dit toch wat ingewikkelder en zijn deze resultaten niet terecht 
gekomen in mijn proefschrift.  
 
Natuurlijk heb ik de afgelopen jaren niet alleen op het lab doorgebracht, 
daarom wil ik ook al mijn vrienden bedanken voor de nodige gezelligheid en 
afleiding. Dankzij deze momenten kon ik er na een drukke week toch weer 
helemaal tegenaan. 
 
Dan natuurlijk mijn (schoon-)familie, dank jullie allemaal voor jullie steun, 
interesse en gezelligheid! Ik heb het maar getroffen met jullie! Tamara en Serge, 
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veel geluk met jullie toekomstige zoontje! Pap en Mam, jullie hebben mij altijd op 
alle mogelijke manieren geholpen. Zonder jullie steun en liefde zou ik het nooit zo 
ver geschopt hebben, bedankt hiervoor!  
 
Lieve Mariska, jij staat altijd klaar om mij op wat voor manier dan ook te 
helpen, zonder jou was dit boekje dan ook zeker nog niet af geweest. Hiervoor 
heb jij ook aardig wat op moeten offeren, maar gelukkig hebben we vanaf nu 
weer meer tijd om samen van de leuke dingen in het leven te genieten. Hopelijk 
mag dit nog lang duren. Ik hou van jou!  
 
 
